{"data": [{"Element": "<div class=\"WordSection1\"> <p class=\"MsoNormal\" style=\"margin-top:3.65pt\"></p> <p align=\"center\" class=\"MsoListParagraph\" style=\"margin-top:3.65pt;margin-right:\r 0in;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center\"><b><span lang=\"SV\">PRODUKTRESUM\u00c9</span></b></p> <p class=\"MsoListParagraph\" style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt\"></p> <p class=\"MsoListParagraph\" style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt\"></p> <p class=\"MsoListParagraph\" style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><b><span lang=\"SV\">1.</span></b><b><span lang=\"SV\">L\u00c4KEMEDLETSNAMN</span></b></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abacavir Accord 300 mg filmdragerade tabletter</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>2.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>KVALITATIV OCH KVANTITATIVSAMMANS\u00c4TTNING</span></h1> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Varje filmdragerad tablett inneh\u00e5ller 300 mg abakavir.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r fullst\u00e4ndig f\u00f6rteckning \u00f6ver hj\u00e4lp\u00e4mnen, se avsnitt 6.1.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>3.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>L\u00c4KEMEDELSFORM</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Filmdragerad tablett (tablett)</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Tabletterna \u00e4r sk\u00e5rade, gula, bikonvexa, 18,50 x 7,30 mm kapselformade och pr\u00e4glade med \u201dH\u201d p\u00e5 ena sidan och med \u201dA\u201d och \u201d26\u201d p\u00e5 den andra sidan p\u00e5 var sida om brytsk\u00e5ran.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"><span lang=\"SV\">Tabletten kan delas i tv\u00e5 lika stora doser.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <h1 style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>4.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>KLINISKAUPPGIFTER</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoListParagraph\" style=\"margin-left:0in;text-indent:0in\"><b><span lang=\"SV\">4.1</span></b><b><span lang=\"SV\">Terapeutiskaindikationer</span></b></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abacavir Accord \u00e4r indicerat f\u00f6r antiretroviral kombinationsbehandling vid infektioner med humant immunbristvirus (hiv) hos vuxna, ungdomar och barn (se avsnitt 4.4 och 5.1).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Det kliniska v\u00e4rdet av Abacavir Accord \u00e4r huvudsakligen visat i studier med dosering tv\u00e5 g\u00e5nger dagligen utf\u00f6rda p\u00e5 s.k. behandlingsnaiva vuxna patienter i kombinationsterapi (se avsnitt 5.1).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Innan behandlingen med abakavir p\u00e5b\u00f6rjas, ska varje hivinfekterad patient oavsett etniskt ursprung unders\u00f6kas f\u00f6r att se om de b\u00e4r p\u00e5 HLA\u2011B*5701\u2011allelen (se avsnitt 4.4). Abakavir ska inte anv\u00e4ndas av patienter som \u00e4r k\u00e4nda b\u00e4rare av HLA\u2011B*5701-allelen.</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>4.2</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Dosering ochadministreringss\u00e4tt</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abacavir Accord b\u00f6r f\u00f6rskrivas av l\u00e4kare med erfarenhet av att behandla hivinfektioner.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abacavir Accord kan tas med eller utan f\u00f6da.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.15pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.15pt\"><span lang=\"SV\">F\u00f6r att s\u00e4kerst\u00e4lla att hela dosen administreras b\u00f6r tabletten/tabletterna helst sv\u00e4ljas hela utan att krossas.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir kan \u00e4ven finnas som oral l\u00f6sning f\u00f6r anv\u00e4ndning hos barn \u00f6ver tre m\u00e5nader som v\u00e4ger mindre \u00e4n 14 kg och f\u00f6r patienter d\u00e4r tablettintag \u00e4r ol\u00e4mpligt.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Alternativt, f\u00f6r patienter som inte kan sv\u00e4lja tabletter, kan tabletterna krossas och tills\u00e4ttas i en liten m\u00e4ngd halvfast f\u00f6da eller dryck. Blandningen ska intas omedelbart (se avsnitt 5.2).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\">Vuxna, ungdomar och barn (som v\u00e4ger minst 25 kg):</span></u></i></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\"></span></u></i></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><span lang=\"SV\">Den rekommenderade dosen av Abacavir Accord \u00e4r 600 mg dagligen. Denna dos kan antingen ges som 300 mg (en tablett) tv\u00e5 g\u00e5nger dagligen eller som 600 mg (tv\u00e5 tabletter) en g\u00e5ng dagligen (se avsnitt 4.4 och 5.1).</span></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\">Barn (som v\u00e4ger mindre \u00e4n 25 kg):</span></u></i></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\"></span></u></i></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><span lang=\"SV\">Dosering baserad p\u00e5 viktintervall \u00e4r rekommenderad f\u00f6r Abacavir Accord tabletter.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Barn som v\u00e4ger \u2265 20 kg till &lt; 25 kg: </span></i><span lang=\"SV\">Rekommenderad dos \u00e4r 450 mg dagligen. Denna kan antingen administreras som 150 mg (en halv tablett) som tas p\u00e5 morgonen och 300 mg (en hel tablett) som tas p\u00e5 kv\u00e4llen, eller som 450 mg (en och en halv tablett) som tas en g\u00e5ng dagligen.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Barn som v\u00e4ger 14 till &lt; 20 kg: </span></i><span lang=\"SV\">Rekommenderad dos \u00e4r 300 mg dagligen. Denna kan antingen administreras som 150 mg (en halv tablett) tv\u00e5 g\u00e5nger dagligen eller som 300 mg (en hel tablett) en g\u00e5ng dagligen.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Barn under tre m\u00e5nader: </span></i><span lang=\"SV\">Den kliniska erfarenheten fr\u00e5n barn yngre \u00e4n tre m\u00e5nader \u00e4r begr\u00e4nsad och \u00e4r otillr\u00e4cklig f\u00f6r att fastsl\u00e5 specifik doseringsrekommendation (se avsnitt 5.2).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Patienter som byter fr\u00e5n dosering tv\u00e5 g\u00e5nger per dag till dosering en g\u00e5ng per dag ska b\u00f6rja f\u00f6lja den rekommenderade doseringen f\u00f6r administrering en g\u00e5ng per dag (som beskrivs ovan) ungef\u00e4r 12 timmar efter att den sista dosen inom en tv\u00e5 g\u00e5nger dagligen regim administrerats. D\u00e4refter ska patienten forts\u00e4tta att f\u00f6lja den rekommenderade doseringen f\u00f6r administrering en g\u00e5ng per dag (som beskrivs ovan) med ungef\u00e4r 24 timmars mellanrum. I de fall d\u00e4r patienten ska byta tillbaka till doseringen tv\u00e5 g\u00e5nger per dag ska denna b\u00f6rja f\u00f6lja rekommenderad dosering f\u00f6r administrering tv\u00e5 g\u00e5nger per dag ungef\u00e4r 24 timmar efter att den sista dosen som administrerats en g\u00e5ng per dag intagits.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoNormal\"><i><u><span lang=\"SV\">Speciella patientgrupper</span></u></i></p> <p class=\"MsoNormal\"><i><u><span lang=\"SV\"></span></u></i></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Nedsatt njurfunktion</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Ingen dosjustering av Abacavir Accord beh\u00f6vs hos patienter med nedsatt njurfunktion. Behandling med Abacavir Accord rekommenderas dock inte till patienter med terminal njurinsufficiens (se avsnitt 5.2).</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Nedsatt leverfunktion</span></i></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir metaboliseras huvudsakligen via levern. Ingen definitiv dosrekommendation kan ges till patienter med l\u00e4tt nedsatt leverfunktion (Child\u2011Pugh score 5\u20116). Data saknas f\u00f6r patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning, d\u00e4rf\u00f6r rekommenderas inte anv\u00e4ndning av abakavir s\u00e5vida inte detta bed\u00f6mts som n\u00f6dv\u00e4ndigt. Om abakavir anv\u00e4nds till patienter med l\u00e4tt nedsatt leverfunktion kr\u00e4vs noggrann uppf\u00f6ljning, inklusive \u00f6vervakning av plasmakoncentrationen av abakavir om m\u00f6jligt (se avsnitt 4.4 och 5.2).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">\u00c4ldre</span></i></p> <p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r n\u00e4rvarande saknas farmakokinetiska data f\u00f6r abakavir hos patienter \u00e4ldre \u00e4n 65 \u00e5r.</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.3</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Kontraindikationer</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">\u00d6verk\u00e4nslighet mot abakavir eller mot n\u00e5got hj\u00e4lp\u00e4mne som anges i avsnitt 6.1. Se avsnitt 4.4 och 4.8.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.4</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Varningar ochf\u00f6rsiktighet</span></h1> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"Default\" style=\"border:none;padding:0in\"><u><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">\u00d6verk\u00e4nslighetsreaktioner </span></u><u><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">(se \u00e4ven avsnitt 4.8):</span></u></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir \u00e4r associerat med en risk f\u00f6r \u00f6verk\u00e4nslighetsreaktioner (se avsnitt 4.8) karakt\u00e4riserade av feber och/eller hudutslag tillsammans med andra symtom som tyder p\u00e5 att m\u00e5nga organsystem \u00e4r involverade. \u00d6verk\u00e4nslighetsreaktioner har observerats med abakavir, varav n\u00e5gra har varit livshotande, i s\u00e4llsynta fall d\u00f6dliga, n\u00e4r de inte behandlats p\u00e5 r\u00e4tt s\u00e4tt.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Patienter som testas positiva f\u00f6r HLA\u2011B*5701\u2011allelen l\u00f6per stor risk att utveckla en \u00f6verk\u00e4nslighetsreaktion mot abakavir.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">\u00d6verk\u00e4nslighetsreaktioner mot abakavir har dock rapporterats med l\u00e4gre frekvens hos patienter som inte \u00e4r b\u00e4rare av denna allel.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">D\u00e4rf\u00f6r g\u00e4ller f\u00f6ljande</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">HLA-B*5701\u2011status m\u00e5ste alltid dokumenteras\r f\u00f6rebehandlingsstart.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir ska aldrig s\u00e4ttas in hos patienter med positiv HLA\u2011B*5701-status eller hos patienter med negativ HLA-B*5701-status som har haft en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion mot abakavir under en tidigare abakavirinneh\u00e5llande behandling (t.ex. </span><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">abakavir/lamivudin, abakavir/lamivudin/zidovudin, abakavir/dolutegravir/lamivudin</span><span lang=\"SV\" style=\"font-size:11.0pt\">).</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><b><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir m\u00e5ste s\u00e4ttas ut omedelbart</span></b><span lang=\"SV\" style=\"font-size:11.0pt\">, \u00e4ven i fr\u00e5nvaro av HLA\u2011B*5701-allelen,\r om en \u00f6verk\u00e4nslighetsreaktion misst\u00e4nks. Dr\u00f6jsm\u00e5l med att s\u00e4tta ut abakavir\r efter att \u00f6verk\u00e4nslighet har uppst\u00e5tt kan leda till en livshotandereaktion.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">Efter att abakavir har satts ut p\u00e5 grund av en\r misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion f\u00e5r Abacavir Accord <b>eller n\u00e5got annat l\u00e4kemedel som inneh\u00e5ller abakavir </b>(t.ex. </span><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">abakavir/lamivudin, abakavir/lamivudin/zidovudin, abakavir/dolutegravir/lamivudin</span><span lang=\"SV\" style=\"font-size:11.0pt\">) <b>aldrig \u00e5terins\u00e4ttas</b>.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">\u00c5terins\u00e4ttning av ett abakavirinneh\u00e5llande\r l\u00e4kemedel efter en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion kan leda till att symtomen\r snabbt \u00e5terkommer, inom n\u00e5gra f\u00e5 timmar. Denna \u00e5terkommande reaktion \u00e4r\r vanligtvis sv\u00e5rare \u00e4n den initiala och kan inkludera livshotande hypotension\r och leda till att patientenavlider.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">F\u00f6r att undvika en \u00e5terexponering f\u00f6r abakavir, ska patienter som haft en \u00f6verk\u00e4nslighetsreaktion uppmanas att \u00e5terl\u00e4mna resterande abakavir tabletter.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><b><u><span lang=\"SV\" style=\"font-size:11.0pt\">Klinisk beskrivning av \u00f6verk\u00e4nslighetsreaktioner motabakavir</span></u></b></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">\u00d6verk\u00e4nslighetsreaktioner mot abakavir har\r karakt\u00e4riserats v\u00e4l i kliniska studier och under uppf\u00f6ljning vid normal klinisk\r anv\u00e4ndning. Symtomen har vanligen upptr\u00e4tt inom de f\u00f6rsta sex veckorna\r (mediantid till debut 11 dagar) fr\u00e5n behandlingsstart med abakavir, <b>\u00e4ven om dessa reaktioner kan upptr\u00e4da n\u00e4r som helst under behandling</b>.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">N\u00e4stan alla \u00f6verk\u00e4nslighetsreaktioner inkluderar feber\r och/eller hudutslag. Andra tecken och symtom som observerats som del i\r \u00f6verk\u00e4nslighetsreaktionen mot abakavir beskrivs ing\u00e5ende i avsnitt 4.8\r (Beskrivning av ett urval av biverkningar), d\u00e4ribland symtom fr\u00e5n luftv\u00e4garna\r och magtarmkanalen. Viktigt \u00e4r att s\u00e5dana symtom kan <b>leda till att\r \u00f6verk\u00e4nslighetsreaktionen feldiagnostiseras som en sjukdom i luftv\u00e4garna\r (pneumoni, bronkit, faryngit) eller som engastroenterit</b>.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Symtomen relaterade till \u00f6verk\u00e4nslighetsreaktioner\r f\u00f6rv\u00e4rras vid fortsatt behandling och kan vara livshotande. Symtomen f\u00f6rsvinner\r vanligtvis n\u00e4r behandlingen med Abacavir Accordavbryts.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">I s\u00e4llsynta fall har \u00e4ven patienter som avbrutit\r behandling med abakavir av andra sk\u00e4l \u00e4n en \u00f6verk\u00e4nslighetsreaktion drabbats av\r livshotande reaktioner inom n\u00e5gra timmar fr\u00e5n \u00e5terins\u00e4ttning av\r abakavirbehandling (se avsnitt 4.8 Beskrivning av ett urval av\r biverkningar). \u00c5terins\u00e4ttning av abakavir hos s\u00e5dana patienter m\u00e5ste ske d\u00e4r\r sjukv\u00e5rdsresurser finns l\u00e4tttillg\u00e4ngliga.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> </div> <p class=\"MsoBodyText\" style=\"margin-top:4.55pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Mitokondriell dysfunktion efter\r exponering <i>in utero</i>:</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Nukleos(t)analoger kan i varierande grad\r p\u00e5verka mitokondriell funktion, vilket \u00e4r mest uttalat med stavudin, didanosin\r och zidovudin. Man har rapporterat mitokondriell dysfunktion hos hiv-negativa\r sp\u00e4dbarn som exponerats f\u00f6r nukleosidanaloger <i>in utero </i>och/eller\r postnatalt; dessa har fr\u00e4mst avsett behandling med regimer inneh\u00e5llande\r zidovudin. De v\u00e4sentligaste biverkningarna som rapporterats \u00e4r hematologiska\r rubbningar (anemi, neutropeni) och metabola rubbningar (hyperlaktatemi,\r hyperlipasemi). Dessa biverkningar har ofta varit \u00f6verg\u00e5ende. N\u00e5gra sent\r upptr\u00e4dande neurologiska rubbningar har rapporterats som s\u00e4llsynta (\u00f6kad tonus,\r kramper, onormalt beteende). Om s\u00e5dana neurologiska rubbningar \u00e4r \u00f6verg\u00e5ende\r eller permanenta \u00e4r f\u00f6r n\u00e4rvarande ok\u00e4nt. Dessa fynd ska \u00f6verv\u00e4gas f\u00f6r alla\r barn som <i>in utero </i>exponerats f\u00f6r nukleos(t)idanaloger och som\r uppvisar allvarliga kliniska fynd av ok\u00e4nd etiologi, i synnerhet neurologiska\r fynd. Dessa fynd p\u00e5verkar inte aktuella nationella rekommendationer avseende\r antiretroviral terapi till gravida kvinnor f\u00f6r att f\u00f6rhindra vertikal\r \u00f6verf\u00f6ring av hiv.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Vikt och metabola parametrar:</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Vikt\u00f6kning och \u00f6kade niv\u00e5er av lipider och glukos i blodet kan f\u00f6rekomma under antiretroviral behandling. S\u00e5dana f\u00f6r\u00e4ndringar kan delvis ha samband med sjukdomskontroll och livsstil. Vad g\u00e4ller lipider finns det i vissa fall bel\u00e4gg f\u00f6r en behandlingseffekt medan det inte finns n\u00e5gra starka bel\u00e4gg f\u00f6r ett samband mellan vikt\u00f6kning och n\u00e5gon viss behandling. Betr\u00e4ffande \u00f6vervakning av lipider och glukos i blodet h\u00e4nvisas till etablerade behandlingsriktlinjer f\u00f6r hiv. Lipidrubbningar ska hanteras p\u00e5 ett kliniskt l\u00e4mpligt s\u00e4tt.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Pankreatit:</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Pankreatit har rapporterats men orsakssambandet med abakavirbehandlingen \u00e4r os\u00e4kert.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Trippel nukleosid terapi:</span></u></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Hos patienter med h\u00f6ga virustal (&gt;100 000 kopior/ml) erfordrar valet av trippelkombinationen abakavir, lamivudin och zidovudin ett s\u00e4rskilt \u00f6verv\u00e4gande (se avsnitt 5.1).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Virologisk svikt och resistensutveckling har rapporterats i stor omfattning tidigt i behandlingen n\u00e4r abakavir kombinerats med tenofovirdisoproxilfumarat och lamivudin vid behandling en g\u00e5ng dagligen.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Leversjukdom:</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">S\u00e4kerhet och effekt av abakavir har inte fastst\u00e4llts p\u00e5 patienter med leversjukdom av signifikant omfattning. Abakavir rekommenderas inte till patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning (se avsnitt 4.2 och 5.2).</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Patienter med nedsatt leverfunktion f\u00f6re behandling, inklusive kronisk aktiv hepatit, har en \u00f6kad frekvens av leverfunktionsavvikelser under antiretroviral kombinationsterapi och ska kontrolleras enligt klinisk praxis. Om det hos dessa patienter finns tecken p\u00e5 f\u00f6rs\u00e4mring av leversjukdomen, ska uppeh\u00e5ll eller avbrytande av behandlingen \u00f6verv\u00e4gas.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Patienter med samtidig infektion med kronisk hepatit B eller C:</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Patienter med kronisk hepatit B eller C som behandlas med antiretroviral kombinationsterapi l\u00f6per en \u00f6kad risk f\u00f6r allvarliga leverbiverkningar inklusive s\u00e5dana med d\u00f6dlig utg\u00e5ng. Vid samtidig antiviral behandling av hepatit B eller C, h\u00e4nvisas ocks\u00e5 till aktuell produktinformation f\u00f6r dessa l\u00e4kemedel.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\" style=\"text-align:justify\"><u><span lang=\"SV\">Nedsatt njurfunktion:</span></u></p> <p class=\"MsoBodyText\" style=\"text-align:justify\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir ska inte ges till patienter med gravt nedsatt njurfunktion (se avsnitt 5.2). </span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Immunreaktiveringssyndrom:</span></u></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Hos hivinfekterade\r patienter med sv\u00e5r immunbrist vid tidpunkten f\u00f6r ins\u00e4ttande av antiretroviral\r kombinationsterapi, kan en inflammatorisk reaktion p\u00e5 asymtomatiska eller\r kvarvarande opportunistiska patogener uppst\u00e5 och orsaka allvarliga kliniska\r tillst\u00e5nd eller f\u00f6rv\u00e4rrande av symptom. Vanligtvis har s\u00e5dana reaktioner\r observerats inom de f\u00f6rsta veckorna eller m\u00e5naderna efter ins\u00e4ttande av\r antiretroviral kombinationsterapi. Relevanta exempel \u00e4r cytomegalovirusretinit,\r generella och/eller fokala mykobakteriella infektioner och <i>Pneumocystis carinii </i>pneumoni. Varje symptom p\u00e5 inflammation ska utredas och behandling\r p\u00e5b\u00f6rjas vid behov. Autoimmuna sjukdomar (s\u00e5som Graves sjukdom och autoimmun\r hepatit) har ocks\u00e5 rapporterats i samband med immunreaktivering; emellertid \u00e4r\r den rapporterade tidpunkten f\u00f6r debut mer varierad och dessa h\u00e4ndelser kan\r intr\u00e4ffa flera m\u00e5nader efter att behandlingen p\u00e5b\u00f6rjats.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Osteonekros:</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">\u00c4ven om etiologin anses vara beroende av flera faktorer (inklusive kortikosteroid-anv\u00e4ndning, alkoholkonsumtion, sv\u00e5r immunsuppression, h\u00f6gre kroppsmasseindex), s\u00e5 har fall av osteonekros rapporteras, fr\u00e4mst hos patienter med framskriden hivsjukdom och/eller l\u00e5ngvarig exponering f\u00f6r CART. Patienter ska r\u00e5das att s\u00f6ka l\u00e4kare ifall de f\u00e5r ledv\u00e4rk, stelhet i lederna eller sv\u00e5righet att r\u00f6ra sig.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Opportunistiska infektioner:</span></u></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Patienter som erh\u00e5ller abakavir eller annan antiretroviral behandling kan trots behandlingen forts\u00e4tta att utveckla opportunistiska infektioner eller andra komplikationer till hivinfektionen. Det kliniska f\u00f6rloppet ska d\u00e4rf\u00f6r noggrant kontrolleras av l\u00e4kare med erfarenhet av att behandla dessa infektioner och komplikationer.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">\u00d6verf\u00f6ring av hiv:</span></u></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">En effektiv viral suppression med antiretroviral behandling har visat sig minska risken f\u00f6r sexuellt \u00f6verf\u00f6rd smitta betydligt, men en kvarst\u00e5ende risk kan inte uteslutas. F\u00f6rsiktighets\u00e5tg\u00e4rder f\u00f6r att f\u00f6rhindra \u00f6verf\u00f6ring ska vidtas i enlighet med nationella riktlinjer.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Hj\u00e4rtinfarkt:</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Observationsstudier har visat p\u00e5 ett samband mellan hj\u00e4rtinfarkt och anv\u00e4ndningen av abakavir. Det var \u00f6verv\u00e4gande patienter som tidigare erh\u00e5llit antiretroviral behandling som studerades. Data fr\u00e5n kliniska studier visade ett begr\u00e4nsat antal fall av hj\u00e4rtinfarkt och kunde inte utesluta en liten risk\u00f6kning. Sammantaget visar tillg\u00e4ngliga data fr\u00e5n observationskohorter och randomiserade studier bristande \u00f6verensst\u00e4mmelse, s\u00e5 ett kausalt samband mellan abakavirbehandling och risken f\u00f6r hj\u00e4rtinfarkt kan varken bekr\u00e4ftas eller motbevisas. I dagsl\u00e4get finns det inte n\u00e5gon vedertagen biologisk mekanism som kan f\u00f6rklara en potentiell risk\u00f6kning. Vid f\u00f6rskrivning av abakavir ska \u00e5tg\u00e4rder vidtas f\u00f6r att f\u00f6rs\u00f6ka minimera alla p\u00e5verkbara riskfaktorer (t.ex. r\u00f6kning, hypertension och hyperlipidemi).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.5</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Interaktioner med andra l\u00e4kemedel och \u00f6vrigainteraktioner</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Baserat p\u00e5 resultat fr\u00e5n <i>in vitro\u2011</i>f\u00f6rs\u00f6k\r och med k\u00e4nnedom om abakavirs huvudsakliga metabolismv\u00e4gar, \u00e4r risken l\u00e5g f\u00f6r\r cytokrom P450\u2011medierade interaktioner med andra l\u00e4kemedel. P450 utg\u00f6r\r inte n\u00e5gon viktig v\u00e4g f\u00f6r metabolismen av abakavir och abakavir h\u00e4mmar inte\r metabolismen via CYP3A4. Dessutom har det visats att abakavir <i>in vitro </i>inte\r h\u00e4mmar CYP3A4, CYP2C9 eller CYP2D6 enzymer vid kliniskt relevanta\r koncentrationer. Induktion av levermetabolism har inte observerats i kliniska\r studier. Det \u00e4r d\u00e4rf\u00f6r liten risk f\u00f6r interaktioner med antiretrovirala PIs och\r med andra l\u00e4kemedel som metaboliseras via de mera betydelsefulla P450 enzymerna.\r Kliniska studier har visat att det inte finns n\u00e5gra kliniskt betydelsefulla\r interaktioner mellan abakavir, zidovudin ochlamivudin.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Potenta enzyminducerare som rifampicin, fenobarbital och fenytoin kan via effekt p\u00e5 UDP- glucuronyltransferas minska plasmakoncentrationerna av abakavir n\u00e5got.</span></p> </div>", "ID": "5d86a739-27e5-4285-ab0f-35c37fbba78e", "Styles": "None", "Classes": "['WordSection1']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "                                                                                                                                            ", "ParentId": "10f0b632-e318-49fa-bb29-a7c876358dac"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:3.65pt\"></p>", "ID": "98a281bc-6b28-49bf-a5cc-c2cb908988e2", "Styles": "margin-top:3.65pt", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p align=\"center\" class=\"MsoListParagraph\" style=\"margin-top:3.65pt;margin-right:\r 0in;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center\"><b><span lang=\"SV\">PRODUKTRESUM\u00c9</span></b></p>", "ID": "1100f094-99c1-4f47-86c5-fd37556d60d2", "Styles": "margin-top:3.65pt;margin-right:\r\n0in;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center", "Classes": "['MsoListParagraph']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "PRODUKTRESUM\u00c9", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt\"></p>", "ID": "cf9f9cad-2125-441b-bee7-67137a45460d", "Styles": "margin-top:3.65pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:0in;margin-bottom:.0001pt", "Classes": "['MsoListParagraph']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt\"></p>", "ID": "4e1cc980-e647-4209-82b2-7ad4bd46143d", "Styles": "margin-top:3.65pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:0in;margin-bottom:.0001pt", "Classes": "['MsoListParagraph']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><b><span lang=\"SV\">1.</span></b><b><span lang=\"SV\">L\u00c4KEMEDLETSNAMN</span></b></p>", "ID": "5e5e0673-15ee-4c9d-a0b5-92571a4f0ad1", "Styles": "margin-top:3.65pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in", "Classes": "['MsoListParagraph']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "1. L\u00c4KEMEDLETS NAMN", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "834973cd-9134-49c4-841a-2d3e93333d47", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abacavir Accord 300 mg filmdragerade tabletter</span></p>", "ID": "d3f559f8-4a3b-4c89-a744-1d928af4e712", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abacavir Accord 300 mg filmdragerade tabletter", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "e4963bee-04c2-464e-aa19-e9962600e67d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p>", "ID": "d20f27dc-1db1-4031-bcd5-f2e921e4ed35", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>2.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>KVALITATIV OCH KVANTITATIVSAMMANS\u00c4TTNING</span></h1>", "ID": "56d5bca9-5455-4d75-8d32-4d44281e973d", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "2. KVALITATIV OCH KVANTITATIV SAMMANS\u00c4TTNING", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "81e69dc0-c97a-46ec-85aa-44252add0e98", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Varje filmdragerad tablett inneh\u00e5ller 300 mg abakavir.</span></p>", "ID": "9b09934c-e615-4dad-9fe2-b4e0d1bdce87", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Varje filmdragerad tablett inneh\u00e5ller 300 mg abakavir.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "8a160d9e-6b64-4a36-a387-6192282d47c6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r fullst\u00e4ndig f\u00f6rteckning \u00f6ver hj\u00e4lp\u00e4mnen, se avsnitt 6.1.</span></p>", "ID": "d88a12de-033a-4fe8-83bc-d2a564775fd9", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "F\u00f6r fullst\u00e4ndig f\u00f6rteckning \u00f6ver hj\u00e4lp\u00e4mnen, se avsnitt 6.1.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "2d9a42da-bda5-4206-8ee9-33c37707a7e3", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "8e1b1aa4-3c11-406f-b7ad-dcc092dba67b", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>3.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>L\u00c4KEMEDELSFORM</span></h1>", "ID": "9388697e-d074-46ae-9560-e76ff004cadb", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "3. L\u00c4KEMEDELSFORM", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "aface683-6e91-4a04-9c9c-318bedd38dec", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Filmdragerad tablett (tablett)</span></p>", "ID": "c64d7b41-ce01-4fe9-94da-31ab1629560f", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Filmdragerad tablett (tablett)", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "e7f970b4-3687-4c0d-88dd-0b6f616b2a8c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Tabletterna \u00e4r sk\u00e5rade, gula, bikonvexa, 18,50 x 7,30 mm kapselformade och pr\u00e4glade med \u201dH\u201d p\u00e5 ena sidan och med \u201dA\u201d och \u201d26\u201d p\u00e5 den andra sidan p\u00e5 var sida om brytsk\u00e5ran.</span></p>", "ID": "7123e552-e3fe-49f7-b5b5-4542947c63cc", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Tabletterna \u00e4r sk\u00e5rade, gula, bikonvexa, 18,50 x 7,30 mm kapselformade och pr\u00e4glade med \u201dH\u201d p\u00e5 ena sidan och med \u201dA\u201d och \u201d26\u201d p\u00e5 den andra sidan p\u00e5 var sida om brytsk\u00e5ran.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "afc6d52c-35f0-4c2f-92b5-a5acf39343e6", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"><span lang=\"SV\">Tabletten kan delas i tv\u00e5 lika stora doser.</span></p>", "ID": "b9e3c5d2-f846-4cff-ab97-823584ca3e87", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Tabletten kan delas i tv\u00e5 lika stora doser.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "8e138a91-c6f8-4319-b801-f02db25dadf5", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "2c68b33a-1a89-40a6-bfdf-bfd49e99629f", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<h1 style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>4.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>KLINISKAUPPGIFTER</span></h1>", "ID": "f3d657ef-b792-437b-b098-1e5bfc90745c", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r\n0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4. KLINISKA UPPGIFTER", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "08b80ff1-863e-4cb8-af3a-b5457d09dfb1", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in;text-indent:0in\"><b><span lang=\"SV\">4.1</span></b><b><span lang=\"SV\">Terapeutiskaindikationer</span></b></p>", "ID": "1aef5464-e0d0-4fb2-8de3-b6a755dcaeef", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListParagraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.1 Terapeutiska indikationer", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "a2e5b0bd-930a-4a51-b763-722dde9d4341", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abacavir Accord \u00e4r indicerat f\u00f6r antiretroviral kombinationsbehandling vid infektioner med humant immunbristvirus (hiv) hos vuxna, ungdomar och barn (se avsnitt 4.4 och 5.1).</span></p>", "ID": "e481b58d-d54a-4dba-9c75-becaa1d09332", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abacavir Accord \u00e4r indicerat f\u00f6r antiretroviral kombinationsbehandling vid infektioner med humant immunbristvirus (hiv) hos vuxna, ungdomar och barn (se avsnitt 4.4 och 5.1).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "805918c5-0c39-4dbf-b068-c0a9c77e579a", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Det kliniska v\u00e4rdet av Abacavir Accord \u00e4r huvudsakligen visat i studier med dosering tv\u00e5 g\u00e5nger dagligen utf\u00f6rda p\u00e5 s.k. behandlingsnaiva vuxna patienter i kombinationsterapi (se avsnitt 5.1).</span></p>", "ID": "b55d27d8-3ebd-4c47-9413-d95e8d397f4b", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Det kliniska v\u00e4rdet av Abacavir Accord \u00e4r huvudsakligen visat i studier med dosering tv\u00e5 g\u00e5nger dagligen utf\u00f6rda p\u00e5 s.k. behandlingsnaiva vuxna patienter i kombinationsterapi (se avsnitt 5.1).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "90c54573-e59c-4f1c-b54f-6d91adaf8264", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Innan behandlingen med abakavir p\u00e5b\u00f6rjas, ska varje hivinfekterad patient oavsett etniskt ursprung unders\u00f6kas f\u00f6r att se om de b\u00e4r p\u00e5 HLA\u2011B*5701\u2011allelen (se avsnitt 4.4). Abakavir ska inte anv\u00e4ndas av patienter som \u00e4r k\u00e4nda b\u00e4rare av HLA\u2011B*5701-allelen.</span></p>", "ID": "a4f67934-233b-43ab-b944-d46509ac5f94", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Innan behandlingen med abakavir p\u00e5b\u00f6rjas, ska varje hivinfekterad patient oavsett etniskt ursprung unders\u00f6kas f\u00f6r att se om de b\u00e4r p\u00e5 HLA\u2011B*5701\u2011allelen (se avsnitt 4.4). Abakavir ska inte anv\u00e4ndas av patienter som \u00e4r k\u00e4nda b\u00e4rare av HLA\u2011B*5701-allelen.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "d943948a-e9f1-4f4a-892b-0f5e4b698287", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<h1 style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>4.2</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Dosering ochadministreringss\u00e4tt</span></h1>", "ID": "df3549dc-3294-41f7-83eb-fd3e42c99008", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r\n0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.2 Dosering och administreringss\u00e4tt", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "8ffb4104-7edb-4dfd-8448-48ba6f90ee74", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abacavir Accord b\u00f6r f\u00f6rskrivas av l\u00e4kare med erfarenhet av att behandla hivinfektioner.</span></p>", "ID": "3dde576f-4c40-4b4b-8208-dd76506fae4a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abacavir Accord b\u00f6r f\u00f6rskrivas av l\u00e4kare med erfarenhet av att behandla hivinfektioner.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "4ff22562-45b1-426d-9cb2-0f85aa52b997", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abacavir Accord kan tas med eller utan f\u00f6da.</span></p>", "ID": "9c23917a-f0b6-4431-8285-c1c157cca069", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abacavir Accord kan tas med eller utan f\u00f6da.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.15pt\"></p>", "ID": "eba921db-d471-424b-94bf-7006cefe2ba9", "Styles": "margin-top:.15pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.15pt\"><span lang=\"SV\">F\u00f6r att s\u00e4kerst\u00e4lla att hela dosen administreras b\u00f6r tabletten/tabletterna helst sv\u00e4ljas hela utan att krossas.</span></p>", "ID": "c722db65-f0bc-448d-bc86-31797cfc1839", "Styles": "margin-top:.15pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "F\u00f6r att s\u00e4kerst\u00e4lla att hela dosen administreras b\u00f6r tabletten/tabletterna helst sv\u00e4ljas hela utan att krossas.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "3c254b7d-4de9-4211-82f8-9afb99ab4dfc", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir kan \u00e4ven finnas som oral l\u00f6sning f\u00f6r anv\u00e4ndning hos barn \u00f6ver tre m\u00e5nader som v\u00e4ger mindre \u00e4n 14 kg och f\u00f6r patienter d\u00e4r tablettintag \u00e4r ol\u00e4mpligt.</span></p>", "ID": "d3908ca6-47a8-46d5-9e1f-a572341b0256", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir kan \u00e4ven finnas som oral l\u00f6sning f\u00f6r anv\u00e4ndning hos barn \u00f6ver tre m\u00e5nader som v\u00e4ger mindre \u00e4n 14 kg och f\u00f6r patienter d\u00e4r tablettintag \u00e4r ol\u00e4mpligt.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p>", "ID": "b3e31e33-8d5d-4937-a24d-a317ada11fde", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Alternativt, f\u00f6r patienter som inte kan sv\u00e4lja tabletter, kan tabletterna krossas och tills\u00e4ttas i en liten m\u00e4ngd halvfast f\u00f6da eller dryck. Blandningen ska intas omedelbart (se avsnitt 5.2).</span></p>", "ID": "e37a9ee1-7622-481a-af69-e645067d3f9f", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Alternativt, f\u00f6r patienter som inte kan sv\u00e4lja tabletter, kan tabletterna krossas och tills\u00e4ttas i en liten m\u00e4ngd halvfast f\u00f6da eller dryck. Blandningen ska intas omedelbart (se avsnitt 5.2).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "853a07c5-e960-4ed1-8820-248ccea367a7", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\">Vuxna, ungdomar och barn (som v\u00e4ger minst 25 kg):</span></u></i></p>", "ID": "0f371bc2-78c7-4f0a-ab44-daaa3d040629", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Vuxna, ungdomar och barn (som v\u00e4ger minst 25 kg):", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\"></span></u></i></p>", "ID": "4693a196-781c-4596-9be5-5385644b9e80", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><span lang=\"SV\">Den rekommenderade dosen av Abacavir Accord \u00e4r 600 mg dagligen. Denna dos kan antingen ges som 300 mg (en tablett) tv\u00e5 g\u00e5nger dagligen eller som 600 mg (tv\u00e5 tabletter) en g\u00e5ng dagligen (se avsnitt 4.4 och 5.1).</span></p>", "ID": "f2d4ffed-7427-4e3d-b05d-b13c66271ee1", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Den rekommenderade dosen av Abacavir Accord \u00e4r 600 mg dagligen. Denna dos kan antingen ges som 300 mg (en tablett) tv\u00e5 g\u00e5nger dagligen eller som 600 mg (tv\u00e5 tabletter) en g\u00e5ng dagligen (se avsnitt 4.4 och 5.1).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"></p>", "ID": "8f752e0f-80af-4894-839a-6f20eaaf7ecb", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\">Barn (som v\u00e4ger mindre \u00e4n 25 kg):</span></u></i></p>", "ID": "bd61aac5-7f4e-468d-8425-c21f4b61be29", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Barn (som v\u00e4ger mindre \u00e4n 25 kg):", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\"></span></u></i></p>", "ID": "228deec3-fa72-47d8-885f-b3d9e2ebb375", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><span lang=\"SV\">Dosering baserad p\u00e5 viktintervall \u00e4r rekommenderad f\u00f6r Abacavir Accord tabletter.</span></p>", "ID": "0f5ff9b6-bae2-46c3-bd1f-bf56e766c5bb", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Dosering baserad p\u00e5 viktintervall \u00e4r rekommenderad f\u00f6r Abacavir Accord tabletter.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "be0f9da6-ed4b-4153-8a2a-06d83c252e60", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" id=\"2799bc6a-bfb7-4f82-8a72-cf0e17ba171d\"></p>", "ID": "6cb24ea5-de42-4d8f-9221-2b68a31b76df", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Barn som v\u00e4ger \u226520kg till <25kg: ", "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" id=\"2799bc6a-bfb7-4f82-8a72-cf0e17ba171d\"><i><span lang=\"SV\">Barn som v\u00e4ger \u2265\u00a020\u00a0kg till &lt;\u00a025\u00a0kg: </span></i><span lang=\"SV\">Rekommenderad dos \u00e4r 450\u00a0mg dagligen. Denna kan antingen administreras som 150\u00a0mg (en halv tablett) som tas p\u00e5 morgonen och 300 mg (en hel tablett) som tas p\u00e5 kv\u00e4llen, eller som 450\u00a0mg (en och en halv tablett) som tas en g\u00e5ng dagligen.</span></p>", "ID": "2799bc6a-bfb7-4f82-8a72-cf0e17ba171d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Barn som v\u00e4ger \u226520kg till <25kg: ", "startWith<upper>Text": null, "Text": "Barn som v\u00e4ger \u2265\u00a020\u00a0kg till <\u00a025\u00a0kg: Rekommenderad dos \u00e4r 450\u00a0mg dagligen. Denna kan antingen administreras som 150\u00a0mg (en halv tablett) som tas p\u00e5 morgonen och 300 mg (en hel tablett) som tas p\u00e5 kv\u00e4llen, eller som 450\u00a0mg (en och en halv tablett) som tas en g\u00e5ng dagligen.", "ParentId": "6cb24ea5-de42-4d8f-9221-2b68a31b76df"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "348aaaf5-f780-47bd-8a9c-4adba761ce53", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" id=\"0b60140c-f73b-4448-81a3-b43aa569dd61\" style=\"margin-top:.05pt\"></p>", "ID": "3d1f29f7-5e2c-459d-959f-a75959ff861f", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Barn som v\u00e4ger 14 till <20kg: ", "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" id=\"0b60140c-f73b-4448-81a3-b43aa569dd61\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Barn som v\u00e4ger 14 till &lt;\u00a020\u00a0kg: </span></i><span lang=\"SV\">Rekommenderad dos \u00e4r 300\u00a0mg dagligen. Denna kan antingen administreras som 150\u00a0mg (en halv tablett) tv\u00e5 g\u00e5nger dagligen eller som 300\u00a0mg (en hel tablett) en g\u00e5ng dagligen.</span></p>", "ID": "0b60140c-f73b-4448-81a3-b43aa569dd61", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Barn som v\u00e4ger 14 till <20kg: ", "startWith<upper>Text": null, "Text": "Barn som v\u00e4ger 14 till <\u00a020\u00a0kg: Rekommenderad dos \u00e4r 300\u00a0mg dagligen. Denna kan antingen administreras som 150\u00a0mg (en halv tablett) tv\u00e5 g\u00e5nger dagligen eller som 300\u00a0mg (en hel tablett) en g\u00e5ng dagligen.", "ParentId": "3d1f29f7-5e2c-459d-959f-a75959ff861f"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "4486c648-b9f9-4005-8c3d-d34d27c96583", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" id=\"7166c54b-9543-404c-abce-885e68f705b7\"></p><i><span lang=\"SV\">Barn under tre m\u00e5nader: </span></i><none></none>", "ID": "f45cc5ce-d100-4d44-9b1c-016ea56a2892", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Barn under tre m\u00e5nader: ", "startWith<upper>Text": null, "Text": "Barn under tre m\u00e5nader: ", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" id=\"7166c54b-9543-404c-abce-885e68f705b7\"><span lang=\"SV\">Den kliniska erfarenheten fr\u00e5n barn yngre \u00e4n tre m\u00e5nader \u00e4r begr\u00e4nsad och \u00e4r otillr\u00e4cklig f\u00f6r att fastsl\u00e5 specifik doseringsrekommendation (se avsnitt\u00a05.2).</span></p>", "ID": "7166c54b-9543-404c-abce-885e68f705b7", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Barn under tre m\u00e5nader: ", "startWith<upper>Text": null, "Text": "Den kliniska erfarenheten fr\u00e5n barn yngre \u00e4n tre m\u00e5nader \u00e4r begr\u00e4nsad och \u00e4r otillr\u00e4cklig f\u00f6r att fastsl\u00e5 specifik doseringsrekommendation (se avsnitt\u00a05.2).", "ParentId": "f45cc5ce-d100-4d44-9b1c-016ea56a2892"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "6872701e-d052-4dbc-92eb-499da85b9759", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Patienter som byter fr\u00e5n dosering tv\u00e5 g\u00e5nger per dag till dosering en g\u00e5ng per dag ska b\u00f6rja f\u00f6lja den rekommenderade doseringen f\u00f6r administrering en g\u00e5ng per dag (som beskrivs ovan) ungef\u00e4r 12 timmar efter att den sista dosen inom en tv\u00e5 g\u00e5nger dagligen regim administrerats. D\u00e4refter ska patienten forts\u00e4tta att f\u00f6lja den rekommenderade doseringen f\u00f6r administrering en g\u00e5ng per dag (som beskrivs ovan) med ungef\u00e4r 24 timmars mellanrum. I de fall d\u00e4r patienten ska byta tillbaka till doseringen tv\u00e5 g\u00e5nger per dag ska denna b\u00f6rja f\u00f6lja rekommenderad dosering f\u00f6r administrering tv\u00e5 g\u00e5nger per dag ungef\u00e4r 24 timmar efter att den sista dosen som administrerats en g\u00e5ng per dag intagits.</span></p>", "ID": "1b6b5657-bc1f-44c5-ad2e-938fefc3095a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Patienter som byter fr\u00e5n dosering tv\u00e5 g\u00e5nger per dag till dosering en g\u00e5ng per dag ska b\u00f6rja f\u00f6lja den rekommenderade doseringen f\u00f6r administrering en g\u00e5ng per dag (som beskrivs ovan) ungef\u00e4r 12 timmar efter att den sista dosen inom en tv\u00e5 g\u00e5nger dagligen regim administrerats. D\u00e4refter ska patienten forts\u00e4tta att f\u00f6lja den rekommenderade doseringen f\u00f6r administrering en g\u00e5ng per dag (som beskrivs ovan) med ungef\u00e4r 24 timmars mellanrum. I de fall d\u00e4r patienten ska byta tillbaka till doseringen tv\u00e5 g\u00e5nger per dag ska denna b\u00f6rja f\u00f6lja rekommenderad dosering f\u00f6r administrering tv\u00e5 g\u00e5nger per dag ungef\u00e4r 24 timmar efter att den sista dosen som administrerats en g\u00e5ng per dag intagits.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "07b1d63c-bdd6-46ae-9cdf-480fc18bde8c", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\"><i><u><span lang=\"SV\">Speciella patientgrupper</span></u></i></p>", "ID": "3e399d89-e5a0-4c6d-b92d-48b059843485", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Speciella patientgrupper", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\"><i><u><span lang=\"SV\"></span></u></i></p>", "ID": "71d7449c-8db3-4332-b5bf-5db5158b47a4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">Nedsatt njurfunktion</span></i></p>", "ID": "e199e7d7-c7e0-4b2b-a0b2-0088642ae689", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Nedsatt njurfunktion", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Ingen dosjustering av Abacavir Accord beh\u00f6vs hos patienter med nedsatt njurfunktion. Behandling med Abacavir Accord rekommenderas dock inte till patienter med terminal njurinsufficiens (se avsnitt 5.2).</span></p>", "ID": "90511321-c73e-4405-890b-d0338f205e8e", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Ingen dosjustering av Abacavir Accord beh\u00f6vs hos patienter med nedsatt njurfunktion. Behandling med Abacavir Accord rekommenderas dock inte till patienter med terminal njurinsufficiens (se avsnitt 5.2).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "92b990ab-10c5-4b8d-81b4-d1b25c429901", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">Nedsatt leverfunktion</span></i></p>", "ID": "862d576d-e5a5-4fe0-be34-42482d0ea04b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Nedsatt leverfunktion", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir metaboliseras huvudsakligen via levern. Ingen definitiv dosrekommendation kan ges till patienter med l\u00e4tt nedsatt leverfunktion (Child\u2011Pugh score 5\u20116). Data saknas f\u00f6r patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning, d\u00e4rf\u00f6r rekommenderas inte anv\u00e4ndning av abakavir s\u00e5vida inte detta bed\u00f6mts som n\u00f6dv\u00e4ndigt. Om abakavir anv\u00e4nds till patienter med l\u00e4tt nedsatt leverfunktion kr\u00e4vs noggrann uppf\u00f6ljning, inklusive \u00f6vervakning av plasmakoncentrationen av abakavir om m\u00f6jligt (se avsnitt 4.4 och 5.2).</span></p>", "ID": "e73d85fe-a4f9-4cd1-b677-edd739e6a4d0", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir metaboliseras huvudsakligen via levern. Ingen definitiv dosrekommendation kan ges till patienter med l\u00e4tt nedsatt leverfunktion (Child\u2011Pugh score 5\u20116). Data saknas f\u00f6r patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning, d\u00e4rf\u00f6r rekommenderas inte anv\u00e4ndning av abakavir s\u00e5vida inte detta bed\u00f6mts som n\u00f6dv\u00e4ndigt. Om abakavir anv\u00e4nds till patienter med l\u00e4tt nedsatt leverfunktion kr\u00e4vs noggrann uppf\u00f6ljning, inklusive \u00f6vervakning av plasmakoncentrationen av abakavir om m\u00f6jligt (se avsnitt 4.4 och 5.2).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "3b66ac6e-07ca-4990-83aa-851ed282a8d4", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">\u00c4ldre</span></i></p>", "ID": "d55273a9-71cc-4225-912f-4f726f818a71", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00c4ldre", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r n\u00e4rvarande saknas farmakokinetiska data f\u00f6r abakavir hos patienter \u00e4ldre \u00e4n 65 \u00e5r.</span></p>", "ID": "7ef2580d-0f62-4437-8b0c-2cee91a240b8", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "F\u00f6r n\u00e4rvarande saknas farmakokinetiska data f\u00f6r abakavir hos patienter \u00e4ldre \u00e4n 65 \u00e5r.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "3f5719f0-a48b-45f6-b780-2f179f669e32", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.3</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Kontraindikationer</span></h1>", "ID": "0cedf622-37f7-4b25-a6e6-08d0faf22bfb", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.3 Kontraindikationer", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "12aa8af0-23b2-4918-a7f3-631263bb04a0", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">\u00d6verk\u00e4nslighet mot abakavir eller mot n\u00e5got hj\u00e4lp\u00e4mne som anges i avsnitt 6.1. Se avsnitt 4.4 och 4.8.</span></p>", "ID": "36fd60bb-f03c-4606-aa48-0bf77603fc5c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00d6verk\u00e4nslighet mot abakavir eller mot n\u00e5got hj\u00e4lp\u00e4mne som anges i avsnitt 6.1. Se avsnitt 4.4 och 4.8.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "2ed39e79-aa03-43de-a7c4-1cc88573ff87", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.4</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Varningar ochf\u00f6rsiktighet</span></h1>", "ID": "10f80e18-a32a-4fd3-89cb-a44d47762f28", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.4 Varningar och f\u00f6rsiktighet", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5222d943-29bf-4766-9378-d10d070114ab", "Styles": "None", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"Default\" style=\"border:none;padding:0in\"><u><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">\u00d6verk\u00e4nslighetsreaktioner </span></u><u><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">(se \u00e4ven avsnitt 4.8):</span></u></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir \u00e4r associerat med en risk f\u00f6r \u00f6verk\u00e4nslighetsreaktioner (se avsnitt 4.8) karakt\u00e4riserade av feber och/eller hudutslag tillsammans med andra symtom som tyder p\u00e5 att m\u00e5nga organsystem \u00e4r involverade. \u00d6verk\u00e4nslighetsreaktioner har observerats med abakavir, varav n\u00e5gra har varit livshotande, i s\u00e4llsynta fall d\u00f6dliga, n\u00e4r de inte behandlats p\u00e5 r\u00e4tt s\u00e4tt.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Patienter som testas positiva f\u00f6r HLA\u2011B*5701\u2011allelen l\u00f6per stor risk att utveckla en \u00f6verk\u00e4nslighetsreaktion mot abakavir.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">\u00d6verk\u00e4nslighetsreaktioner mot abakavir har dock rapporterats med l\u00e4gre frekvens hos patienter som inte \u00e4r b\u00e4rare av denna allel.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">D\u00e4rf\u00f6r g\u00e4ller f\u00f6ljande</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">HLA-B*5701\u2011status m\u00e5ste alltid dokumenteras\r f\u00f6rebehandlingsstart.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir ska aldrig s\u00e4ttas in hos patienter med positiv HLA\u2011B*5701-status eller hos patienter med negativ HLA-B*5701-status som har haft en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion mot abakavir under en tidigare abakavirinneh\u00e5llande behandling (t.ex. </span><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">abakavir/lamivudin, abakavir/lamivudin/zidovudin, abakavir/dolutegravir/lamivudin</span><span lang=\"SV\" style=\"font-size:11.0pt\">).</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><b><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir m\u00e5ste s\u00e4ttas ut omedelbart</span></b><span lang=\"SV\" style=\"font-size:11.0pt\">, \u00e4ven i fr\u00e5nvaro av HLA\u2011B*5701-allelen,\r om en \u00f6verk\u00e4nslighetsreaktion misst\u00e4nks. Dr\u00f6jsm\u00e5l med att s\u00e4tta ut abakavir\r efter att \u00f6verk\u00e4nslighet har uppst\u00e5tt kan leda till en livshotandereaktion.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">Efter att abakavir har satts ut p\u00e5 grund av en\r misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion f\u00e5r Abacavir Accord <b>eller n\u00e5got annat l\u00e4kemedel som inneh\u00e5ller abakavir </b>(t.ex. </span><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">abakavir/lamivudin, abakavir/lamivudin/zidovudin, abakavir/dolutegravir/lamivudin</span><span lang=\"SV\" style=\"font-size:11.0pt\">) <b>aldrig \u00e5terins\u00e4ttas</b>.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">\u00c5terins\u00e4ttning av ett abakavirinneh\u00e5llande\r l\u00e4kemedel efter en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion kan leda till att symtomen\r snabbt \u00e5terkommer, inom n\u00e5gra f\u00e5 timmar. Denna \u00e5terkommande reaktion \u00e4r\r vanligtvis sv\u00e5rare \u00e4n den initiala och kan inkludera livshotande hypotension\r och leda till att patientenavlider.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">F\u00f6r att undvika en \u00e5terexponering f\u00f6r abakavir, ska patienter som haft en \u00f6verk\u00e4nslighetsreaktion uppmanas att \u00e5terl\u00e4mna resterande abakavir tabletter.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><b><u><span lang=\"SV\" style=\"font-size:11.0pt\">Klinisk beskrivning av \u00f6verk\u00e4nslighetsreaktioner motabakavir</span></u></b></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">\u00d6verk\u00e4nslighetsreaktioner mot abakavir har\r karakt\u00e4riserats v\u00e4l i kliniska studier och under uppf\u00f6ljning vid normal klinisk\r anv\u00e4ndning. Symtomen har vanligen upptr\u00e4tt inom de f\u00f6rsta sex veckorna\r (mediantid till debut 11 dagar) fr\u00e5n behandlingsstart med abakavir, <b>\u00e4ven om dessa reaktioner kan upptr\u00e4da n\u00e4r som helst under behandling</b>.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">N\u00e4stan alla \u00f6verk\u00e4nslighetsreaktioner inkluderar feber\r och/eller hudutslag. Andra tecken och symtom som observerats som del i\r \u00f6verk\u00e4nslighetsreaktionen mot abakavir beskrivs ing\u00e5ende i avsnitt 4.8\r (Beskrivning av ett urval av biverkningar), d\u00e4ribland symtom fr\u00e5n luftv\u00e4garna\r och magtarmkanalen. Viktigt \u00e4r att s\u00e5dana symtom kan <b>leda till att\r \u00f6verk\u00e4nslighetsreaktionen feldiagnostiseras som en sjukdom i luftv\u00e4garna\r (pneumoni, bronkit, faryngit) eller som engastroenterit</b>.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Symtomen relaterade till \u00f6verk\u00e4nslighetsreaktioner\r f\u00f6rv\u00e4rras vid fortsatt behandling och kan vara livshotande. Symtomen f\u00f6rsvinner\r vanligtvis n\u00e4r behandlingen med Abacavir Accordavbryts.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> <p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">I s\u00e4llsynta fall har \u00e4ven patienter som avbrutit\r behandling med abakavir av andra sk\u00e4l \u00e4n en \u00f6verk\u00e4nslighetsreaktion drabbats av\r livshotande reaktioner inom n\u00e5gra timmar fr\u00e5n \u00e5terins\u00e4ttning av\r abakavirbehandling (se avsnitt 4.8 Beskrivning av ett urval av\r biverkningar). \u00c5terins\u00e4ttning av abakavir hos s\u00e5dana patienter m\u00e5ste ske d\u00e4r\r sjukv\u00e5rdsresurser finns l\u00e4tttillg\u00e4ngliga.</span></p> <p class=\"Default\" style=\"border:none;padding:0in\"></p> </div>", "ID": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "                               ", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><u><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">\u00d6verk\u00e4nslighetsreaktioner </span></u><u><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">(se \u00e4ven avsnitt 4.8):</span></u></p>", "ID": "55025741-3a7a-49f6-9500-0562142ab4f4", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00d6verk\u00e4nslighetsreaktioner (se \u00e4ven avsnitt 4.8):", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "948691d4-f72e-451a-beb7-65329cb8ca2e", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir \u00e4r associerat med en risk f\u00f6r \u00f6verk\u00e4nslighetsreaktioner (se avsnitt 4.8) karakt\u00e4riserade av feber och/eller hudutslag tillsammans med andra symtom som tyder p\u00e5 att m\u00e5nga organsystem \u00e4r involverade. \u00d6verk\u00e4nslighetsreaktioner har observerats med abakavir, varav n\u00e5gra har varit livshotande, i s\u00e4llsynta fall d\u00f6dliga, n\u00e4r de inte behandlats p\u00e5 r\u00e4tt s\u00e4tt.</span></p>", "ID": "5eb75f2d-759d-4e86-8228-08280a51c9d3", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir \u00e4r associerat med en risk f\u00f6r \u00f6verk\u00e4nslighetsreaktioner (se avsnitt 4.8) karakt\u00e4riserade av feber och/eller hudutslag tillsammans med andra symtom som tyder p\u00e5 att m\u00e5nga organsystem \u00e4r involverade. \u00d6verk\u00e4nslighetsreaktioner har observerats med abakavir, varav n\u00e5gra har varit livshotande, i s\u00e4llsynta fall d\u00f6dliga, n\u00e4r de inte behandlats p\u00e5 r\u00e4tt s\u00e4tt.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Patienter som testas positiva f\u00f6r HLA\u2011B*5701\u2011allelen l\u00f6per stor risk att utveckla en \u00f6verk\u00e4nslighetsreaktion mot abakavir.</span></p>", "ID": "39ce08e7-91d0-4ca2-abdc-ebdc4d407c89", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Patienter som testas positiva f\u00f6r HLA\u2011B*5701\u2011allelen l\u00f6per stor risk att utveckla en \u00f6verk\u00e4nslighetsreaktion mot abakavir.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">\u00d6verk\u00e4nslighetsreaktioner mot abakavir har dock rapporterats med l\u00e4gre frekvens hos patienter som inte \u00e4r b\u00e4rare av denna allel.</span></p>", "ID": "3a5cea57-3f4c-4081-98c0-8bd6b65fad20", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00d6verk\u00e4nslighetsreaktioner mot abakavir har dock rapporterats med l\u00e4gre frekvens hos patienter som inte \u00e4r b\u00e4rare av denna allel.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "95f39f01-44d7-45bf-95a0-28b14f73c004", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">D\u00e4rf\u00f6r g\u00e4ller f\u00f6ljande</span></p>", "ID": "fa05bc19-b5fc-4095-a6e9-debddb78f6c9", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "D\u00e4rf\u00f6r g\u00e4ller f\u00f6ljande", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "2fe2d03d-7710-4d55-a32b-028284782780", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">HLA-B*5701\u2011status m\u00e5ste alltid dokumenteras\r f\u00f6rebehandlingsstart.</span></p>", "ID": "60a716b5-99ad-44c4-8ccd-02f0f4546eda", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 HLA-B*5701\u2011status m\u00e5ste alltid dokumenteras f\u00f6re behandlingsstart.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "1394ae36-ea03-4b4f-9689-69fa2955ce50", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir ska aldrig s\u00e4ttas in hos patienter med positiv HLA\u2011B*5701-status eller hos patienter med negativ HLA-B*5701-status som har haft en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion mot abakavir under en tidigare abakavirinneh\u00e5llande behandling (t.ex. </span><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">abakavir/lamivudin, abakavir/lamivudin/zidovudin, abakavir/dolutegravir/lamivudin</span><span lang=\"SV\" style=\"font-size:11.0pt\">).</span></p>", "ID": "2a0edf3f-fb41-4b5a-b938-1ec98631abcc", "Styles": "margin-left:42.55pt;text-indent:-42.55pt;border:none;\r\npadding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 Abakavir ska aldrig s\u00e4ttas in hos patienter med positiv HLA\u2011B*5701-status eller hos patienter med negativ HLA-B*5701-status som har haft en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion mot abakavir under en tidigare abakavirinneh\u00e5llande behandling (t.ex. abakavir/lamivudin, abakavir/lamivudin/zidovudin, abakavir/dolutegravir/lamivudin ).", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "a9e42fc0-edbb-43ce-a5a1-661f64078754", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><b><span lang=\"SV\" style=\"font-size:11.0pt\">Abakavir m\u00e5ste s\u00e4ttas ut omedelbart</span></b><span lang=\"SV\" style=\"font-size:11.0pt\">, \u00e4ven i fr\u00e5nvaro av HLA\u2011B*5701-allelen,\r om en \u00f6verk\u00e4nslighetsreaktion misst\u00e4nks. Dr\u00f6jsm\u00e5l med att s\u00e4tta ut abakavir\r efter att \u00f6verk\u00e4nslighet har uppst\u00e5tt kan leda till en livshotandereaktion.</span></p>", "ID": "f49f37c6-31e5-47a5-8c14-b8ba64e41287", "Styles": "margin-left:42.55pt;text-indent:-42.55pt;border:none;\r\npadding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 Abakavir m\u00e5ste s\u00e4ttas ut omedelbart , \u00e4ven i fr\u00e5nvaro av HLA\u2011B*5701-allelen, om en \u00f6verk\u00e4nslighetsreaktion misst\u00e4nks. Dr\u00f6jsm\u00e5l med att s\u00e4tta ut abakavir efter att \u00f6verk\u00e4nslighet har uppst\u00e5tt kan leda till en livshotande reaktion.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "b6b9ae13-d70b-4887-a514-a2d54a81d1d6", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">Efter att abakavir har satts ut p\u00e5 grund av en\r misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion f\u00e5r Abacavir Accord <b>eller n\u00e5got annat l\u00e4kemedel som inneh\u00e5ller abakavir </b>(t.ex. </span><span lang=\"SV\" style=\"font-size:11.0pt;color:windowtext\">abakavir/lamivudin, abakavir/lamivudin/zidovudin, abakavir/dolutegravir/lamivudin</span><span lang=\"SV\" style=\"font-size:11.0pt\">) <b>aldrig \u00e5terins\u00e4ttas</b>.</span></p>", "ID": "16fada4c-0e4d-42eb-89b0-51aa5ab223f9", "Styles": "margin-left:42.55pt;text-indent:-42.55pt;border:none;\r\npadding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 Efter att abakavir har satts ut p\u00e5 grund av en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion f\u00e5r Abacavir Accord eller n\u00e5got annat l\u00e4kemedel som inneh\u00e5ller abakavir (t.ex. abakavir/lamivudin, abakavir/lamivudin/zidovudin, abakavir/dolutegravir/lamivudin ) aldrig \u00e5terins\u00e4ttas .", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "2f7ed27e-4213-4713-a9c1-59c5378ac9f8", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">\u00c5terins\u00e4ttning av ett abakavirinneh\u00e5llande\r l\u00e4kemedel efter en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion kan leda till att symtomen\r snabbt \u00e5terkommer, inom n\u00e5gra f\u00e5 timmar. Denna \u00e5terkommande reaktion \u00e4r\r vanligtvis sv\u00e5rare \u00e4n den initiala och kan inkludera livshotande hypotension\r och leda till att patientenavlider.</span></p>", "ID": "dfa74c7c-7344-481b-a74a-b4b4845ad474", "Styles": "margin-left:42.55pt;text-indent:-42.55pt;border:none;\r\npadding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 \u00c5terins\u00e4ttning av ett abakavirinneh\u00e5llande l\u00e4kemedel efter en misst\u00e4nkt \u00f6verk\u00e4nslighetsreaktion kan leda till att symtomen snabbt \u00e5terkommer, inom n\u00e5gra f\u00e5 timmar. Denna \u00e5terkommande reaktion \u00e4r vanligtvis sv\u00e5rare \u00e4n den initiala och kan inkludera livshotande hypotension och leda till att patienten avlider.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "2a7730ee-2a94-434e-a37a-3c0d3138aef7", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"margin-left:42.55pt;text-indent:-42.55pt;border:none;\r padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt;font-family:Symbol;\r color:windowtext\">\u00b7</span><span lang=\"SV\" style=\"font-size:11.0pt\">F\u00f6r att undvika en \u00e5terexponering f\u00f6r abakavir, ska patienter som haft en \u00f6verk\u00e4nslighetsreaktion uppmanas att \u00e5terl\u00e4mna resterande abakavir tabletter.</span></p>", "ID": "c3645e5a-ff7f-45a4-b8c4-934b11dbebc6", "Styles": "margin-left:42.55pt;text-indent:-42.55pt;border:none;\r\npadding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 F\u00f6r att undvika en \u00e5terexponering f\u00f6r abakavir, ska patienter som haft en \u00f6verk\u00e4nslighetsreaktion uppmanas att \u00e5terl\u00e4mna resterande abakavir tabletter.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "2ca63e1c-a0fb-4745-9197-f64775734afc", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><b><u><span lang=\"SV\" style=\"font-size:11.0pt\">Klinisk beskrivning av \u00f6verk\u00e4nslighetsreaktioner motabakavir</span></u></b></p>", "ID": "3de3a949-edbb-4959-9728-edb74bba217a", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Klinisk beskrivning av \u00f6verk\u00e4nslighetsreaktioner mot abakavir", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "65d0c2bd-3987-49fa-bbb7-c0ee8763b256", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">\u00d6verk\u00e4nslighetsreaktioner mot abakavir har\r karakt\u00e4riserats v\u00e4l i kliniska studier och under uppf\u00f6ljning vid normal klinisk\r anv\u00e4ndning. Symtomen har vanligen upptr\u00e4tt inom de f\u00f6rsta sex veckorna\r (mediantid till debut 11 dagar) fr\u00e5n behandlingsstart med abakavir, <b>\u00e4ven om dessa reaktioner kan upptr\u00e4da n\u00e4r som helst under behandling</b>.</span></p>", "ID": "9d6399e2-022a-47ab-9dea-a11e19f18cc8", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00d6verk\u00e4nslighetsreaktioner mot abakavir har karakt\u00e4riserats v\u00e4l i kliniska studier och under uppf\u00f6ljning vid normal klinisk anv\u00e4ndning. Symtomen har vanligen upptr\u00e4tt inom de f\u00f6rsta sex veckorna (mediantid till debut 11 dagar) fr\u00e5n behandlingsstart med abakavir, \u00e4ven om dessa reaktioner kan upptr\u00e4da n\u00e4r som helst under behandling .", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "eea717bd-2600-4acc-8364-273621f4e0ad", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">N\u00e4stan alla \u00f6verk\u00e4nslighetsreaktioner inkluderar feber\r och/eller hudutslag. Andra tecken och symtom som observerats som del i\r \u00f6verk\u00e4nslighetsreaktionen mot abakavir beskrivs ing\u00e5ende i avsnitt 4.8\r (Beskrivning av ett urval av biverkningar), d\u00e4ribland symtom fr\u00e5n luftv\u00e4garna\r och magtarmkanalen. Viktigt \u00e4r att s\u00e5dana symtom kan <b>leda till att\r \u00f6verk\u00e4nslighetsreaktionen feldiagnostiseras som en sjukdom i luftv\u00e4garna\r (pneumoni, bronkit, faryngit) eller som engastroenterit</b>.</span></p>", "ID": "d0843a33-1117-4c46-9b02-87fff8ef84cd", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "N\u00e4stan alla \u00f6verk\u00e4nslighetsreaktioner inkluderar feber och/eller hudutslag. Andra tecken och symtom som observerats som del i \u00f6verk\u00e4nslighetsreaktionen mot abakavir beskrivs ing\u00e5ende i avsnitt 4.8 (Beskrivning av ett urval av biverkningar), d\u00e4ribland symtom fr\u00e5n luftv\u00e4garna och magtarmkanalen. Viktigt \u00e4r att s\u00e5dana symtom kan leda till att \u00f6verk\u00e4nslighetsreaktionen feldiagnostiseras som en sjukdom i luftv\u00e4garna (pneumoni, bronkit, faryngit) eller som en gastroenterit .", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "104f930e-a22c-4234-b1bb-0e52da80b9a1", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">Symtomen relaterade till \u00f6verk\u00e4nslighetsreaktioner\r f\u00f6rv\u00e4rras vid fortsatt behandling och kan vara livshotande. Symtomen f\u00f6rsvinner\r vanligtvis n\u00e4r behandlingen med Abacavir Accordavbryts.</span></p>", "ID": "d7d002b4-e8ba-4e2c-b78c-84fb8c449401", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Symtomen relaterade till \u00f6verk\u00e4nslighetsreaktioner f\u00f6rv\u00e4rras vid fortsatt behandling och kan vara livshotande. Symtomen f\u00f6rsvinner vanligtvis n\u00e4r behandlingen med Abacavir Accord avbryts.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "0d75940d-60f2-4568-957b-acb5dab8ca2c", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"><span lang=\"SV\" style=\"font-size:11.0pt\">I s\u00e4llsynta fall har \u00e4ven patienter som avbrutit\r behandling med abakavir av andra sk\u00e4l \u00e4n en \u00f6verk\u00e4nslighetsreaktion drabbats av\r livshotande reaktioner inom n\u00e5gra timmar fr\u00e5n \u00e5terins\u00e4ttning av\r abakavirbehandling (se avsnitt 4.8 Beskrivning av ett urval av\r biverkningar). \u00c5terins\u00e4ttning av abakavir hos s\u00e5dana patienter m\u00e5ste ske d\u00e4r\r sjukv\u00e5rdsresurser finns l\u00e4tttillg\u00e4ngliga.</span></p>", "ID": "04760308-2571-452e-9bed-3b2651d2cbd8", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I s\u00e4llsynta fall har \u00e4ven patienter som avbrutit behandling med abakavir av andra sk\u00e4l \u00e4n en \u00f6verk\u00e4nslighetsreaktion drabbats av livshotande reaktioner inom n\u00e5gra timmar fr\u00e5n \u00e5terins\u00e4ttning av abakavirbehandling (se avsnitt 4.8 Beskrivning av ett urval av biverkningar). \u00c5terins\u00e4ttning av abakavir hos s\u00e5dana patienter m\u00e5ste ske d\u00e4r sjukv\u00e5rdsresurser finns l\u00e4tt tillg\u00e4ngliga.", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"Default\" style=\"border:none;padding:0in\"></p>", "ID": "a32b732a-6de1-4e57-856f-6b2c8921f62d", "Styles": "border:none;padding:0in", "Classes": "['Default']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "a994f5a1-db7e-4fdb-a83d-984e0b4ea918"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:4.55pt\"></p>", "ID": "6ddb68fb-eb4f-4ec1-a443-18c1a950d226", "Styles": "margin-top:4.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Mitokondriell dysfunktion efter\r exponering <i>in utero</i>:</span></u></p>", "ID": "52c3060a-7be5-42a4-9d89-33f899c3f06d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Mitokondriell dysfunktion efter exponering in utero :", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "2798c3d7-7a77-42ca-8244-c46e2cb3ef20", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Nukleos(t)analoger kan i varierande grad\r p\u00e5verka mitokondriell funktion, vilket \u00e4r mest uttalat med stavudin, didanosin\r och zidovudin. Man har rapporterat mitokondriell dysfunktion hos hiv-negativa\r sp\u00e4dbarn som exponerats f\u00f6r nukleosidanaloger <i>in utero </i>och/eller\r postnatalt; dessa har fr\u00e4mst avsett behandling med regimer inneh\u00e5llande\r zidovudin. De v\u00e4sentligaste biverkningarna som rapporterats \u00e4r hematologiska\r rubbningar (anemi, neutropeni) och metabola rubbningar (hyperlaktatemi,\r hyperlipasemi). Dessa biverkningar har ofta varit \u00f6verg\u00e5ende. N\u00e5gra sent\r upptr\u00e4dande neurologiska rubbningar har rapporterats som s\u00e4llsynta (\u00f6kad tonus,\r kramper, onormalt beteende). Om s\u00e5dana neurologiska rubbningar \u00e4r \u00f6verg\u00e5ende\r eller permanenta \u00e4r f\u00f6r n\u00e4rvarande ok\u00e4nt. Dessa fynd ska \u00f6verv\u00e4gas f\u00f6r alla\r barn som <i>in utero </i>exponerats f\u00f6r nukleos(t)idanaloger och som\r uppvisar allvarliga kliniska fynd av ok\u00e4nd etiologi, i synnerhet neurologiska\r fynd. Dessa fynd p\u00e5verkar inte aktuella nationella rekommendationer avseende\r antiretroviral terapi till gravida kvinnor f\u00f6r att f\u00f6rhindra vertikal\r \u00f6verf\u00f6ring av hiv.</span></p>", "ID": "be42e4f0-d95b-4a1f-af54-ca9775c13f78", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Nukleos(t)analoger kan i varierande grad p\u00e5verka mitokondriell funktion, vilket \u00e4r mest uttalat med stavudin, didanosin och zidovudin. Man har rapporterat mitokondriell dysfunktion hos hiv-negativa sp\u00e4dbarn som exponerats f\u00f6r nukleosidanaloger in utero och/eller postnatalt; dessa har fr\u00e4mst avsett behandling med regimer inneh\u00e5llande zidovudin. De v\u00e4sentligaste biverkningarna som rapporterats \u00e4r hematologiska rubbningar (anemi, neutropeni) och metabola rubbningar (hyperlaktatemi, hyperlipasemi). Dessa biverkningar har ofta varit \u00f6verg\u00e5ende. N\u00e5gra sent upptr\u00e4dande neurologiska rubbningar har rapporterats som s\u00e4llsynta (\u00f6kad tonus, kramper, onormalt beteende). Om s\u00e5dana neurologiska rubbningar \u00e4r \u00f6verg\u00e5ende eller permanenta \u00e4r f\u00f6r n\u00e4rvarande ok\u00e4nt. Dessa fynd ska \u00f6verv\u00e4gas f\u00f6r alla barn som in utero exponerats f\u00f6r nukleos(t)idanaloger och som uppvisar allvarliga kliniska fynd av ok\u00e4nd etiologi, i synnerhet neurologiska fynd. Dessa fynd p\u00e5verkar inte aktuella nationella rekommendationer avseende antiretroviral terapi till gravida kvinnor f\u00f6r att f\u00f6rhindra vertikal \u00f6verf\u00f6ring av hiv.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "f9f908a0-49df-48fe-85c3-ef262f29d83a", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Vikt och metabola parametrar:</span></u></p>", "ID": "c85f34b7-a28c-4f67-99c8-c7de44127c51", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Vikt och metabola parametrar:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "fb00733a-3242-4f63-9d0c-b9d4659ded46", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Vikt\u00f6kning och \u00f6kade niv\u00e5er av lipider och glukos i blodet kan f\u00f6rekomma under antiretroviral behandling. S\u00e5dana f\u00f6r\u00e4ndringar kan delvis ha samband med sjukdomskontroll och livsstil. Vad g\u00e4ller lipider finns det i vissa fall bel\u00e4gg f\u00f6r en behandlingseffekt medan det inte finns n\u00e5gra starka bel\u00e4gg f\u00f6r ett samband mellan vikt\u00f6kning och n\u00e5gon viss behandling. Betr\u00e4ffande \u00f6vervakning av lipider och glukos i blodet h\u00e4nvisas till etablerade behandlingsriktlinjer f\u00f6r hiv. Lipidrubbningar ska hanteras p\u00e5 ett kliniskt l\u00e4mpligt s\u00e4tt.</span></p>", "ID": "7431049f-4a46-49fd-ac09-09a3ce4cc24a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Vikt\u00f6kning och \u00f6kade niv\u00e5er av lipider och glukos i blodet kan f\u00f6rekomma under antiretroviral behandling. S\u00e5dana f\u00f6r\u00e4ndringar kan delvis ha samband med sjukdomskontroll och livsstil. Vad g\u00e4ller lipider finns det i vissa fall bel\u00e4gg f\u00f6r en behandlingseffekt medan det inte finns n\u00e5gra starka bel\u00e4gg f\u00f6r ett samband mellan vikt\u00f6kning och n\u00e5gon viss behandling. Betr\u00e4ffande \u00f6vervakning av lipider och glukos i blodet h\u00e4nvisas till etablerade behandlingsriktlinjer f\u00f6r hiv. Lipidrubbningar ska hanteras p\u00e5 ett kliniskt l\u00e4mpligt s\u00e4tt.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "cfe92a10-ea5e-4c23-9d69-73b7e61c63d3", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Pankreatit:</span></u></p>", "ID": "dc9a0738-0da8-4ae6-9ef2-09c050e2509d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Pankreatit:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "2b83545a-59c3-4f10-864e-58b18fb0b859", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Pankreatit har rapporterats men orsakssambandet med abakavirbehandlingen \u00e4r os\u00e4kert.</span></p>", "ID": "b577125f-96f9-40a6-9dee-8acd5fcfd765", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Pankreatit har rapporterats men orsakssambandet med abakavirbehandlingen \u00e4r os\u00e4kert.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "56aff7b2-fea8-4ae4-8cec-6ea314cea9ed", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Trippel nukleosid terapi:</span></u></p>", "ID": "f415ff98-44ed-4821-80d2-d5f395f428f2", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Trippel nukleosid terapi:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "807002b3-1124-43d4-a67a-58782af39ef9", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Hos patienter med h\u00f6ga virustal (&gt;100 000 kopior/ml) erfordrar valet av trippelkombinationen abakavir, lamivudin och zidovudin ett s\u00e4rskilt \u00f6verv\u00e4gande (se avsnitt 5.1).</span></p>", "ID": "46076a7d-e65e-44ba-87ec-4b17dacece88", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Hos patienter med h\u00f6ga virustal (>100 000 kopior/ml) erfordrar valet av trippelkombinationen abakavir, lamivudin och zidovudin ett s\u00e4rskilt \u00f6verv\u00e4gande (se avsnitt 5.1).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "bf9578d8-d44b-4be7-99d3-135c556c9cb5", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Virologisk svikt och resistensutveckling har rapporterats i stor omfattning tidigt i behandlingen n\u00e4r abakavir kombinerats med tenofovirdisoproxilfumarat och lamivudin vid behandling en g\u00e5ng dagligen.</span></p>", "ID": "07cdb72a-c98b-46b5-9454-5629045ba223", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Virologisk svikt och resistensutveckling har rapporterats i stor omfattning tidigt i behandlingen n\u00e4r abakavir kombinerats med tenofovirdisoproxilfumarat och lamivudin vid behandling en g\u00e5ng dagligen.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "44211ec7-48a7-4e52-b5c2-932008d26ea5", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Leversjukdom:</span></u></p>", "ID": "990b4155-c2be-481c-ba5b-186e36ab1b2b", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Leversjukdom:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "1cb6f3e8-9f91-40cf-86ae-5d0771f5dfd8", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">S\u00e4kerhet och effekt av abakavir har inte fastst\u00e4llts p\u00e5 patienter med leversjukdom av signifikant omfattning. Abakavir rekommenderas inte till patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning (se avsnitt 4.2 och 5.2).</span></p>", "ID": "b42bbd32-630c-40bb-b90c-5b1fd5cf2b75", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "S\u00e4kerhet och effekt av abakavir har inte fastst\u00e4llts p\u00e5 patienter med leversjukdom av signifikant omfattning. Abakavir rekommenderas inte till patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning (se avsnitt 4.2 och 5.2).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "c5daf61c-60ae-4321-84bd-57bf914aa76b", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Patienter med nedsatt leverfunktion f\u00f6re behandling, inklusive kronisk aktiv hepatit, har en \u00f6kad frekvens av leverfunktionsavvikelser under antiretroviral kombinationsterapi och ska kontrolleras enligt klinisk praxis. Om det hos dessa patienter finns tecken p\u00e5 f\u00f6rs\u00e4mring av leversjukdomen, ska uppeh\u00e5ll eller avbrytande av behandlingen \u00f6verv\u00e4gas.</span></p>", "ID": "6684b01b-c0bc-47f0-aee3-28d9036c64ba", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Patienter med nedsatt leverfunktion f\u00f6re behandling, inklusive kronisk aktiv hepatit, har en \u00f6kad frekvens av leverfunktionsavvikelser under antiretroviral kombinationsterapi och ska kontrolleras enligt klinisk praxis. Om det hos dessa patienter finns tecken p\u00e5 f\u00f6rs\u00e4mring av leversjukdomen, ska uppeh\u00e5ll eller avbrytande av behandlingen \u00f6verv\u00e4gas.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "0f9bbdbe-93b9-49ea-ae9b-e3d78cb1600a", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Patienter med samtidig infektion med kronisk hepatit B eller C:</span></u></p>", "ID": "027ab257-0af1-4817-af96-0b0d2ea03913", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Patienter med samtidig infektion med kronisk hepatit B eller C:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "052b1500-aeff-4693-84c2-e887972ca3c1", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Patienter med kronisk hepatit B eller C som behandlas med antiretroviral kombinationsterapi l\u00f6per en \u00f6kad risk f\u00f6r allvarliga leverbiverkningar inklusive s\u00e5dana med d\u00f6dlig utg\u00e5ng. Vid samtidig antiviral behandling av hepatit B eller C, h\u00e4nvisas ocks\u00e5 till aktuell produktinformation f\u00f6r dessa l\u00e4kemedel.</span></p>", "ID": "29e878eb-5107-4c86-b19e-dd8179407f73", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Patienter med kronisk hepatit B eller C som behandlas med antiretroviral kombinationsterapi l\u00f6per en \u00f6kad risk f\u00f6r allvarliga leverbiverkningar inklusive s\u00e5dana med d\u00f6dlig utg\u00e5ng. Vid samtidig antiviral behandling av hepatit B eller C, h\u00e4nvisas ocks\u00e5 till aktuell produktinformation f\u00f6r dessa l\u00e4kemedel.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "565d0586-7d73-4a6e-890a-28b5f5aa3fbd", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"text-align:justify\"><u><span lang=\"SV\">Nedsatt njurfunktion:</span></u></p>", "ID": "1a6ac064-7c93-42b2-94cc-b0f6c3cba079", "Styles": "text-align:justify", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Nedsatt njurfunktion:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"text-align:justify\"><u><span lang=\"SV\"></span></u></p>", "ID": "791e6a1c-133e-4265-bb8d-33066ec82a0e", "Styles": "text-align:justify", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir ska inte ges till patienter med gravt nedsatt njurfunktion (se avsnitt 5.2). </span></p>", "ID": "afb5a72c-f256-4714-bedd-07c9340ceee0", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir ska inte ges till patienter med gravt nedsatt njurfunktion (se avsnitt 5.2). ", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "2a8ad7cf-6b2a-4c4e-8847-f073114e0a70", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Immunreaktiveringssyndrom:</span></u></p>", "ID": "f3da04ac-d745-4864-9fa5-945a896c1c56", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Immunreaktiveringssyndrom:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "b7d27905-bcab-4a9c-8c7a-e59c16390651", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Hos hivinfekterade\r patienter med sv\u00e5r immunbrist vid tidpunkten f\u00f6r ins\u00e4ttande av antiretroviral\r kombinationsterapi, kan en inflammatorisk reaktion p\u00e5 asymtomatiska eller\r kvarvarande opportunistiska patogener uppst\u00e5 och orsaka allvarliga kliniska\r tillst\u00e5nd eller f\u00f6rv\u00e4rrande av symptom. Vanligtvis har s\u00e5dana reaktioner\r observerats inom de f\u00f6rsta veckorna eller m\u00e5naderna efter ins\u00e4ttande av\r antiretroviral kombinationsterapi. Relevanta exempel \u00e4r cytomegalovirusretinit,\r generella och/eller fokala mykobakteriella infektioner och <i>Pneumocystis carinii </i>pneumoni. Varje symptom p\u00e5 inflammation ska utredas och behandling\r p\u00e5b\u00f6rjas vid behov. Autoimmuna sjukdomar (s\u00e5som Graves sjukdom och autoimmun\r hepatit) har ocks\u00e5 rapporterats i samband med immunreaktivering; emellertid \u00e4r\r den rapporterade tidpunkten f\u00f6r debut mer varierad och dessa h\u00e4ndelser kan\r intr\u00e4ffa flera m\u00e5nader efter att behandlingen p\u00e5b\u00f6rjats.</span></p>", "ID": "31aad12b-69fe-40df-9ed0-4b05e36c604f", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Hos hivinfekterade patienter med sv\u00e5r immunbrist vid tidpunkten f\u00f6r ins\u00e4ttande av antiretroviral kombinationsterapi, kan en inflammatorisk reaktion p\u00e5 asymtomatiska eller kvarvarande opportunistiska patogener uppst\u00e5 och orsaka allvarliga kliniska tillst\u00e5nd eller f\u00f6rv\u00e4rrande av symptom. Vanligtvis har s\u00e5dana reaktioner observerats inom de f\u00f6rsta veckorna eller m\u00e5naderna efter ins\u00e4ttande av antiretroviral kombinationsterapi. Relevanta exempel \u00e4r cytomegalovirusretinit, generella och/eller fokala mykobakteriella infektioner och Pneumocystis carinii pneumoni. Varje symptom p\u00e5 inflammation ska utredas och behandling p\u00e5b\u00f6rjas vid behov. Autoimmuna sjukdomar (s\u00e5som Graves sjukdom och autoimmun hepatit) har ocks\u00e5 rapporterats i samband med immunreaktivering; emellertid \u00e4r den rapporterade tidpunkten f\u00f6r debut mer varierad och dessa h\u00e4ndelser kan intr\u00e4ffa flera m\u00e5nader efter att behandlingen p\u00e5b\u00f6rjats.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "c335a8b1-f61d-46d6-9313-776693cb1e92", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Osteonekros:</span></u></p>", "ID": "7001b8d1-966c-4882-a5d6-a063e6a23392", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Osteonekros:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "c800a9d6-98b8-45be-b55a-1ec0ec0f8a95", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">\u00c4ven om etiologin anses vara beroende av flera faktorer (inklusive kortikosteroid-anv\u00e4ndning, alkoholkonsumtion, sv\u00e5r immunsuppression, h\u00f6gre kroppsmasseindex), s\u00e5 har fall av osteonekros rapporteras, fr\u00e4mst hos patienter med framskriden hivsjukdom och/eller l\u00e5ngvarig exponering f\u00f6r CART. Patienter ska r\u00e5das att s\u00f6ka l\u00e4kare ifall de f\u00e5r ledv\u00e4rk, stelhet i lederna eller sv\u00e5righet att r\u00f6ra sig.</span></p>", "ID": "48c774d4-3a25-40d6-a836-c6bec96ea137", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00c4ven om etiologin anses vara beroende av flera faktorer (inklusive kortikosteroid-anv\u00e4ndning, alkoholkonsumtion, sv\u00e5r immunsuppression, h\u00f6gre kroppsmasseindex), s\u00e5 har fall av osteonekros rapporteras, fr\u00e4mst hos patienter med framskriden hivsjukdom och/eller l\u00e5ngvarig exponering f\u00f6r CART. Patienter ska r\u00e5das att s\u00f6ka l\u00e4kare ifall de f\u00e5r ledv\u00e4rk, stelhet i lederna eller sv\u00e5righet att r\u00f6ra sig.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "a0e768fa-4cbc-452a-a276-fcf58d0585c9", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Opportunistiska infektioner:</span></u></p>", "ID": "555be67b-aec1-4ee4-92e5-44e329ec5d75", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Opportunistiska infektioner:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "11e03a0f-4b3c-48a4-b55c-5a6e398e6058", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Patienter som erh\u00e5ller abakavir eller annan antiretroviral behandling kan trots behandlingen forts\u00e4tta att utveckla opportunistiska infektioner eller andra komplikationer till hivinfektionen. Det kliniska f\u00f6rloppet ska d\u00e4rf\u00f6r noggrant kontrolleras av l\u00e4kare med erfarenhet av att behandla dessa infektioner och komplikationer.</span></p>", "ID": "d84b958e-d5c4-42f4-906c-f36f65753bdf", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Patienter som erh\u00e5ller abakavir eller annan antiretroviral behandling kan trots behandlingen forts\u00e4tta att utveckla opportunistiska infektioner eller andra komplikationer till hivinfektionen. Det kliniska f\u00f6rloppet ska d\u00e4rf\u00f6r noggrant kontrolleras av l\u00e4kare med erfarenhet av att behandla dessa infektioner och komplikationer.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "5380e7dd-07f6-4ab8-b591-7e1b7d52caba", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">\u00d6verf\u00f6ring av hiv:</span></u></p>", "ID": "861d4580-1e14-4d81-8037-72f0f837e951", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00d6verf\u00f6ring av hiv:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "9f6f4ada-0f11-4902-9393-b3e79b983050", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">En effektiv viral suppression med antiretroviral behandling har visat sig minska risken f\u00f6r sexuellt \u00f6verf\u00f6rd smitta betydligt, men en kvarst\u00e5ende risk kan inte uteslutas. F\u00f6rsiktighets\u00e5tg\u00e4rder f\u00f6r att f\u00f6rhindra \u00f6verf\u00f6ring ska vidtas i enlighet med nationella riktlinjer.</span></p>", "ID": "ae64bf47-af58-488f-8fff-84cc67e50772", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "En effektiv viral suppression med antiretroviral behandling har visat sig minska risken f\u00f6r sexuellt \u00f6verf\u00f6rd smitta betydligt, men en kvarst\u00e5ende risk kan inte uteslutas. F\u00f6rsiktighets\u00e5tg\u00e4rder f\u00f6r att f\u00f6rhindra \u00f6verf\u00f6ring ska vidtas i enlighet med nationella riktlinjer.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "cf482544-3d84-4fe6-ad2c-c3bf65767b83", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Hj\u00e4rtinfarkt:</span></u></p>", "ID": "8a4b75cf-607d-4433-ad33-14c5fa98b6e8", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Hj\u00e4rtinfarkt:", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "eb9c7965-95c0-4a82-adec-b771c3f9d970", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Observationsstudier har visat p\u00e5 ett samband mellan hj\u00e4rtinfarkt och anv\u00e4ndningen av abakavir. Det var \u00f6verv\u00e4gande patienter som tidigare erh\u00e5llit antiretroviral behandling som studerades. Data fr\u00e5n kliniska studier visade ett begr\u00e4nsat antal fall av hj\u00e4rtinfarkt och kunde inte utesluta en liten risk\u00f6kning. Sammantaget visar tillg\u00e4ngliga data fr\u00e5n observationskohorter och randomiserade studier bristande \u00f6verensst\u00e4mmelse, s\u00e5 ett kausalt samband mellan abakavirbehandling och risken f\u00f6r hj\u00e4rtinfarkt kan varken bekr\u00e4ftas eller motbevisas. I dagsl\u00e4get finns det inte n\u00e5gon vedertagen biologisk mekanism som kan f\u00f6rklara en potentiell risk\u00f6kning. Vid f\u00f6rskrivning av abakavir ska \u00e5tg\u00e4rder vidtas f\u00f6r att f\u00f6rs\u00f6ka minimera alla p\u00e5verkbara riskfaktorer (t.ex. r\u00f6kning, hypertension och hyperlipidemi).</span></p>", "ID": "3f7666ef-10e4-4834-aa2a-3cdb5e4555e2", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Observationsstudier har visat p\u00e5 ett samband mellan hj\u00e4rtinfarkt och anv\u00e4ndningen av abakavir. Det var \u00f6verv\u00e4gande patienter som tidigare erh\u00e5llit antiretroviral behandling som studerades. Data fr\u00e5n kliniska studier visade ett begr\u00e4nsat antal fall av hj\u00e4rtinfarkt och kunde inte utesluta en liten risk\u00f6kning. Sammantaget visar tillg\u00e4ngliga data fr\u00e5n observationskohorter och randomiserade studier bristande \u00f6verensst\u00e4mmelse, s\u00e5 ett kausalt samband mellan abakavirbehandling och risken f\u00f6r hj\u00e4rtinfarkt kan varken bekr\u00e4ftas eller motbevisas. I dagsl\u00e4get finns det inte n\u00e5gon vedertagen biologisk mekanism som kan f\u00f6rklara en potentiell risk\u00f6kning. Vid f\u00f6rskrivning av abakavir ska \u00e5tg\u00e4rder vidtas f\u00f6r att f\u00f6rs\u00f6ka minimera alla p\u00e5verkbara riskfaktorer (t.ex. r\u00f6kning, hypertension och hyperlipidemi).", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "3c7c78c7-6156-417d-b4bb-06be4a80f148", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.5</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Interaktioner med andra l\u00e4kemedel och \u00f6vrigainteraktioner</span></h1>", "ID": "e24f4136-a89b-48c8-8951-70a7000cea85", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.5 Interaktioner med andra l\u00e4kemedel och \u00f6vriga interaktioner", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "2cf57db6-d4d7-44ca-9bcb-1fc3fcb6051b", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Baserat p\u00e5 resultat fr\u00e5n <i>in vitro\u2011</i>f\u00f6rs\u00f6k\r och med k\u00e4nnedom om abakavirs huvudsakliga metabolismv\u00e4gar, \u00e4r risken l\u00e5g f\u00f6r\r cytokrom P450\u2011medierade interaktioner med andra l\u00e4kemedel. P450 utg\u00f6r\r inte n\u00e5gon viktig v\u00e4g f\u00f6r metabolismen av abakavir och abakavir h\u00e4mmar inte\r metabolismen via CYP3A4. Dessutom har det visats att abakavir <i>in vitro </i>inte\r h\u00e4mmar CYP3A4, CYP2C9 eller CYP2D6 enzymer vid kliniskt relevanta\r koncentrationer. Induktion av levermetabolism har inte observerats i kliniska\r studier. Det \u00e4r d\u00e4rf\u00f6r liten risk f\u00f6r interaktioner med antiretrovirala PIs och\r med andra l\u00e4kemedel som metaboliseras via de mera betydelsefulla P450 enzymerna.\r Kliniska studier har visat att det inte finns n\u00e5gra kliniskt betydelsefulla\r interaktioner mellan abakavir, zidovudin ochlamivudin.</span></p>", "ID": "c0715f5e-d9e7-4799-831b-69b2508d448a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Baserat p\u00e5 resultat fr\u00e5n in vitro\u2011 f\u00f6rs\u00f6k och med k\u00e4nnedom om abakavirs huvudsakliga metabolismv\u00e4gar, \u00e4r risken l\u00e5g f\u00f6r cytokrom P450\u2011medierade interaktioner med andra l\u00e4kemedel. P450 utg\u00f6r inte n\u00e5gon viktig v\u00e4g f\u00f6r metabolismen av abakavir och abakavir h\u00e4mmar inte metabolismen via CYP3A4. Dessutom har det visats att abakavir in vitro inte h\u00e4mmar CYP3A4, CYP2C9 eller CYP2D6 enzymer vid kliniskt relevanta koncentrationer. Induktion av levermetabolism har inte observerats i kliniska studier. Det \u00e4r d\u00e4rf\u00f6r liten risk f\u00f6r interaktioner med antiretrovirala PIs och med andra l\u00e4kemedel som metaboliseras via de mera betydelsefulla P450 enzymerna. Kliniska studier har visat att det inte finns n\u00e5gra kliniskt betydelsefulla interaktioner mellan abakavir, zidovudin och lamivudin.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "477313ea-c1c5-4d7e-9b01-55c903f81adc", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Potenta enzyminducerare som rifampicin, fenobarbital och fenytoin kan via effekt p\u00e5 UDP- glucuronyltransferas minska plasmakoncentrationerna av abakavir n\u00e5got.</span></p>", "ID": "ac8f2937-713f-41b3-aac2-68ceee6aa1f8", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Potenta enzyminducerare som rifampicin, fenobarbital och fenytoin kan via effekt p\u00e5 UDP- glucuronyltransferas minska plasmakoncentrationerna av abakavir n\u00e5got.", "ParentId": "5d86a739-27e5-4285-ab0f-35c37fbba78e"}, {"Element": "<span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "f5086601-bede-4bd6-b26e-3c4f5f16ee4f", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": " ", "ParentId": "10f0b632-e318-49fa-bb29-a7c876358dac"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "084af542-28ad-4b7d-8cc3-4948f6c17be5", "Styles": "page-break-before:always", "Classes": "None", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "f5086601-bede-4bd6-b26e-3c4f5f16ee4f"}, {"Element": "<div class=\"WordSection2\"> <p class=\"MsoBodyText\" style=\"margin-top:3.65pt;text-align:justify\"><i><span lang=\"SV\">Etanol: </span></i><span lang=\"SV\">Abakavirs metabolism p\u00e5verkas av samtidigt intaget etanol med en \u00f6kning av AUC p\u00e5 ca 41 %. Dessa fynd bed\u00f6ms ej kliniskt betydelsefulla vid en totalbed\u00f6mning. Abakavir p\u00e5verkar inte metabolismen av etanol.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Metadon: </span></i><span lang=\"SV\">I en\r farmakokinetikstudie d\u00e4r metadon gavs tillsammans med abakavir i dosen 600 mg\r tv\u00e5 <span style=\"position:relative;top:-1.0pt\">g\u00e5nger dagligen, visades en 35 %\u2011ig minskning av abakavir C</span>max <span style=\"position:relative;top:-1.0pt\">samt en timmes f\u00f6rdr\u00f6jning av t</span>max men AUC var of\u00f6r\u00e4ndrat. De farmakokinetiska\r f\u00f6r\u00e4ndringarna som noterades f\u00f6r abakavir bed\u00f6mdes inte kliniskt\r betydelsefulla. I denna studie \u00f6kade abakavir metadons systemiska clearance med\r 22 %. Induktion av enzymer som metaboliserar l\u00e4kemedel kan d\u00e4rf\u00f6r inte\r uteslutas. Patienter som samtidigt behandlas med metadon och abakavir b\u00f6r\r d\u00e4rf\u00f6r f\u00f6ljas med avseende p\u00e5 tecken som tyder p\u00e5 abstinenssymtom vilka\r indikerar en underbehandling och i enstaka fall kan kr\u00e4va en dosjustering av\r metadon.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Retinoider: </span></i><span lang=\"SV\">Retinoidderivat elimineras via alkoholdehydrogenas. Interaktion med abakavir \u00e4r m\u00f6jlig men har \u00e4nnu inte studerats.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <h1 style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>4.6</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Fertilitet, graviditet ochamning</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Graviditet</span></u></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Som en generell regel, vid beslut att anv\u00e4nda antiretrovirala l\u00e4kemedel f\u00f6r att behandla hivinfektion hos gravida kvinnor och f\u00f6ljaktligen f\u00f6r att minska risken f\u00f6r vertikal \u00f6verf\u00f6ring av hiv till det nyf\u00f6dda barnet, ska b\u00e5de djurdata s\u00e5v\u00e4l som klinisk erfarenhet hos gravida kvinnor tas i beaktning.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Djurstudier har visat toxicitet f\u00f6r v\u00e4xande embryo och foster hos r\u00e5tta men inte hos kanin (se avsnitt 5.3). Abakavir har visats vara karcinogen i djurmodeller (se avsnitt 5.3). Den kliniska relevansen av dessa data f\u00f6r m\u00e4nniskor \u00e4r ok\u00e4nd.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Hos gravida kvinnor tyder mer \u00e4n 800 fall av exponering efter f\u00f6rsta trimestern och mer \u00e4n 1 000 fall av exponering efter andra och tredje trimestern inte p\u00e5 missbildningar eller fetal/neonatal p\u00e5verkan av abakavir. Risken f\u00f6r missbildning \u00e4r osannolik hos m\u00e4nniska baserat p\u00e5 dessa data.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Mitokondriell dysfunktion</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Nukleosid och nukleotidanaloger har visat sig orsaka varierande grad av mitokondriell skada in vitro och in vivo. Det har rapporterats om mitokondriell dysfunktion hos hivnegativa sp\u00e4dbarn vilka exponerats f\u00f6r nukleosidanaloger in utero och/eller postnatalt (se avsnitt 4.4).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Amning</span></u></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"><span lang=\"SV\">Abakavir och dess metaboliter uts\u00f6ndras i mj\u00f6lken hos lakterande r\u00e5ttor. Abakavir uts\u00f6ndras \u00e4ven i br\u00f6stmj\u00f6lk hos m\u00e4nniskor. Uppgifter saknas vad betr\u00e4ffar abakavirs s\u00e4kerhet n\u00e4r det ges till sp\u00e4dbarn yngre \u00e4n 3 m\u00e5nader. Det rekommenderas att hivinfekterade m\u00f6drar inte under n\u00e5gra omst\u00e4ndigheter ammar sina sp\u00e4dbarn, detta f\u00f6r att undvika \u00f6verf\u00f6ring av hivsmitta.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Fertilitet</span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Djurstudier visade att abakavir inte hade\r n\u00e5gon p\u00e5verkan p\u00e5 fertilitet (se avsnitt5.3).</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.7</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Effekter p\u00e5 f\u00f6rm\u00e5gan att framf\u00f6ra fordon och anv\u00e4ndamaskiner</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt;text-align:justify\"><span lang=\"SV\">Inga studier har utf\u00f6rts.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.8</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Biverkningar</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r m\u00e5nga rapporterade biverkningar kan det vara sv\u00e5rt att avg\u00f6ra om de \u00e4r relaterade till abakavir, till det stora antalet l\u00e4kemedel som anv\u00e4nds vid hivinfektion eller till sj\u00e4lva sjukdomen.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">M\u00e5nga av biverkningarna som redovisas nedan \u00e4r vanligt f\u00f6rekommande (illam\u00e5ende, kr\u00e4kningar, diarr\u00e9, feber, letargi, utslag) hos patienter som \u00e4r \u00f6verk\u00e4nsliga mot abakavir. Patienter med n\u00e5got av</span></p> </div>", "ID": "7b8a0829-0d04-405e-9f80-32de68eba2ce", "Styles": "None", "Classes": "['WordSection2']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "                                    ", "ParentId": "10f0b632-e318-49fa-bb29-a7c876358dac"}, {"Element": "<p class=\"MsoBodyText\" id=\"03376a35-fa73-46c1-ba8e-1933fd0440a5\" style=\"margin-top:3.65pt;text-align:justify\"></p><i><span lang=\"SV\">Etanol: </span></i><none></none>", "ID": "920db19d-7ed5-4ef0-b354-49e0097c3bf6", "Styles": "margin-top:3.65pt;text-align:justify", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Etanol: ", "startWith<upper>Text": null, "Text": "Etanol: ", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" id=\"03376a35-fa73-46c1-ba8e-1933fd0440a5\" style=\"margin-top:3.65pt;text-align:justify\"><span lang=\"SV\">Abakavirs metabolism p\u00e5verkas av samtidigt intaget etanol med en \u00f6kning av AUC p\u00e5 ca 41\u00a0%. Dessa fynd bed\u00f6ms ej kliniskt betydelsefulla vid en totalbed\u00f6mning. Abakavir p\u00e5verkar inte metabolismen av etanol.</span></p>", "ID": "03376a35-fa73-46c1-ba8e-1933fd0440a5", "Styles": "margin-top:3.65pt;text-align:justify", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Etanol: ", "startWith<upper>Text": null, "Text": "Abakavirs metabolism p\u00e5verkas av samtidigt intaget etanol med en \u00f6kning av AUC p\u00e5 ca 41\u00a0%. Dessa fynd bed\u00f6ms ej kliniskt betydelsefulla vid en totalbed\u00f6mning. Abakavir p\u00e5verkar inte metabolismen av etanol.", "ParentId": "920db19d-7ed5-4ef0-b354-49e0097c3bf6"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "664b1b89-7313-4e97-80e5-7fbbc069ff6c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" id=\"9f57c574-d446-4075-86da-3cba6783c9d6\"></p><i><span lang=\"SV\">Metadon: </span></i><none></none>", "ID": "9a2c3d22-832b-4f83-a8dd-64789a209f19", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Metadon: ", "startWith<upper>Text": null, "Text": "Metadon: ", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" id=\"9f57c574-d446-4075-86da-3cba6783c9d6\"><span lang=\"SV\">I en\r\nfarmakokinetikstudie d\u00e4r metadon gavs tillsammans med abakavir i dosen 600\u00a0mg\r\ntv\u00e5 <span style=\"position:relative;top:-1.0pt\">g\u00e5nger dagligen, visades en 35\u00a0%\u2011ig minskning av abakavir C</span>max <span style=\"position:relative;top:-1.0pt\">samt en timmes f\u00f6rdr\u00f6jning av t</span>max men AUC var of\u00f6r\u00e4ndrat. De farmakokinetiska\r\nf\u00f6r\u00e4ndringarna som noterades f\u00f6r abakavir bed\u00f6mdes inte kliniskt\r\nbetydelsefulla. I denna studie \u00f6kade abakavir metadons systemiska clearance med\r\n22\u00a0%. Induktion av enzymer som metaboliserar l\u00e4kemedel kan d\u00e4rf\u00f6r inte\r\nuteslutas. Patienter som samtidigt behandlas med metadon och abakavir b\u00f6r\r\nd\u00e4rf\u00f6r f\u00f6ljas med avseende p\u00e5 tecken som tyder p\u00e5 abstinenssymtom vilka\r\nindikerar en underbehandling och i enstaka fall kan kr\u00e4va en dosjustering av\r\nmetadon.</span></p>", "ID": "9f57c574-d446-4075-86da-3cba6783c9d6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Metadon: ", "startWith<upper>Text": null, "Text": "I en\r\nfarmakokinetikstudie d\u00e4r metadon gavs tillsammans med abakavir i dosen 600\u00a0mg\r\ntv\u00e5 g\u00e5nger dagligen, visades en 35\u00a0%\u2011ig minskning av abakavir Cmax samt en timmes f\u00f6rdr\u00f6jning av tmax men AUC var of\u00f6r\u00e4ndrat. De farmakokinetiska\r\nf\u00f6r\u00e4ndringarna som noterades f\u00f6r abakavir bed\u00f6mdes inte kliniskt\r\nbetydelsefulla. I denna studie \u00f6kade abakavir metadons systemiska clearance med\r\n22\u00a0%. Induktion av enzymer som metaboliserar l\u00e4kemedel kan d\u00e4rf\u00f6r inte\r\nuteslutas. Patienter som samtidigt behandlas med metadon och abakavir b\u00f6r\r\nd\u00e4rf\u00f6r f\u00f6ljas med avseende p\u00e5 tecken som tyder p\u00e5 abstinenssymtom vilka\r\nindikerar en underbehandling och i enstaka fall kan kr\u00e4va en dosjustering av\r\nmetadon.", "ParentId": "9a2c3d22-832b-4f83-a8dd-64789a209f19"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "2f9b094c-19ff-4cb8-aea2-b37a212d8169", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" id=\"4f998d42-3a4f-4571-819a-efeef4437b30\"></p><i><span lang=\"SV\">Retinoider: </span></i><none></none>", "ID": "48a442e3-76f5-4aaf-91b1-034b07457dd6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Retinoider: ", "startWith<upper>Text": null, "Text": "Retinoider: ", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" id=\"4f998d42-3a4f-4571-819a-efeef4437b30\"><span lang=\"SV\">Retinoidderivat elimineras via alkoholdehydrogenas. Interaktion med abakavir \u00e4r m\u00f6jlig men har \u00e4nnu inte studerats.</span></p>", "ID": "4f998d42-3a4f-4571-819a-efeef4437b30", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Retinoider: ", "startWith<upper>Text": null, "Text": "Retinoidderivat elimineras via alkoholdehydrogenas. Interaktion med abakavir \u00e4r m\u00f6jlig men har \u00e4nnu inte studerats.", "ParentId": "48a442e3-76f5-4aaf-91b1-034b07457dd6"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "3c34589a-2e7b-4a83-9c07-e44aa06d522c", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<h1 style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>4.6</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Fertilitet, graviditet ochamning</span></h1>", "ID": "198fd040-e8e5-4183-9d4a-7299f99a7327", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r\n0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.6 Fertilitet, graviditet och amning", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "94f71748-f3ae-4fd3-8a6a-37a2625ed0e2", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Graviditet</span></u></p>", "ID": "92893cf2-e4f1-4b91-8bcc-b261e071b069", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Graviditet", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "795bf79d-7f91-4a96-bb84-6cbe5d80490c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Som en generell regel, vid beslut att anv\u00e4nda antiretrovirala l\u00e4kemedel f\u00f6r att behandla hivinfektion hos gravida kvinnor och f\u00f6ljaktligen f\u00f6r att minska risken f\u00f6r vertikal \u00f6verf\u00f6ring av hiv till det nyf\u00f6dda barnet, ska b\u00e5de djurdata s\u00e5v\u00e4l som klinisk erfarenhet hos gravida kvinnor tas i beaktning.</span></p>", "ID": "c7be4640-3d16-4b6b-8353-25a920ec26b5", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Som en generell regel, vid beslut att anv\u00e4nda antiretrovirala l\u00e4kemedel f\u00f6r att behandla hivinfektion hos gravida kvinnor och f\u00f6ljaktligen f\u00f6r att minska risken f\u00f6r vertikal \u00f6verf\u00f6ring av hiv till det nyf\u00f6dda barnet, ska b\u00e5de djurdata s\u00e5v\u00e4l som klinisk erfarenhet hos gravida kvinnor tas i beaktning.", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "345b65c8-225b-4c70-bb7a-c23d2a3e1d4d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Djurstudier har visat toxicitet f\u00f6r v\u00e4xande embryo och foster hos r\u00e5tta men inte hos kanin (se avsnitt 5.3). Abakavir har visats vara karcinogen i djurmodeller (se avsnitt 5.3). Den kliniska relevansen av dessa data f\u00f6r m\u00e4nniskor \u00e4r ok\u00e4nd.</span></p>", "ID": "a2368443-81d1-4fb3-8c53-1dac9976896e", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Djurstudier har visat toxicitet f\u00f6r v\u00e4xande embryo och foster hos r\u00e5tta men inte hos kanin (se avsnitt 5.3). Abakavir har visats vara karcinogen i djurmodeller (se avsnitt 5.3). Den kliniska relevansen av dessa data f\u00f6r m\u00e4nniskor \u00e4r ok\u00e4nd.", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "19bb83af-67d0-4a64-aad7-a6cf46766930", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Hos gravida kvinnor tyder mer \u00e4n 800 fall av exponering efter f\u00f6rsta trimestern och mer \u00e4n 1 000 fall av exponering efter andra och tredje trimestern inte p\u00e5 missbildningar eller fetal/neonatal p\u00e5verkan av abakavir. Risken f\u00f6r missbildning \u00e4r osannolik hos m\u00e4nniska baserat p\u00e5 dessa data.</span></p>", "ID": "5c914042-ea47-41bc-beb9-902676508733", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Hos gravida kvinnor tyder mer \u00e4n 800 fall av exponering efter f\u00f6rsta trimestern och mer \u00e4n 1 000 fall av exponering efter andra och tredje trimestern inte p\u00e5 missbildningar eller fetal/neonatal p\u00e5verkan av abakavir. Risken f\u00f6r missbildning \u00e4r osannolik hos m\u00e4nniska baserat p\u00e5 dessa data.", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "b45c033c-94b8-4d11-8003-f3e4509cd0e1", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">Mitokondriell dysfunktion</span></i></p>", "ID": "103c083e-240f-4130-9141-414f8a9a555a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Mitokondriell dysfunktion", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Nukleosid och nukleotidanaloger har visat sig orsaka varierande grad av mitokondriell skada in vitro och in vivo. Det har rapporterats om mitokondriell dysfunktion hos hivnegativa sp\u00e4dbarn vilka exponerats f\u00f6r nukleosidanaloger in utero och/eller postnatalt (se avsnitt 4.4).</span></p>", "ID": "5e935b10-b08b-460e-9075-c59062970c42", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Nukleosid och nukleotidanaloger har visat sig orsaka varierande grad av mitokondriell skada in vitro och in vivo. Det har rapporterats om mitokondriell dysfunktion hos hivnegativa sp\u00e4dbarn vilka exponerats f\u00f6r nukleosidanaloger in utero och/eller postnatalt (se avsnitt 4.4).", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "527e5391-98db-4ab9-b290-d9384f33c4df", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Amning</span></u></p>", "ID": "4cf28a89-b2c4-4768-9cc2-b1ae347b996f", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Amning", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "9a2efc64-0478-4ee6-b181-02451a42e2a3", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"><span lang=\"SV\">Abakavir och dess metaboliter uts\u00f6ndras i mj\u00f6lken hos lakterande r\u00e5ttor. Abakavir uts\u00f6ndras \u00e4ven i br\u00f6stmj\u00f6lk hos m\u00e4nniskor. Uppgifter saknas vad betr\u00e4ffar abakavirs s\u00e4kerhet n\u00e4r det ges till sp\u00e4dbarn yngre \u00e4n 3 m\u00e5nader. Det rekommenderas att hivinfekterade m\u00f6drar inte under n\u00e5gra omst\u00e4ndigheter ammar sina sp\u00e4dbarn, detta f\u00f6r att undvika \u00f6verf\u00f6ring av hivsmitta.</span></p>", "ID": "8452506f-4b36-4d58-9473-81657881720b", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir och dess metaboliter uts\u00f6ndras i mj\u00f6lken hos lakterande r\u00e5ttor. Abakavir uts\u00f6ndras \u00e4ven i br\u00f6stmj\u00f6lk hos m\u00e4nniskor. Uppgifter saknas vad betr\u00e4ffar abakavirs s\u00e4kerhet n\u00e4r det ges till sp\u00e4dbarn yngre \u00e4n 3 m\u00e5nader. Det rekommenderas att hivinfekterade m\u00f6drar inte under n\u00e5gra omst\u00e4ndigheter ammar sina sp\u00e4dbarn, detta f\u00f6r att undvika \u00f6verf\u00f6ring av hivsmitta.", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "9b54725b-50fe-4222-b65d-9f7f01554a51", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Fertilitet</span></u></p>", "ID": "31d91edc-fed8-40cf-b1ae-cfa8bccb7852", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Fertilitet", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Djurstudier visade att abakavir inte hade\r n\u00e5gon p\u00e5verkan p\u00e5 fertilitet (se avsnitt5.3).</span></p>", "ID": "7576e202-1b66-497b-b4c0-e2210b4f226e", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Djurstudier visade att abakavir inte hade n\u00e5gon p\u00e5verkan p\u00e5 fertilitet (se avsnitt 5.3).", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "c5af3875-bc0f-4e92-a95b-92c664be65e4", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.7</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Effekter p\u00e5 f\u00f6rm\u00e5gan att framf\u00f6ra fordon och anv\u00e4ndamaskiner</span></h1>", "ID": "ad060550-ccca-465c-8b5e-f70d298dd3b2", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.7 Effekter p\u00e5 f\u00f6rm\u00e5gan att framf\u00f6ra fordon och anv\u00e4nda maskiner", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "003a0d48-4ab6-482f-a2c3-9f8b963605fc", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt;text-align:justify\"><span lang=\"SV\">Inga studier har utf\u00f6rts.</span></p>", "ID": "21573016-2f0a-4841-8669-516fe8f8c2da", "Styles": "margin-top:.05pt;text-align:justify", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Inga studier har utf\u00f6rts.", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "7c39eb73-e222-46c0-b7ef-eced970546c9", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>4.8</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Biverkningar</span></h1>", "ID": "2221f231-1506-4298-b969-e1c29dcb1a0b", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.8 Biverkningar", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "57467353-0382-4e3b-b40a-ea93e1e1befe", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r m\u00e5nga rapporterade biverkningar kan det vara sv\u00e5rt att avg\u00f6ra om de \u00e4r relaterade till abakavir, till det stora antalet l\u00e4kemedel som anv\u00e4nds vid hivinfektion eller till sj\u00e4lva sjukdomen.</span></p>", "ID": "939acc73-96cb-4f44-8929-a6b91966aded", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "F\u00f6r m\u00e5nga rapporterade biverkningar kan det vara sv\u00e5rt att avg\u00f6ra om de \u00e4r relaterade till abakavir, till det stora antalet l\u00e4kemedel som anv\u00e4nds vid hivinfektion eller till sj\u00e4lva sjukdomen.", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p>", "ID": "2f2cd870-0220-4594-a6b9-9160fd0a4bbc", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">M\u00e5nga av biverkningarna som redovisas nedan \u00e4r vanligt f\u00f6rekommande (illam\u00e5ende, kr\u00e4kningar, diarr\u00e9, feber, letargi, utslag) hos patienter som \u00e4r \u00f6verk\u00e4nsliga mot abakavir. Patienter med n\u00e5got av</span></p>", "ID": "ac42f75c-2bee-4b5c-b23b-21964d7c50b4", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "M\u00e5nga av biverkningarna som redovisas nedan \u00e4r vanligt f\u00f6rekommande (illam\u00e5ende, kr\u00e4kningar, diarr\u00e9, feber, letargi, utslag) hos patienter som \u00e4r \u00f6verk\u00e4nsliga mot abakavir. Patienter med n\u00e5got av", "ParentId": "7b8a0829-0d04-405e-9f80-32de68eba2ce"}, {"Element": "<span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "56e229e3-1899-4697-a469-ea1ec75b03a0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": " ", "ParentId": "10f0b632-e318-49fa-bb29-a7c876358dac"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "a209f2cf-504c-4166-8ff8-4ea6055f52e5", "Styles": "page-break-before:always", "Classes": "None", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "56e229e3-1899-4697-a469-ea1ec75b03a0"}, {"Element": "<div class=\"WordSection3\"> <p class=\"MsoBodyText\" style=\"margin-top:3.65pt\"><span lang=\"SV\">dessa symtom ska d\u00e4rf\u00f6r noggrant utv\u00e4rderas r\u00f6rande f\u00f6rekomst av s\u00e5dan \u00f6verk\u00e4nslighet (se avsnitt 4.4). Mycket s\u00e4llsynta fall av erythema multiforme, Stevens Johnsons syndrom eller toxisk epidermal nekrolys har rapporterats d\u00e4r \u00f6verk\u00e4nslighet mot abakavir inte kunnat uteslutas. I dessa fall ska behandling med abakavir avbrytas f\u00f6r all framtid.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">M\u00e5nga av de medicinska incidenterna har inte lett till att behandlingen beh\u00f6vt avbrytas. F\u00f6ljande indelning har anv\u00e4nts f\u00f6r klassificering mycket vanlig (&gt;1/10), vanlig (&gt;1/100, &lt;1/10), mindre vanlig (&gt;1/1 000, &lt;1/100), s\u00e4llsynt (&gt;1/10 000, &lt;1/1 000), mycket s\u00e4llsynt (&lt;1/10 000).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><u><span lang=\"SV\">Metabolism och nutrition</span></u></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Vanlig: </span></i><span lang=\"SV\">anorexia</span></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Mycket s\u00e4llsynt: </span></i><span lang=\"SV\">laktacidos</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Centrala och perifera nervsystemet</span></u></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Vanlig: </span></i><span lang=\"SV\">huvudv\u00e4rk</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Magtarmkanalen</span></u><span lang=\"SV\"> <i>Vanlig: </i>illam\u00e5ende, kr\u00e4kningar, diarr\u00e9</span></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">S\u00e4llsynt: </span></i><span lang=\"SV\">pankreatit</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Hud och subkutan v\u00e4vnad</span></u></p> <p class=\"MsoNormal\" style=\"margin-top:.1pt\"><i><span lang=\"SV\">Vanlig: </span></i><span lang=\"SV\">utslag (utan systemiska symtom)</span></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Mycket s\u00e4llsynt: </span></i><span lang=\"SV\">erythema multiforme, Steven\u2011Johnsons syndrom och toxisk epidermal nekrolys</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Allm\u00e4nna symtom och/eller symtom vid administreringsst\u00e4llet</span></u></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Vanlig: </span></i><span lang=\"SV\">feber, letargi, tr\u00f6tthet </span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Beskrivning av ett urval biverkningar</span></u></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt;text-align:justify\"><i><u><span lang=\"SV\"></span></u></i></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt;text-align:justify\"><i><u><span lang=\"SV\">\u00d6verk\u00e4nslighetsreaktion mot abakavir</span></u></i></p> <p class=\"MsoBodyText\" style=\"text-align:justify\"><span lang=\"SV\">Tecken och symtom\r p\u00e5 denna \u00f6verk\u00e4nslighetsreaktion redovisas nedan. De har identifierats antingen\r i kliniska studier eller i s\u00e4kerhets\u00f6vervakningen vid normal klinisk\r anv\u00e4ndning. De som markerats med \u2019fetstil \u2019 har rapporterats <b>hos minst 10 % </b>av patienterna med \u00f6verk\u00e4nslighetsreaktion.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">N\u00e4stan alla patienter som utvecklar \u00f6verk\u00e4nslighetsreaktioner f\u00e5r feber och/eller hudutslag (vanligen makulopapul\u00e4ra eller urtikariella) som delsymtom men fall av \u00f6verk\u00e4nslighet utan hudutslag eller feber har intr\u00e4ffat. Andra huvudsymtom \u00e4r symtom fr\u00e5n magtarmkanalen och andningsv\u00e4garna samt allm\u00e4nna symtom som letargi och allm\u00e4n sjukdomsk\u00e4nsla.</span></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Hud                                             </span></i><b><span lang=\"SV\">Hudutslag </span></b><span lang=\"SV\">(vanligen makulopapul\u00e4ra eller urtikariella)</span></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Magtarmkanalen                          </span></i><b><span lang=\"SV\">Illam\u00e5ende, kr\u00e4kningar, diarr\u00e9, buksm\u00e4rta</span></b><span lang=\"SV\">, muns\u00e5r</span></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Andningsv\u00e4gar                             </span></i><b><span lang=\"SV\">Dyspn\u00e9, hosta, </span></b><span lang=\"SV\">ont i halsen, \u2019adult respiratory distresssyndrome\u2019, lungsvikt</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.35pt;margin-right:0in;margin-bottom:\r 0in;margin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">\u00d6vrigt                                          </span></i><b><span lang=\"SV\">Feber, letargi, allm\u00e4n sjukdomsk\u00e4nsla</span></b><span lang=\"SV\">, \u00f6dem,\r lymfadenopati, hypotension, konjunktivit,anafylaxi</span></p> <p class=\"MsoBodyText\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Neurologi/psykiatri                       </span></i><b><span lang=\"SV\">Huvudv\u00e4rk</span></b><span lang=\"SV\">,parestesi</span></p> <p class=\"MsoBodyText\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Blod                                             </span></i><span lang=\"SV\">Lymfopeni</span></p> <p class=\"MsoBodyText\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;\r margin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Lever/pankreas                             </span></i><b><span lang=\"SV\">F\u00f6rh\u00f6jda leverv\u00e4rden, </span></b><span lang=\"SV\">hepatit<b>,</b>leversvikt</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt;margin-right:0in;margin-bottom:\r 0in;margin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Muskel/skelett                              </span></i><b><span lang=\"SV\">Myalgi</span></b><span lang=\"SV\">, myolys (s\u00e4llsynt), artralgi, f\u00f6rh\u00f6jtkreatinfosfokinas</span></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Urologi                                        </span></i><span lang=\"SV\">F\u00f6rh\u00f6jt kreatinin,njursvikt</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Symtomen relaterade till denna \u00f6verk\u00e4nslighetsreaktion f\u00f6rv\u00e4rras vid fortsatt behandling och kan vara livshotande, och har i s\u00e4llsynta fall varit d\u00f6dlig.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">\u00c5terins\u00e4ttning av abakavir efter en \u00f6verk\u00e4nslighetsreaktion kan leda till att symtomen \u00e5terkommer, inom n\u00e5gra f\u00e5 timmar. Denna \u00e5terkommande reaktion \u00e4r vanligtvis sv\u00e5rare \u00e4n den initiala och kan inkludera livshotande hypotension och leda till att patienten avlider. Liknande reaktioner har ocks\u00e5 intr\u00e4ffat i s\u00e4llsynta fall efter att abakavir \u00e5terinsatts hos patienter som innan behandlingen avbr\u00f6ts endast haft ett av huvudsymtomen p\u00e5 \u00f6verk\u00e4nslighet (se ovan), och har i mycket s\u00e4llsynta fall \u00e4ven setts hos patienter som har \u00e5terupptagit behandlingen utan f\u00f6reg\u00e5ende symtom p\u00e5 en \u00f6verk\u00e4nslighetsreaktion (dvs. patienter som tidigare ansetts tolerera abakavir).</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Metabola parametrar</span></i></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Vikt\u00f6kning och \u00f6kade niv\u00e5er av lipider och glukos i blodet kan f\u00f6rekomma under antiretroviral behandling (se avsnitt 4.4).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Immunreaktiveringssyndrom</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Hos hivinfekterade patienter med sv\u00e5r immunbrist vid tidpunkten f\u00f6r ins\u00e4ttande av antiretroviral kombinationsterapi, kan en inflammatorisk reaktion mot asymtomatiska eller kvarvarande opportunistiska infektioner uppst\u00e5. Autoimmuna sjukdomar (s\u00e5som Graves sjukdom och autoimmun hepatit) har ocks\u00e5 rapporterats i samband med immunreaktivering; emellertid \u00e4r den rapporterade tidpunkten f\u00f6r debut mer varierad och dessa h\u00e4ndelser kan intr\u00e4ffa flera m\u00e5nader efter att behandlingen p\u00e5b\u00f6rjats (se avsnitt 4.4).</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Osteonekros</span></i></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Fall av osteonekros har rapporterats, speciellt hos patienter med k\u00e4nda riskfaktorer, framskriden hivsjukdom eller l\u00e5ngvarig exponering f\u00f6r CART. Frekvensen av detta \u00e4r ok\u00e4nd (se avsnitt 4.4).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">F\u00f6r\u00e4ndringar i labortoriekemiska parametrar</span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">I kontrollerade kliniska studier var laboratorieavvikelser relaterade till abakavirbehandling ovanliga och inga skillnader i incidens noterades mellan patienterna i abakavir- och kontrollgrupperna.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Pediatrisk population</span></u></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">1 206 hivinfekterade pediatriska patienter i \u00e5ldern 3 m\u00e5nader till 17 \u00e5r inkluderades i studien ARROW (COL105677), 669 av dessa fick abakavir och lamivudin antingen en eller tv\u00e5 g\u00e5nger dagligen (se avsnitt 5.1). Inga ytterligare s\u00e4kerhetsproblem j\u00e4mf\u00f6rt med vuxna har identifierats bland de pediatriska patienter som f\u00e5tt l\u00e4kemedlet antingen en eller tv\u00e5 g\u00e5nger dagligen</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"text-align:justify\"><u><span lang=\"SV\">Rapportering av misst\u00e4nkta biverkningar</span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Det \u00e4r viktigt att rapportera misst\u00e4nkta biverkningar efter att l\u00e4kemedlet godk\u00e4nts. Det g\u00f6r det m\u00f6jligt att kontinuerligt \u00f6vervaka l\u00e4kemedlets nytta-riskf\u00f6rh\u00e5llande. H\u00e4lso- och sjukv\u00e5rdspersonal uppmanas att rapportera varje misst\u00e4nkt biverkning via:</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">L\u00e4kemedelsverket</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Box 26</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">751 03 Uppsala</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\"><a href=\"http://www.lakemedelsverket.se\">www.lakemedelsverket.se</a> </span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <h1 style=\"margin-top:4.55pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>4.9</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>\u00d6verdosering</span></h1> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Enstaka doser p\u00e5 upp till 1 200 mg och dygnsdoser p\u00e5 1 800 mg abakavir har administrerats till patienter i kliniska studier. Inga andra biverkningar rapporterades ut\u00f6ver dem som rapporterades vid normala doser. Effekten av h\u00f6gre doser \u00e4r inte k\u00e4nd. Om \u00f6verdosering intr\u00e4ffar ska patienten \u00f6vervakas noggrant avseende tecken p\u00e5 toxicitet (se avsnitt 4.8) och symtomatisk terapi ska ges vid behov. Det \u00e4r inte k\u00e4nt om abakavir kan elimineras via peritoneal- eller hemodialys.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>5.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>FARMAKOLOGISKAEGENSKAPER</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoListParagraph\" style=\"margin-left:0in;text-indent:0in\"><b><span lang=\"SV\">5.1</span></b><b><span lang=\"SV\">Farmakodynamiskaegenskaper</span></b></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Farmakoterapeutisk grupp: nukleosidanalog\r omv\u00e4nt transkriptash\u00e4mmare, ATC kod: J05AF06. <u>Verkningsmekanism</u></span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Abakavir \u00e4r en NRTI\r och \u00e4r en potent selektiv h\u00e4mmare av hiv\u20111 och hiv\u20112. Abakavir\r metaboliseras intracellul\u00e4rt till den aktiva metaboliten carbovir 5\u2019\u2011trifosfat\r (TP). <i>In vitro\u2011</i>studier har visat att dess verkningsmekanism\r gentemot hiv \u00e4r dess h\u00e4mning av hivs omv\u00e4nt transkriptasenzym, vilket\r resulterar i ett kedjeavbrott och avbrytande av den virala replikationscykeln.\r Ingen antagonism mot abakavirs antivirala effekt i cellodling observerades vid\r kombination med nukleosidanalogerna (NRTI) didanosin, emtricitabin, lamivudin,\r stavudin, tenofovir eller zidovudin, icke-nukleosidanalogen (NNRTI) nevirapin,\r eller proteash\u00e4mmaren (PI) amprenavir.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Resistens</span></u></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:4.6pt\"><i><span lang=\"SV\">Resistens in vitro: </span></i><span lang=\"SV\">Abakavirresistenta isolat av hiv-1 har\r selekterats fram <i>in vitro </i>och \u00e4r associerade med specifika\r genotypf\u00f6r\u00e4ndringar i regionen kodande f\u00f6r omv\u00e4nt transkriptas (M184V, K65R,\r L74V, och Y115F). Viral resistens mot abakavir utvecklas relativt l\u00e5ngsamt <i>in vitro </i>och kr\u00e4ver multipla <span style=\"position:relative;top:-1.0pt\">mutationer\r f\u00f6r en kliniskt relevant \u00f6kning i EC<sub>50</sub></span> <span style=\"position:relative;top:-1.0pt\">av \u201dwild-type\u201d virus.</span></span></p> <p class=\"MsoBodyText\" style=\"margin-top:.4pt\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Resistens in vivo (behandlingsnaiva patienter)</span></i><span lang=\"SV\">. I pivotala kliniska studier visade isolat fr\u00e5n flertalet patienter med virologisk svikt vid behandling med abakavir antingen inga NRTI\u2011relaterade f\u00f6r\u00e4ndringar j\u00e4mf\u00f6rt med baseline (45 %) eller endast M184V eller M184I-selektion (45 %). Den totala selektionsfrekvensen f\u00f6r M184V eller M184I var h\u00f6g (54 %). Mindre vanlig var selektionen av L74V (5 %), K65R (1 %) och Y115F (1 %). N\u00e4r zidovudin inkluderas i behandlingen har frekvensen av L74V och K65R visat sig minska i n\u00e4rvaro av abakavir (med zidovudin: 0/40, utan zidovudin: 15/192, 8 %).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:11.4pt;border-collapse:collapse;border:none\"> <tr style=\"height:50.6pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.45pt;text-align:left\"></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">Behandling</span></b></p> </td> <td style=\"width:79.7pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.05pt;text-align:left\"></p> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><b><span lang=\"SV\">Abakavir\r   + lamivudin/ zidovudin<sup>1</sup></span></b></p> </td> <td style=\"width:79.95pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><b><span lang=\"SV\">Abakavir +   lamivudin + NNRTI</span></b></p> </td> <td style=\"width:79.85pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Abakavir + lamivudin + PI (eller PI/ritonavir)</span></b></p> </td> <td style=\"width:79.85pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.45pt;text-align:left\"></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">Totalt</span></b></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"106\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.1pt;text-align:left\"><b><span lang=\"SV\">Antal patienter</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">282</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">1094</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">909</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">2285</span></p> </td> </tr> <tr style=\"height:37.85pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">Antal med   virologisk svikt</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">43</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">90</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">158</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">291</span></p> </td> </tr> <tr style=\"height:50.6pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Antal genotyper vid p\u00e5g\u00e5ende</span></b></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">behandling</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">40 (100 %)</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:.2pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">51 (100 %)<sup>2</sup></span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">141 (100 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">232 (100 %)</span></p> </td> </tr> <tr style=\"height:25.4pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><b><span lang=\"SV\">K65R</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">0</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">1 (2 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">2 (1 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">3 (1 %)</span></p> </td> </tr> <tr style=\"height:12.8pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><b><span lang=\"SV\">L74V</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">0</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">9 (18 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">3 (2%)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">12 (5 %)</span></p> </td> </tr> <tr style=\"height:12.7pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Y115F</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">0</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\"><span lang=\"SV\">2 (4 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">0</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">2 (1 %)</span></p> </td> </tr> <tr style=\"height:12.8pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><b><span lang=\"SV\">M184V/I</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">34 (85 %)</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">22 (43 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">70 (50 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">126 (54 %)</span></p> </td> </tr> <tr style=\"height:12.65pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">TAMs<sup><span style=\"position:relative;\r   top:-4.0pt\">3</span></sup></span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">3 (8 %)</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\"><span lang=\"SV\">2 (4 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">4 (3 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">9 (4 %)</span></p> </td> </tr> </table> <p class=\"MsoListParagraph\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"SV\">1.</span><span lang=\"SV\" style=\"color:white\">Lamivudine/Zidovudine</span><span lang=\"SV\"> \u00e4r en\r fast kombination av lamivudin ochzidovudin</span></p> <p class=\"MsoListParagraph\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:\r 0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt\"><span lang=\"SV\">2.</span><span lang=\"SV\">Inkluderar tre fall av icke-virologisk svikt och fyra obekr\u00e4ftade fall\r av virologisksvikt.</span></p> <p class=\"MsoBodyText\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"SV\">3   Antal individer med \u22651 Tymidinanalog\u2011mutationer (TAMs, i e 41, 67, 70, 210, 215, 219).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">TAMs skulle kunna selekteras d\u00e5 tymidinanaloger \u00e4r associerade med abakavir. I en metaanalys av sex kliniska studier selekterades inga TAMs vid behandlingar d\u00e4r abakavir men inte zidovudin ingick (0/127), men selekterades d\u00e4remot i de behandlingar d\u00e4r abakavir och tymidinanalogen zidovudin ingick (22/86, 26 %).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Resistens in vivo (tidigare behandlade patienter): </span></i><span lang=\"SV\">Kliniskt signifikant minskad k\u00e4nslighet f\u00f6r abakavir har visats i kliniska isolat fr\u00e5n patienter med virologisk svikt, vilka tidigare behandlats med och \u00e4r resistenta mot andra nukleosidh\u00e4mmare. I en metaanalys av fem kliniska studier d\u00e4r abakavir adderades f\u00f6r att f\u00f6rst\u00e4rka behandlingen hade 123 av 166 individer (74%) M184V/I, 50 (30%) hade T215Y/F, 45 (27 %) hade M41L, 30 (18 %) hade K70R och 25 (15 %) hade D67N. K65R saknades och L74V och Y115F var ovanliga ((\u22643 %). Logistisk regressionsmodellering av f\u00f6ruts\u00e4gbara v\u00e4rden f\u00f6r genotyp (justerade f\u00f6r basline plasma hiv\u20111 RNA [vRNA], CD4+cellantal, antal och l\u00e4ngd p\u00e5 tidigare antiretrovirala behandlingar) visade att f\u00f6rekomst av tre eller fler mutationer f\u00f6rknippade med NRTI\u2011resistens var associerade med minskad respons vecka 4 (p=0,015) eller fyra eller fler mutationer vecka  4 (median)(p\u22640,012). Dessutom orsakar \u201d69\u2011insertion\u201d\u2011komplexet eller Q151M\u2011mutationen (vanligt f\u00f6rekommande i kombination med A62V, V751, F77L och F116) en h\u00f6gre niv\u00e5 av resistens mot abakavir.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:.85in;border-collapse:collapse;border:none\"> <tr style=\"height:25.3pt\"> <td rowspan=\"2\" style=\"width:129.35pt;border:solid black 1.0pt;\r   border-right:solid black 1.5pt;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"172\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.1pt;text-align:left\"></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">Omv\u00e4nt transkriptash\u00e4mmar-   mutationer vid baseline</span></b></p> </td> <td colspan=\"3\" style=\"width:222.6pt;border-top:solid black 1.0pt;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"297\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Vecka 4</span></b></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">(n = 166)</span></b></p> </td> </tr> <tr style=\"height:50.6pt\"> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">n</span></b></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Median f\u00f6r\u00e4ndring</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:1.9pt\"><b><span lang=\"SV\" style=\"position:relative;top:-1.0pt\">vRNA (log</span></b><b><span lang=\"SV\">10   c/ml)</span></b></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:50.6pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><b><span lang=\"SV\">Procent med</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><b><span lang=\"SV\">&lt;400 kopior/ml   vRNA</span></b></p> </td> </tr> <tr style=\"height:12.55pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Inga</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\"><span lang=\"SV\">15</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\"><span lang=\"SV\">-0,96</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:12.55pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\"><span lang=\"SV\">40 %</span></p> </td> </tr> <tr style=\"height:12.7pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Endast M184V</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\"><span lang=\"SV\">75</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\"><span lang=\"SV\">-0,74</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:12.7pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\"><span lang=\"SV\">64 %</span></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">En NRTI   mutation, vilken som helst</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">82</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">-0,72</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:25.3pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">65 %</span></p> </td> </tr> <tr style=\"height:37.85pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Tv\u00e5 NRTI-associerade mutationer,   vilka som helst</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">22</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">-0,82</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:37.85pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">32 %</span></p> </td> </tr> <tr style=\"height:38.0pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:38.0pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Tre NRTI-associerade mutationer,   vilka som helst</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:38.0pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">19</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:38.0pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">-0,30</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:38.0pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">5 %</span></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">Fyra eller   fler NRTI- associerade mutationer</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">28</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">-0,07</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:25.3pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">11 %</span></p> </td> </tr> </table> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Fenotypisk resistens och korsresistens</span></i></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Fenotypisk resistens mot abakavir kr\u00e4ver M184V med minst ytterligare en annan abakavirselekterad mutation, eller M184V med multipla TAMs. Fenotypisk korsresistens mot andra NRTIs med endast M184V- eller M184I\u2011mutationer \u00e4r begr\u00e4nsad. Zidovudin, didanosin, stavudin och tenofovir bibeh\u00e5ller sin antiretrovirala aktivitet mot den typen av hiv\u20111\u2011varianter. F\u00f6rekomst av M184V med K65R f\u00f6rorsakar korsresistens mellan abakavir, tenofovir, didanosin och lamivudin. M184V med L74V f\u00f6rorsakar korsresistens mellan abakavir, didanosin och lamivudin. F\u00f6rekomst av M184V med Y115F f\u00f6rorsakar korsresistens mellan abakavir och lamivudin. V\u00e4gledning f\u00f6r l\u00e4mplig anv\u00e4ndning av abakavir kan f\u00e5s om nuvarande rekommenderad resistensalgoritm anv\u00e4nds.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Korsresistens mellan abakavir och antiretroviraler fr\u00e5n andra klasser (t.ex. PIs eller NNRTIs) \u00e4r inte trolig</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Klinisk effekt och s\u00e4kerhet</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Det visade kliniska v\u00e4rdet med abakavir \u00e4r fr\u00e4mst baserat p\u00e5 resultat fr\u00e5n studier med behandlingsnaiva vuxna patienter som tog abakavir 300  mg tv\u00e5 g\u00e5nger dagligen i kombination med zidovudin och lamivudin.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Dosering (300 mg) tv\u00e5 g\u00e5nger dagligen:</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoListParagraph\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"SV\" style=\"font-family:Symbol\">\u00b7</span><i><span lang=\"SV\">Behandlingsnaivavuxna</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Hos vuxna patienter som behandlats med abakavir i kombination med lamivudin och zidovudin hade ca 70 % av patienterna (Intention To Treat-analys vid 48 veckor) inte n\u00e5gra detekterbara virusniv\u00e5er (&lt; 400 kopior/ml) samt en motsvarande h\u00f6jning av antalet CD4\u2011celler.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">I en randomiserad dubbelblind placebokontrollerad studie p\u00e5 vuxna patienter j\u00e4mf\u00f6rdes kombinationen abakavir, lamivudin och zidovudin med kombinationen indinavir, lamivudin och zidovudin. P\u00e5 grund av den h\u00f6ga andelen patienter med f\u00f6rtida behandlingsavbrott (42 % av patienterna hade avbrutit den randomiserade behandlingen under de f\u00f6rsta 48 veckorna) kunde inte n\u00e5gon definitiv slutsats dras betr\u00e4ffande ekvivalens mellan behandlingsalternativen efter 48 veckor. Fast\u00e4n en likartad antiviral effekt observerades mellan de abakavir- och indinavirinneh\u00e5llande regimerna vad g\u00e4ller andel patienter med ej detekterbar virusniv\u00e5 (\u2264400 kopior/ml; intention to treat analys (ITT), 47 % versus 49 %; as treated analys (AT), 86 % versus 94 % f\u00f6r abakavir- respektive indinavirkombinationen), var resultatet b\u00e4ttre f\u00f6r indinavirkombinationen, s\u00e4rskilt i gruppen patienter med h\u00f6ga initiala virustal (&gt;100 000 kopior/ml f\u00f6re behandlingen; ITT, 46 % versus 55 %; AT, 84 % versus 93% f\u00f6r abakavir respektive indinavir).</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">I en dubbelblind, kontrollerad, multicenterstudie (CNA30024) randomiserades 654 hivinfekterade behandlingsnaiva patienter till att f\u00e5 antingen 300 mg abakavir tv\u00e5 g\u00e5nger dagligen eller 300 mg zidovudin tv\u00e5 g\u00e5nger dagligen, i b\u00e5da fallen i kombination med 150 mg lamivudin tv\u00e5 g\u00e5nger dagligen och 600 mg efavirenz en g\u00e5ng dagligen. Den dubbelblinda behandlingen p\u00e5gick i minst 48 veckor. I \u201dintent to treat\u201d (ITT)\u2011populationen uppn\u00e5dde 70 % av patienterna i abakavirgruppen, j\u00e4mf\u00f6rt med 69 % av patienterna i zidovudingruppen, ett virologiskt svar p\u00e5 plasma hiv-1-RNA p\u00e5 \u226450 kopior/ml i vecka 48 (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnaden: 0,8, 95 % CI -6,3, 7,9). I analysen av \u201das treated\u201d (AT) var skillnaden mellan de b\u00e5da behandlingsarmarna mer m\u00e4rkbar, 88% av patienterna i abakavirgruppen j\u00e4mf\u00f6rt med 95 % av patienterna i zidovudingruppen (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnaden: -6,8, 95 % CI -11,8, -1,7). Emellertid var b\u00e5da analyserna \u00f6verensst\u00e4mmande n\u00e4r det g\u00e4ller slutsatsen om \u201dnon\u2011inferiority\u201d mellan b\u00e5da behandlingsarmarna.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">ACTC5095 var en randomiserad (1:1:1), dubbelblind, placebokontrollerad pr\u00f6vning med 1 147 antiretroviralt naiva hiv\u20111\u2011infekterade vuxna, som j\u00e4mf\u00f6rde tre olika behandlingsregimer: zidovudin (ZDV), lamivudin (3TC), abakavir (ABC) och efavirenz (EFV) eller ZDV/3TC/EFV eller ZDV/3TC/ABC. Vid uppf\u00f6ljning efter 32 veckor (median) visade sig trippelterapin med de tre nukleosiderna ZDV/3TC/ABC vara virologiskt underl\u00e4gsen de andra tv\u00e5 armarna. 26 % av individerna i ZDV/3TC/ABC\u2011armen, 16 % i ZDV/3TC/EFV\u2011armen och 13 % i armen med 4 l\u00e4kemedel, fick virologisk svikt (hiv\u2011RNA &gt;200 kopior/ml). I vecka 48 var andelen individer med hiv\u2011RNA &lt;50 kopior/ml 63 %, 80 % respektive 86 % i ZDV/3TC/ABC-, ZDV/3TC/EFV- respektive ZDV/3TC/ABC/EFV\u2011armen. S\u00e4kerhetskommitt\u00e9n f\u00f6r studien stoppade ZDV/3TC/ABC\u2011armen vid denna tidpunkt baserat p\u00e5 den st\u00f6rre andelen patienter med virologisk svikt. De \u00e5terst\u00e5ende armarna fortsatte i blindad version. Vid uppf\u00f6ljning efter 144 veckor (median) fick 25 % av individerna i ZDV/3TC/ABC/EFV-armen och 26 % i ZDV/3TC/EFV-armen virologisk svikt. Det var ingen signifikant skillnad i tid till f\u00f6rsta virologiska svikt (p-0,73, \u201dlog-rank test\u201d) mellan de 2 armarna. I denna studie f\u00f6rb\u00e4ttrade inte till\u00e4gg av ABC till ZDV/3TC/EFV effekten signifikant.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:13.45pt;border-collapse:collapse;border:none\"> <tr style=\"height:25.3pt\"> <td style=\"width:113.4pt;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"151\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"></p> </td> <td style=\"width:66.6pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"89\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"></p> </td> <td style=\"width:75.1pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"100\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">ZDV/3TC/AB   C</span></p> </td> <td style=\"width:86.85pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"116\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">ZDV/3TC/EFV</span></p> </td> <td style=\"width:111.55pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"149\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">ZDV/3TC/ABC/EFV</span></p> </td> </tr> <tr style=\"height:12.55pt\"> <td rowspan=\"2\" style=\"width:113.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"151\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">Virologisk   svikt (hiv\u2011RNA &gt;200 kopior/ml)</span></p> </td> <td style=\"width:66.6pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:12.55pt\" valign=\"top\" width=\"89\"> <p class=\"TableParagraph\"><span lang=\"SV\">32 veckor</span></p> </td> <td style=\"width:75.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"100\"> <p class=\"TableParagraph\"><span lang=\"SV\">26 %</span></p> </td> <td style=\"width:86.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"116\"> <p class=\"TableParagraph\"><span lang=\"SV\">16 %</span></p> </td> <td style=\"width:111.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"149\"> <p class=\"TableParagraph\"><span lang=\"SV\">13 %</span></p> </td> </tr> <tr style=\"height:12.55pt\"> <td style=\"width:66.6pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:12.55pt\" valign=\"top\" width=\"89\"> <p class=\"TableParagraph\"><span lang=\"SV\">144 veckor</span></p> </td> <td style=\"width:75.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"100\"> <p class=\"TableParagraph\"><span lang=\"SV\">-</span></p> </td> <td style=\"width:86.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"116\"> <p class=\"TableParagraph\"><span lang=\"SV\">26 %</span></p> </td> <td style=\"width:111.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"149\"> <p class=\"TableParagraph\"><span lang=\"SV\">25 %</span></p> </td> </tr> <tr style=\"height:50.6pt\"> <td style=\"width:113.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"151\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.55pt;text-align:left\"></p> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">Virologisk   framg\u00e5ng (48 veckor hiv\u2011RNA &lt;50 kopior/ml)</span></p> </td> <td style=\"width:66.6pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:50.6pt\" valign=\"top\" width=\"89\"> <p class=\"TableParagraph\"></p> </td> <td style=\"width:75.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"100\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">63 %</span></p> </td> <td style=\"width:86.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"116\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">80 %</span></p> </td> <td style=\"width:111.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"149\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">86 %</span></p> </td> </tr> </table> <p class=\"MsoListParagraph\" style=\"margin-left:0in\"></p> <p class=\"MsoListParagraph\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"SV\" style=\"font-family:Symbol\">\u00b7</span><i><span lang=\"SV\">Behandlingserfarnavuxna</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\" style=\"text-align:justify\"><span lang=\"SV\">Till vuxna\r patienter med m\u00e5ttlig tidigare exponering f\u00f6r antiretrovirala l\u00e4kemedel gav\r till\u00e4gget av abakavir till befintlig antiretroviral kombinationsbehandling\r blygsamma effekter n\u00e4r det g\u00e4llde att <span style=\"position:relative;\r top:-1.0pt\">minska virusm\u00e4ngden (medianf\u00f6r\u00e4ndring 0,44 log<sub>10</sub></span> <span style=\"position:relative;top:-1.0pt\">kopior/ml vid 16 veckor).</span></span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Hos patienter med omfattande erfarenhet av behandling med NRTIs var effekten av abakavir marginell. V\u00e4rdet av att addera abakavir till en antiretroviral kombinationsbehandling beror p\u00e5 typ och duration av tidigare behandling, vilken kan ha selekterat fram hiv\u20111\u2011varianter med korsresistens mot abakavir.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Dosering (600 mg) en g\u00e5ng dagligen</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoListParagraph\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><span lang=\"SV\" style=\"font-family:Symbol\">\u00b7</span><i><span lang=\"SV\">Behandlingsnaivavuxna</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Dosering en g\u00e5ng dagligen st\u00f6ds av en 48\u2011veckors dubbelblind, kontrollerad mulitcenterstudie (CNA30021) p\u00e5 770 hivinfekterade terapinaiva vuxna, som huvudsakligen var symtomfria - Centre for Disease Control and Prevention (CDC) stadie A. De randomiserades till att f\u00e5 antingen 600 mg abakavir en g\u00e5ng dagligen eller 300 mg tv\u00e5 g\u00e5nger dagligen, i kombination med efavirenz och lamivudin som gavs en g\u00e5ng dagligen. Liknande klinisk framg\u00e5ng (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnad -1,7, 95 % CI -8,4, 4,9) s\u00e5gs i b\u00e5da behandlingsregimerna. Fr\u00e5n dessa resultat kan man dra slutsatsen att vid 95 % konfidens \u00e4r den verkliga skillnaden inte st\u00f6rre \u00e4n 8,4 % till f\u00f6rdel f\u00f6r tv\u00e5 g\u00e5nger dagligen doseringen. Denna potentiella skillnad \u00e4r tillr\u00e4ckligt liten f\u00f6r att kunna dra en generell slutsats av \u201dnon\u2011inferiority\u201d f\u00f6r abakavir en g\u00e5ng dagligen \u00f6ver abakavir tv\u00e5 g\u00e5nger dagligen.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Det var en l\u00e5g, likartad total incidens av virologisk svikt (virusm\u00e4ngd \u226450 kopior/ml) i b\u00e5de behandlingsgruppen med dosering en g\u00e5ng dagligen och den med dosering tv\u00e5 g\u00e5nger dagligen (10 % respektive 8 %). I den begr\u00e4nsade m\u00e4ngden prov som fanns tillg\u00e4ngliga f\u00f6r genotypisk analys fanns en trend mot ett h\u00f6gre antal NRTI\u2011mutationer vid dosering med abakavir en g\u00e5ng per dag j\u00e4mf\u00f6rt med dosering tv\u00e5 g\u00e5nger per dag. N\u00e5gon tydlig slutsats kunde inte dras p.g.a. den begr\u00e4nsade datam\u00e4ngden som kunde erh\u00e5llas fr\u00e5n denna studie. L\u00e5ngtidsdata f\u00f6r abakavir med dosering en g\u00e5ng dagligen (l\u00e4ngre \u00e4n 48 veckor) \u00e4r f\u00f6r n\u00e4rvarande begr\u00e4nsade.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoListParagraph\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><span lang=\"SV\" style=\"font-family:Symbol\">\u00b7</span><i><span lang=\"SV\">Behandlingserfarnavuxna</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.4pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">I studie CAL30001 randomiserades 182 behandlingserfarna\r patienter med virologisk svikt till behandling med antingen den fasta\r doskombinationen abakavir/lamivudin en g\u00e5ng dagligen eller abakavir 300 mg\r tv\u00e5 g\u00e5nger dagligen plus lamivudin 300 mg en g\u00e5ng dagligen, b\u00e5da i\r kombination med tenofovir och en PI eller en NNRTI under 48 veckor.\r Resultat visar att gruppen med fast doskombination inte var s\u00e4mre \u00e4n (non\r inferior) gruppen som fick abakavir tv\u00e5 g\u00e5nger per dag, baserat p\u00e5 en liknande\r nedg\u00e5ng av hiv\u20111\u2011RNA uppm\u00e4tt genom medelv\u00e4rdet av AUC minus\r baseline<span style=\"position:relative;top:-1.0pt\"> (AAUCMB, -1,65 log<sub>10</sub></span> <span style=\"position:relative;top:-1.0pt\">kopior/ml respektive -1,83 log<sub>10</sub></span> <span style=\"position:relative;top:-1.0pt\">kopior/ml, 95 % CI -0,13, 0,38). Andelen </span>patienter med hiv\u20111\u2011RNA &lt; 50 kopior/ml (50 %\r mot 47 %) och &lt;400 kopior/ml (54 % mot 57 %) var ocks\u00e5\r likartad i de b\u00e5da grupperna. Dessa resultat b\u00f6r emellertid tolkas med\r f\u00f6rsiktighet, eftersom endast patienter med m\u00e5ttlig behandlingserfarenhet\r ingick i denna studie och n\u00e4r behandling sattes in fanns en obalans i\r virusm\u00e4ngd mellan de b\u00e5da armarna.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">260 patienter med virologisk suppression p\u00e5 en f\u00f6rsta linjens terapi best\u00e5ende av abakavir 300 mg plus lamivudin 150 mg, b\u00e5da givna tv\u00e5 g\u00e5nger dagligen, i kombination med en PI eller NNRTI, randomiserades i en studie, ESS 30008, till att forts\u00e4tta denna regim eller att byta till den fasta kombinationen abakavir/lamivudin plus en PI eller NNRTI under 48 veckor. Resultat visar att gruppen med den fasta kombinationen uppn\u00e5dde samma virologiska utfall (\u201dnon\u2011inferior\u201d) som abakavir plus lamividingruppen, baserat p\u00e5 andelen individer med hiv\u20111\u2011RNA &lt;50 kopior/ml (90 % respektive 85 %, 95 % CI -2,7, 13,5).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Ytterligare information</span></i></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><span lang=\"SV\">Effekt och s\u00e4kerhet av abakavir givet som en del av olika kombinationsbehandlingar, \u00e4r fortfarande inte fullst\u00e4ndigt utredd (i synnerhet kombinationer med NNRTIs).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir penetrerar till cerebrospinalv\u00e4tskan (se avsnitt 5.2) och har visats minska niv\u00e5erna av hiv\u20111\u2011RNA i likvor. Dock noterades inga effekter p\u00e5 neuropsykologiska variabler n\u00e4r det gavs till patienter med AIDS\u2011relaterad demens.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\">Pediatrisk population</span></u></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">En randomiserad j\u00e4mf\u00f6relse av en doseringsregim med administrering av abakavir och lamivudin en g\u00e5ng dagligen j\u00e4mf\u00f6rt med tv\u00e5 g\u00e5nger dagligen genomf\u00f6rdes inom en randomiserad, multicenter, kontrollerad studie av hivinfekterade pediatriska patienter. 1 206 barn i \u00e5ldern 3 m\u00e5nader till 17 \u00e5r inkluderades i studien ARROW (COL105677) och doserades efter viktintervall enligt doseringsrekommendationerna i V\u00e4rldsh\u00e4lsoorganisationens behandlingsriktlinje (Antiretroviral behandling av hivinfektion hos sp\u00e4dbarn och barn, 2006). Efter 36 veckor p\u00e5 en regim med doseringen av abakavir och lamivudin tv\u00e5 g\u00e5nger dagligen randomiserades l\u00e4mpliga 669 patienter till att antingen forts\u00e4tta med dosering tv\u00e5 g\u00e5nger dagligen eller till att byta dosering till abakavir och lamivudin en g\u00e5ng dagligen under minst 96 veckor. Notera att fr\u00e5n denna studie erh\u00f6lls inga kliniska data f\u00f6r barn under ett \u00e5r. Resultaten sammanfattas i tabellen nedan:</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin-top:0in\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\r \"Times New Roman\",serif;color:windowtext'>Virologiskt svar baserat p\u00e5 plasma hiv-1 RNA l\u00e4gre \u00e4n 80 kopior/ml vid vecka 48 och vecka 96 hos personer som randomiserats i studien ARROW antingen till doseringen abakavir + lamivudin en g\u00e5ng dagligen eller tv\u00e5 g\u00e5nger dagligen. (observerad analys).</span></h1> <p class=\"MsoBodyText\" style=\"margin-top:.15pt\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:7.35pt;border-collapse:collapse;border:none\"> <tr style=\"height:25.3pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"></p> </td> <td style=\"width:120.85pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"161\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">Tv\u00e5 g\u00e5nger   dagligen N (%)</span></b></p> </td> <td style=\"width:155.55pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"207\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">En g\u00e5ng   dagligen N (%)</span></b></p> </td> </tr> <tr style=\"height:12.55pt\"> <td colspan=\"3\" style=\"width:446.5pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"595\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Vecka 0 (Efter \u2265 36 veckor p\u00e5   behandling)</span></b></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Plasma hiv-1 RNA &lt;80 kopior/ml</span></p> </td> <td style=\"width:120.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"161\"> <p class=\"TableParagraph\"><span lang=\"SV\">250/331 (76)</span></p> </td> <td style=\"width:155.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"207\"> <p class=\"TableParagraph\"><span lang=\"SV\">237/335 (71)</span></p> </td> </tr> <tr style=\"height:37.9pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Riskskillnad (en g\u00e5ng dagligen-tv\u00e5   g\u00e5nger dagligen)</span></p> </td> <td colspan=\"2\" style=\"width:276.4pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"369\"> <p class=\"TableParagraph\"><span lang=\"SV\">-4,8 % (95 % KI -11,5 %   till +1,9 %), p=0,16</span></p> </td> </tr> <tr style=\"height:12.55pt\"> <td colspan=\"3\" style=\"width:446.5pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"595\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Vecka 48</span></b></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Plasma hiv-1 RNA &lt;80 kopior/ml</span></p> </td> <td style=\"width:120.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"161\"> <p class=\"TableParagraph\"><span lang=\"SV\">242/331 (73)</span></p> </td> <td style=\"width:155.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"207\"> <p class=\"TableParagraph\"><span lang=\"SV\">236/330 (72)</span></p> </td> </tr> <tr style=\"height:37.9pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Riskskillnad (en g\u00e5ng dagligen-tv\u00e5   g\u00e5nger dagligen)</span></p> </td> <td colspan=\"2\" style=\"width:276.4pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"369\"> <p class=\"TableParagraph\"><span lang=\"SV\">-1,6 % (95 % KI -8,4 %   till +5,2 %), p=0,65</span></p> </td> </tr> <tr style=\"height:12.55pt\"> <td colspan=\"3\" style=\"width:446.5pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"595\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Vecka 96</span></b></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Plasma hiv\u20111 RNA &lt;80 kopior/ml</span></p> </td> <td style=\"width:120.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"161\"> <p class=\"TableParagraph\"><span lang=\"SV\">234/326 (72)</span></p> </td> <td style=\"width:155.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"207\"> <p class=\"TableParagraph\"><span lang=\"SV\">230/331 (69)</span></p> </td> </tr> <tr style=\"height:37.9pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Riskskillnad (en g\u00e5ng dagligen\u2013tv\u00e5   g\u00e5nger dagligen)</span></p> </td> <td colspan=\"2\" style=\"width:276.4pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"369\"> <p class=\"TableParagraph\"><span lang=\"SV\">-2,3 % (95 % KI -9,3 %   till +4,7 %), p=0,52</span></p> </td> </tr> </table> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Non\u2011inferiority uppvisades i gruppen som fick abakavir + lamivudin en g\u00e5ng dagligen j\u00e4mf\u00f6rt med gruppen som fick abakavir + lamivudin tv\u00e5 g\u00e5nger dagligen enligt den f\u00f6rbest\u00e4mda non-inferiority marginalen p\u00e5 -12 %, f\u00f6r prim\u00e4r endpoint &lt;80 kopior/ml vid vecka 48 samt vid vecka 96 (sekund\u00e4r endpoint) och alla andra testade gr\u00e4nsv\u00e4rden (&lt;200 kopior/ml, &lt;400 kopior/ml, &lt;1 000 kopior/ ml). Samtliga av dessa v\u00e4rden var v\u00e4l inom marginalen f\u00f6r non\u2011inferiority. Subgruppsanalyser med syfte att testa f\u00f6r heterogenitet vid en g\u00e5ng mot tv\u00e5 g\u00e5nger dagligen visade ingen signifikant p\u00e5verkan av k\u00f6n, \u00e5lder eller virusm\u00e4ngd vid randomisering. Slutsatserna st\u00f6dde non-inferiority oavsett analysmetod.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"margin-top:3.65pt\"><span lang=\"SV\">I en separat studie p\u00e5 barn d\u00e4r \u00f6ppna NRTI-kombinationer (med eller utan nelfinavir) j\u00e4mf\u00f6rdes hade en h\u00f6gre andel behandlade med abakavir och lamivudin (71 %) eller abakakvir och zidovudin (60 %) hiv-1-RNA \u2264400 kopior/ml efter 48 veckor j\u00e4mf\u00f6rt med dem behandlade med lamivudin och zidovudin (47%) (P = 0,09, Intention To Treat\u2011analys). Analogt med dessa resultat noterades h\u00f6gre procentsiffror f\u00f6r de barn som behandlades med abakavirinneh\u00e5llande regimer vad g\u00e4ller hiv-1-RNA \u226450 kopior/ml efter 48 veckor (53 %, 42 % respektive 28 %; P = 0,07).</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"margin-top:4.55pt\"><span lang=\"SV\">I en farmakokinetisk studie (PENTA 15), bytte fyra virologiskt kontrollerade patienter som var yngre \u00e4n 12 m\u00e5nader gamla fr\u00e5n abakavir plus lamivudin oral l\u00f6sning tv\u00e5 g\u00e5nger dagligen till doseringsregimen en g\u00e5ng dagligen. Tre av patienterna hade om\u00e4tbara virusniv\u00e5er och en hade plasma hiv\u2011RNA p\u00e5 900 kopior/ml vid vecka 48. Inga s\u00e4kerhetsproblem observerades hos dessa patienter.</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>5.2</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Farmakokinetiskaegenskaper</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Absorption</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir absorberas snabbt och v\u00e4l efter\r oral tillf\u00f6rsel. Den absoluta biotillg\u00e4ngligheten hos vuxna <span style=\"position:relative;top:-1.0pt\">efter oralt intag \u00e4r ca 83 %. Efter\r oral administrering \u00e4r den genomsnittliga tiden (t<sub>max</sub>) till maximala\r serumkoncentrationer (C<sub>max</sub>) av abakavir ca 1,5 timmar f\u00f6r\r tablettberedningen och ca 1,0 timmar f\u00f6r </span>l\u00f6sningen.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.2pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\" style=\"position:relative;top:-1.0pt\">Vid\r terapeutisk dosering med dosen 300 mg tv\u00e5 g\u00e5nger dagligen \u00e4r medelv\u00e4rdet\r (CV) av C<sub>max</sub> och C<sub>min</sub></span><span lang=\"SV\"> f\u00f6r abakavir\r vid steady\u2011state ca 3,00 mikrogram/ml (30 %) respektive 0,01\r mikrogram/ml (99 %). Medelv\u00e4rdet (CV) f\u00f6r AUC var \u00f6ver ett dosintervall p\u00e5\r 12 timmar 6,02 mikrogram timme/ml (29 %) <span style=\"position:\r relative;top:-1.0pt\">motsvarande ett dagligt AUC p\u00e5 ca 12,0 mikrogram\r timme/ml. C<sub>max</sub>\u2011v\u00e4rdet f\u00f6r den orala l\u00f6sningen \u00e4r n\u00e5got h\u00f6gre\r \u00e4n f\u00f6r tabletterna. Efter en tablettdos p\u00e5 600 mg abakavir var medelv\u00e4rdet (CV)\r f\u00f6r C<sub>max</sub> </span>ca 4,26 mikrogram/ml (28 %) och\r medelv\u00e4rdet (CV) av AUC<sub>\u221e</sub> var 11,95 mikrogram timme/ml (21 %).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.2pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\" style=\"position:relative;top:-1.0pt\">F\u00f6da\r f\u00f6rdr\u00f6jer absorptionen och minskar C<sub>max</sub></span><span lang=\"SV\"> <span style=\"position:relative;top:-1.0pt\">men p\u00e5verkar inte de totala plasmakoncentrationerna </span>(AUC). Abacavir Accord kan d\u00e4rf\u00f6r tas med eller\r utan f\u00f6da.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Administrering av krossade tabletter med en liten m\u00e4ngd halvfast f\u00f6da eller dryck f\u00f6rv\u00e4ntas inte ha n\u00e5gon p\u00e5verkan p\u00e5 den farmaceutiska kvaliteten och borde d\u00e4rf\u00f6r inte f\u00f6r\u00e4ndra den kliniska effekten. Denna slutsats baseras p\u00e5 fysiologisk-kemiska och farmakokinetiska data och f\u00f6ruts\u00e4tter att patienten krossar och intar hela dosen (100 % av tabletten) omedelbart.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Distribution</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Efter intraven\u00f6s administrering var distributionsvolymen ca 0,8 liter/kg, vilket talar f\u00f6r att abakavir fritt penetrerar till kroppens v\u00e4vnader.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Studier p\u00e5 hivinfekterade patienter har\r visat god penetration av abakavir till CSF, AUC-ratio i likvor/plasma p\u00e5 30\r till 44 %. N\u00e4r abakavir ges i dosen 600 mg tv\u00e5 g\u00e5nger dagligen \u00e4r\r observerade <span style=\"position:relative;top:-1.0pt\">maximala koncentrationer\r i likvor 9 g\u00e5nger h\u00f6gre \u00e4n abakavirs IC<sub>50</sub></span> <span style=\"position:relative;top:-1.0pt\">som \u00e4r 0,08 mikrog/ml eller 0,26 </span>mikroM.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">In vitro</span></i><span lang=\"SV\">-studier avseende bindning till plasmaproteiner pekar p\u00e5 att abakavir endast har en l\u00e5g till m\u00e5ttlig bindningsgrad (ca 49 %) till humana plasmaproteiner vid terapeutiska koncentrationer. Detta talar f\u00f6r en l\u00e5g risk f\u00f6r l\u00e4kemedelsinteraktioner genom p\u00e5verkan p\u00e5 plasmaproteinbindning.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Metabolism</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir metaboliseras huvudsakligen i levern med cirka 2 % av den administrerade dosen uts\u00f6ndrad renalt i of\u00f6r\u00e4ndrad form. Huvudsaklig metabolismv\u00e4g hos m\u00e4nniska \u00e4r via alkoholdehydrogenas och via glukuronidering varvid 5\u00b4\u2011karboxylsyra och 5\u00b4\u2011glukuronid bildas. Dessa utg\u00f6r omkring 66 % av administrerad dos. Metaboliterna uts\u00f6ndras i urinen.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Eliminering</span></u></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Den genomsnittliga halveringstiden f\u00f6r abakavir \u00e4r ca 1,5 timmar. Det sker ingen signifikant ackumulering av abakavir efter upprepade orala doser av 300 mg tv\u00e5 g\u00e5nger dagligen. Eliminationen av abakavir sker via levermetabolism med efterf\u00f6ljande uts\u00f6ndring av metaboliter i f\u00f6rsta hand i urinen. I urinen \u00e5terfinns omkring 83 % av administrerad abakavirdos som metaboliter och of\u00f6r\u00e4ndrat abakavir. Resten av dosen elimineras via feces.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><u><span lang=\"SV\">Intracellul\u00e4r farmakokinetik</span></u></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">I en studie p\u00e5 20 hivinfekterade\r patienter som fick 300 mg abakavir tv\u00e5 g\u00e5nger dagligen, med bara en 300 mg\r dos tagen f\u00f6re provtagningsperioden p\u00e5 24\u2011timmar, var det geometriska\r terminala medelv\u00e4rdet f\u00f6r halveringstiden av intracellul\u00e4rt carbovir\u2011TP\r vid steady\u2011state 20,6 timmar, j\u00e4mf\u00f6rt med 2,6 timmar som var\r det uppm\u00e4tta geometriska medelv\u00e4rdet f\u00f6r halveringstiden av abakavir i plasma i\r denna studie. I en cross\u2011over\u2011studie med 27 hivinfekterade\r patienter var exponeringen f\u00f6r intracellul\u00e4rt<span style=\"position:relative;\r top:-1.0pt\"> carbovir\u2011TP h\u00f6gre f\u00f6r abakavir 600 mg en g\u00e5ng dagligen (AUC</span><sub>24,ss</sub> <span style=\"position:relative;top:-1.0pt\">+32%, C</span><sub>max24,ss\r </sub><span style=\"position:relative;top:-1.0pt\">+99% ochC</span><sub>trough</sub> +18 %)\r j\u00e4mf\u00f6rt med 300 mg tv\u00e5 g\u00e5nger dagligen. Sammantaget st\u00f6der dessa data anv\u00e4ndning\r av abakavir 600 mg en g\u00e5ng dagligen f\u00f6r behandling av hivinfekterade\r patienter. Dessutom har effekten och s\u00e4kerheten av abakavir doserat en g\u00e5ng\r dagligen visats i en pivotal klinisk studie (CNA30021 \u2013 Se avsnitt 5.1\r Klinisk erfarenhet).</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.4pt\"></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\">Speciella patientgrupper</span></u></p> <p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p> <p class=\"MsoBodyText\"><i><span lang=\"SV\">Nedsatt leverfunktion</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"><span lang=\"SV\">Abakavir metaboliseras huvudsakligen i levern. Abakavirs farmakokinetik har studerats hos patienter med mild leverfunktionsneds\u00e4ttning (Child\u2011Pugh score 5\u20116) vilka erh\u00f6ll 600 mg abakavir som en singeldos, median (intervall) AUC\u2011v\u00e4rdet var 24,1 (10,4 till 54,8) \u00b5g\u00b7h/ml. Resultaten visade att abakavirs genomsnittliga AUC (90 % CI) \u00f6kar 1,89 g\u00e5nger (1,32; 2,70) och att halveringstiden f\u00f6r abakavir \u00f6kar i genomsnitt 1,58 g\u00e5nger (1,22; 2,04). P\u00e5 grund av v\u00e4sentligt varierande abakavirexponeringar var det inte m\u00f6jligt att fastst\u00e4lla n\u00e5gon definitiv rekommendation f\u00f6r hur stor dosreduktion som beh\u00f6vs hos patienter med mild neds\u00e4ttning av leverfunktionen.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir rekommenderas inte till patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Nedsattnjurfunktion</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"><span lang=\"SV\">Abakavir\r metaboliseras huvudsakligen i levern. Cirka 2 % av given dos abakavir\r uts\u00f6ndras of\u00f6r\u00e4ndrad i urinen. Abakavirs farmakokinetik hos patienter med\r njursjukdom i slutstadiet \u00e4r likartad den hos patienter med normal\r njurfunktion. D\u00e4rf\u00f6r beh\u00f6vs inte n\u00e5gon dosreduktion hos patienter med nedsatt\r njurfunktion. P\u00e5 grund av den begr\u00e4nsade erfarenheten b\u00f6r Abacavir Accord\r undvikas hos patienter med gravt nedsattnjurfunktion.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><u><span lang=\"SV\">Pediatrisk population</span></u></p> <p class=\"MsoBodyText\" style=\"margin-top:.1pt\"><span lang=\"SV\">Enligt studier utf\u00f6rda p\u00e5 barn absorberas abakavir snabbt och v\u00e4l efter intag av oral l\u00f6sning och tablettformuleringar. Exponeringen av abakavir i plasma har visat sig vara densamma f\u00f6r b\u00e5da formuleringarna n\u00e4r de administreras med samma dosering. Barn som f\u00e5r abakavir oral l\u00f6sning enligt rekommenderad doseringsregim uppn\u00e5r liknande exponering av abakavir i plasma som hos vuxna.</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Barn som f\u00e5r abakavir orala tabletter enligt rekommenderad doseringsregim uppn\u00e5r h\u00f6gre exponering av abakavir i plasma \u00e4n barn som f\u00e5r oral l\u00f6sning eftersom h\u00f6gre doser i mg/kg administreras med tabletten.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r n\u00e4rvarande saknas tillr\u00e4ckligt med s\u00e4kerhetsdata f\u00f6r att kunna rekommendera Abacavir Accord till barn yngre \u00e4n tre m\u00e5nader. De begr\u00e4nsade data som f\u00f6religger pekar p\u00e5 att dosen 2 mg/kg oral l\u00f6sning till barn yngre \u00e4n 30 dagar ger upphov till liknande eller h\u00f6gre AUC j\u00e4mf\u00f6rt med dosen 8 mg/kg oral l\u00f6sning till \u00e4ldre barn.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Farmakokinetisk data har erh\u00e5llits fr\u00e5n 3 farmakokinetiska studier (PENTA 13, PENTA 15 och substudien ARROW PK) p\u00e5 barn yngre \u00e4n 12 \u00e5r gamla. Data visas i tabellen nedan: </span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">Sammanfattning av abakavir AUC (0\u201124) (mikrog.h/ml) i plasma vid steady state och statistiska j\u00e4mf\u00f6relser f\u00f6r oral administrering en och tv\u00e5 g\u00e5nger dagligen mellan olika studier</span></b></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt;page-break-after:avoid\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:11.5pt;border-collapse:collapse;border:none\"> <tr style=\"height:98.0pt\"> <td style=\"width:89.4pt;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">Studie</span></b></p> </td> <td style=\"width:91.1pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">\u00c5ldersgrupp</span></b></p> </td> <td style=\"width:91.1pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">Abakavir</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">16 mg/kg Dosering <span style=\"letter-spacing:-.35pt\">en </span>g\u00e5ng\r   <span style=\"letter-spacing:-.15pt\">dagligen </span>Geometriskt medelv\u00e4rde</span></b></p> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">(95%   KI)</span></b></p> </td> <td style=\"width:91.1pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">Abakavir</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">8 mg/kg Dosering tv\u00e5 g\u00e5nger dagligen Geometriskt medelv\u00e4rde</span></b></p> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">(95%   KI)</span></b></p> </td> <td style=\"width:90.25pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">J\u00e4mf\u00f6relse mellan dosering en och tv\u00e5 g\u00e5nger dagligen GLS mean ratio   (90 % Kl)</span></b></p> </td> </tr> <tr style=\"height:14.85pt\"> <td style=\"width:89.4pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">ARROW PK</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">3 till 12 \u00e5r</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">15,3</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">15,6</span></p> </td> <td style=\"width:90.25pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">0,98</span></p> </td> </tr> <tr style=\"height:13.95pt\"> <td style=\"width:89.4pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">Substudie</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(N=36)</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(13,3\u201117,5)</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(13,7\u201117,8)</span></p> </td> <td style=\"width:90.25pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(0,89, 1,08)</span></p> </td> </tr> <tr style=\"height:13.1pt\"> <td style=\"width:89.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">Del 1</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:90.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> </tr> <tr style=\"height:14.85pt\"> <td style=\"width:89.4pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">PENTA 13</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">2 till 12 \u00e5r</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">13,4</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">9,91</span></p> </td> <td style=\"width:90.25pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">1,35</span></p> </td> </tr> <tr style=\"height:13.05pt\"> <td style=\"width:89.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(N=14)</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(11,8-15,2)</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(8,3-11,9)</span></p> </td> <td style=\"width:90.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(1,19-1,54)</span></p> </td> </tr> <tr style=\"height:14.9pt\"> <td style=\"width:89.4pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">PENTA 15</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">3 till 36 m\u00e5nader</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">11,6</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">10,9</span></p> </td> <td style=\"width:90.25pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">1,07</span></p> </td> </tr> <tr style=\"height:13.1pt\"> <td style=\"width:89.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">(N=18)</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">(9,89-13,5)</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">(8,9-13,2)</span></p> </td> <td style=\"width:90.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">(0,92-1,23)</span></p> </td> </tr> </table> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r de fyra patienterna i studien PENTA 15 som var under 12 m\u00e5nader och som bytte fr\u00e5n doseringsregimen tv\u00e5 g\u00e5nger dagligen till en g\u00e5ng dagligen (se avsnitt 5.1) var det geometriska medelv\u00e4rdet f\u00f6r AUC (0\u201124) (95 % KI) f\u00f6r lamivudin i plasma 15,9 (8,86, 28,5) \u00b5g.h/ml vid dosering en g\u00e5ng dagligen och 12,7 (6,52, 24,6) \u00b5g.h/ml vid dosering tv\u00e5 g\u00e5nger dagligen.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">\u00c4ldre</span></i></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavirs farmakokinetik har inte studerats hos patienter \u00e4ldre \u00e4n 65 \u00e5r.</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>5.3</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Prekliniskas\u00e4kerhetsuppgifter</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir var inte mutagent i bakterietester\r men visade aktivitet <i>in vitro </i>i kromosomaberrationstest utf\u00f6rt p\u00e5\r humana lymfocyter, muslymfomtest och <i>in vivo </i>i mikrok\u00e4rntest. Detta\r \u00f6verensst\u00e4mmer med k\u00e4nda effekter av andra nukleosidanaloger<i>. </i>Dessa\r resultat indikerar att abakavir vid h\u00f6ga koncentrationer, s\u00e5v\u00e4l <i>in vitro </i>som <i>in vivo</i>, medf\u00f6r liten risk f\u00f6r kromosomskador<i>.</i></span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Karcinogenicitetsstudier med oralt administrerat abakavir till mus och r\u00e5tta visade en \u00f6kning av incidensen maligna och icke-maligna tum\u00f6rer. Maligna tum\u00f6rer intr\u00e4ffade i preputialk\u00f6rteln hos handjur och i klitoralk\u00f6rteln hos hondjur av b\u00e5da djurslagen och hos hanr\u00e5ttor i tyreoidea samt hos honr\u00e5ttor i levern, urinbl\u00e5san, lymfk\u00f6rtlarna och i underhuden.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Majoriteten av dessa tum\u00f6rer intr\u00e4ffade vid den h\u00f6gsta abakavirdosen p\u00e5 330 mg/kg/dag hos mus och 600 mg/kg/dag hos r\u00e5tta med undantag av tum\u00f6rerna i preputialk\u00f6rteln som uppkom hos m\u00f6ss vid dosen 110 mg/kg. Den systemiska exponeringen vid de h\u00f6gsta dosniv\u00e5er d\u00e5 ingen effekt konstaterats hos m\u00f6ss och r\u00e5ttor motsvarade 3 respektive 7 g\u00e5nger den humana exponeringen vid rekommenderad dosering. S\u00e5 l\u00e4nge som abakavirs karcinogena potential hos m\u00e4nniska \u00e4r ok\u00e4nd, talar dessa data f\u00f6r att l\u00e4kemedlets potentiella kliniska f\u00f6rdelar \u00f6verv\u00e4ger risken f\u00f6r karcinogena effekter hos m\u00e4nniska.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">I prekliniska toxikologiska studier visades behandling med abakavir \u00f6ka levervikterna hos r\u00e5tta och apa. Den kliniska betydelsen av detta \u00e4r inte k\u00e4nd. Fr\u00e5n kliniska studier finns inga fynd som visar att abakavir \u00e4r levertoxiskt. Dessutom har hos m\u00e4nniska inte observerats autoinduktion av abakavirs metabolism eller induktion av andra l\u00e4kemedels metabolism i levern.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Mild myokardiell degeneration i hj\u00e4rtat hos mus och r\u00e5tta observerades efter administrering av abakavir under tv\u00e5 \u00e5r. De systemiska exponeringarna motsvarade 7 till 24 g\u00e5nger den f\u00f6rv\u00e4ntade systemiska exponeringen hos m\u00e4nniska. Den kliniska relevansen av dessa fynd har inte kunnat avg\u00f6ras.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">I reproduktionstoxikologiska studier har hos r\u00e5tta noterats embryonal och fetal toxicitet men inte hos kanin. Dessa fynd omfattade minskad kroppsvikt och \u00f6dem hos fostren, en \u00f6kning av antalet skelettf\u00f6r\u00e4ndringar/missbildningar samt ett \u00f6kat antal tidiga intrauterina d\u00f6dsfall och antalet d\u00f6df\u00f6dda djur. P\u00e5 grund av denna embryonala/fetala toxicitet kan inga slutsatser dras avseende abakavirs teratogena potential.</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">En fertilitetsstudie p\u00e5 r\u00e5tta har visat att abakavir inte har n\u00e5gon effekt p\u00e5 fertiliteten hos han- eller hondjur.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>FARMACEUTISKAUPPGIFTER</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoListParagraph\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><b><span lang=\"SV\">6.1</span></b><b><span lang=\"SV\">F\u00f6rteckning \u00f6verhj\u00e4lp\u00e4mnen</span></b></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">K\u00e4rna:</span></i></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Mikrokristallin cellulosa PH102 (E460)</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Natriumst\u00e4rkelseglykolat (typ A)</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Kiseldioxid, kolloidal vattenfri</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Magnesiumstearat (E470b)</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><i><span lang=\"SV\">Filmdragering:</span></i></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Polyvinylalkohol, delvis hydrolyserad (E1203)</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Titandioxid (E171)</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Talk (E553b)</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">J\u00e4rnoxid (gul) (E172)</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Makrogol (E1521)</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.2</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Inkompatibiliteter</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Ej relevant</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.3</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>H\u00e5llbarhet</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">2 \u00e5r</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>6.4</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>S\u00e4rskildaf\u00f6rvaringsanvisningar</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Inga s\u00e4rskild f\u00f6rvaringanvisningar.</span></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.5</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>F\u00f6rpackningstyp ochinneh\u00e5ll</span></h1> <p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Vitt ogenomskinligt blister av PVC\u2011aluminium inneh\u00e5llande 30, 60, 90 och 120 tabletter.</span></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Blister av aluminium\u2011aluminium inneh\u00e5llande 30, 60, 90 och 120 tabletter.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Eventuellt kommer inte alla f\u00f6rpackningsstorlekar att marknadsf\u00f6ras.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.6</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>S\u00e4rskilda anvisningar f\u00f6rdestruktion</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">Inga s\u00e4rskilda anvisningar f\u00f6r destruktion.</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>7.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>INNEHAVARE AV GODK\u00c4NNANDE F\u00d6RF\u00d6RS\u00c4LJNING</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoNormal\"><span lang=\"SV\">Accord Healthcare B.V.</span></p> <p class=\"MsoNormal\"><span lang=\"SV\">Winthontlaan 200</span></p> <p class=\"MsoNormal\"><span lang=\"SV\">3526 KV Utrecht</span></p> <p class=\"MsoNormal\"><span lang=\"SV\">Nederl\u00e4nderna</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>8.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>NUMMER P\u00c5 GODK\u00c4NNANDE F\u00d6RF\u00d6RS\u00c4LJNING</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">59643</span></p> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>9.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>DATUM F\u00d6R F\u00d6RSTA GODK\u00c4NNANDE/F\u00d6RNYATGODK\u00c4NNANDE</span></h1> <p class=\"MsoBodyText\"></p> <p class=\"MsoBodyText\"><span lang=\"SV\">2020-06-22/2021-07-25</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p> <h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>10.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>DATUM F\u00d6R \u00d6VERSYN AVPRODUKTRESUM\u00c9N</span></h1> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"><span lang=\"SV\">2020-12-22</span></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p> <p class=\"MsoNormal\"><span lang=\"SV\">Ytterligare information om detta l\u00e4kemedel\r finns p\u00e5 L\u00e4kemedelsverkets webbplats <a href=\"http://www.lakemedelsverket.se\">www.lakemedelsverket.se</a> </span></p> </div>", "ID": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25", "Styles": "None", "Classes": "['WordSection3']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "                                                                                                                                                                                                                                                                                                                  ", "ParentId": "10f0b632-e318-49fa-bb29-a7c876358dac"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:3.65pt\"><span lang=\"SV\">dessa symtom ska d\u00e4rf\u00f6r noggrant utv\u00e4rderas r\u00f6rande f\u00f6rekomst av s\u00e5dan \u00f6verk\u00e4nslighet (se avsnitt 4.4). Mycket s\u00e4llsynta fall av erythema multiforme, Stevens Johnsons syndrom eller toxisk epidermal nekrolys har rapporterats d\u00e4r \u00f6verk\u00e4nslighet mot abakavir inte kunnat uteslutas. I dessa fall ska behandling med abakavir avbrytas f\u00f6r all framtid.</span></p>", "ID": "c09af69b-a829-43dd-ab35-240c6bf9d85e", "Styles": "margin-top:3.65pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "dessa symtom ska d\u00e4rf\u00f6r noggrant utv\u00e4rderas r\u00f6rande f\u00f6rekomst av s\u00e5dan \u00f6verk\u00e4nslighet (se avsnitt 4.4). Mycket s\u00e4llsynta fall av erythema multiforme, Stevens Johnsons syndrom eller toxisk epidermal nekrolys har rapporterats d\u00e4r \u00f6verk\u00e4nslighet mot abakavir inte kunnat uteslutas. I dessa fall ska behandling med abakavir avbrytas f\u00f6r all framtid.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p>", "ID": "245fda07-d1e4-498b-8abb-82bd83842f41", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">M\u00e5nga av de medicinska incidenterna har inte lett till att behandlingen beh\u00f6vt avbrytas. F\u00f6ljande indelning har anv\u00e4nts f\u00f6r klassificering mycket vanlig (&gt;1/10), vanlig (&gt;1/100, &lt;1/10), mindre vanlig (&gt;1/1 000, &lt;1/100), s\u00e4llsynt (&gt;1/10 000, &lt;1/1 000), mycket s\u00e4llsynt (&lt;1/10 000).</span></p>", "ID": "5e79885f-e086-4b15-83df-f70ce8de1627", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "M\u00e5nga av de medicinska incidenterna har inte lett till att behandlingen beh\u00f6vt avbrytas. F\u00f6ljande indelning har anv\u00e4nts f\u00f6r klassificering mycket vanlig (>1/10), vanlig (>1/100, <1/10), mindre vanlig (>1/1 000, <1/100), s\u00e4llsynt (>1/10 000, <1/1 000), mycket s\u00e4llsynt (<1/10 000).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "a115ea5f-a44a-424e-b828-e94a1709baf0", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><u><span lang=\"SV\">Metabolism och nutrition</span></u></p>", "ID": "752f7884-05fb-419b-b4cb-ea365fe0214d", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Metabolism och nutrition", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"f6b5ec02-ffd0-4ca3-a845-c866b5dade7a\" style=\"margin-top:.05pt\"></p><i><span lang=\"SV\">Vanlig: </span></i><none></none>", "ID": "dc4b82d3-4f6f-4716-8e4e-d71bb34e1903", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Vanlig: ", "startWith<upper>Text": null, "Text": "Vanlig: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"f6b5ec02-ffd0-4ca3-a845-c866b5dade7a\" style=\"margin-top:.05pt\"><span lang=\"SV\">anorexia</span></p>", "ID": "f6b5ec02-ffd0-4ca3-a845-c866b5dade7a", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Vanlig: ", "startWith<upper>Text": null, "Text": "anorexia", "ParentId": "dc4b82d3-4f6f-4716-8e4e-d71bb34e1903"}, {"Element": "<p class=\"MsoNormal\" id=\"654c634d-6d9f-4350-b9d2-fe3e99b230f3\"></p><i><span lang=\"SV\">Mycket s\u00e4llsynt: </span></i><none></none>", "ID": "206390ae-99c7-4082-b317-5a504102f2ab", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Mycket s\u00e4llsynt: ", "startWith<upper>Text": null, "Text": "Mycket s\u00e4llsynt: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"654c634d-6d9f-4350-b9d2-fe3e99b230f3\"><span lang=\"SV\">laktacidos</span></p>", "ID": "654c634d-6d9f-4350-b9d2-fe3e99b230f3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Mycket s\u00e4llsynt: ", "startWith<upper>Text": null, "Text": "laktacidos", "ParentId": "206390ae-99c7-4082-b317-5a504102f2ab"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "48a5f958-7bf3-431b-a6fa-9d5716b8cad4", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Centrala och perifera nervsystemet</span></u></p>", "ID": "7870aea5-2ac4-49ea-baeb-d3faf74473c7", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Centrala och perifera nervsystemet", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"899e0a2b-190f-4907-a606-1c35879d68aa\"></p><i><span lang=\"SV\">Vanlig: </span></i><none></none>", "ID": "87cdfa67-ca16-4bff-b9c3-aa9c057c2936", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Vanlig: ", "startWith<upper>Text": null, "Text": "Vanlig: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"899e0a2b-190f-4907-a606-1c35879d68aa\"><span lang=\"SV\">huvudv\u00e4rk</span></p>", "ID": "899e0a2b-190f-4907-a606-1c35879d68aa", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Vanlig: ", "startWith<upper>Text": null, "Text": "huvudv\u00e4rk", "ParentId": "87cdfa67-ca16-4bff-b9c3-aa9c057c2936"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "a683fa38-6b27-400b-82b1-b676c803206a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"0eeff938-47b8-4e2e-aebd-59b2768c8f50\"></p><u><span lang=\"SV\">Magtarmkanalen</span></u><none></none>", "ID": "d1a33d82-7883-4ad8-a169-63e9f3755e1c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": true, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": "Magtarmkanalen ", "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Magtarmkanalen", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"0eeff938-47b8-4e2e-aebd-59b2768c8f50\"><span lang=\"SV\"> <i>Vanlig: </i>illam\u00e5ende, kr\u00e4kningar, diarr\u00e9</span></p>", "ID": "0eeff938-47b8-4e2e-aebd-59b2768c8f50", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": null, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": true, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": "Magtarmkanalen ", "startWith<i>Text": null, "startWith<upper>Text": null, "Text": " Vanlig: illam\u00e5ende, kr\u00e4kningar, diarr\u00e9", "ParentId": "d1a33d82-7883-4ad8-a169-63e9f3755e1c"}, {"Element": "<p class=\"MsoNormal\" id=\"0aedbb99-21a4-456e-abeb-6bd21f0be5ff\"></p><i><span lang=\"SV\">S\u00e4llsynt: </span></i><none></none>", "ID": "5e9022d3-810c-43dc-a32b-3d64f092de96", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "S\u00e4llsynt: ", "startWith<upper>Text": null, "Text": "S\u00e4llsynt: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"0aedbb99-21a4-456e-abeb-6bd21f0be5ff\"><span lang=\"SV\">pankreatit</span></p>", "ID": "0aedbb99-21a4-456e-abeb-6bd21f0be5ff", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "S\u00e4llsynt: ", "startWith<upper>Text": null, "Text": "pankreatit", "ParentId": "5e9022d3-810c-43dc-a32b-3d64f092de96"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "df6bedf8-86c0-45c4-aff4-c013530de879", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Hud och subkutan v\u00e4vnad</span></u></p>", "ID": "f53efadc-0a93-43ca-9498-3fee0bcb3983", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Hud och subkutan v\u00e4vnad", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"ab0d3097-5565-4c9a-8924-3c7614590922\" style=\"margin-top:.1pt\"></p><i><span lang=\"SV\">Vanlig: </span></i><none></none>", "ID": "d5cb7315-dd99-4d02-b29d-12da265ac7eb", "Styles": "margin-top:.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Vanlig: ", "startWith<upper>Text": null, "Text": "Vanlig: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"ab0d3097-5565-4c9a-8924-3c7614590922\" style=\"margin-top:.1pt\"><span lang=\"SV\">utslag (utan systemiska symtom)</span></p>", "ID": "ab0d3097-5565-4c9a-8924-3c7614590922", "Styles": "margin-top:.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Vanlig: ", "startWith<upper>Text": null, "Text": "utslag (utan systemiska symtom)", "ParentId": "d5cb7315-dd99-4d02-b29d-12da265ac7eb"}, {"Element": "<p class=\"MsoBodyText\" id=\"7674a899-de60-4bdc-8759-1ec0670033a5\"></p><i><span lang=\"SV\">Mycket s\u00e4llsynt: </span></i><none></none>", "ID": "d9198c15-a170-4b8f-b61e-992889f881b7", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Mycket s\u00e4llsynt: ", "startWith<upper>Text": null, "Text": "Mycket s\u00e4llsynt: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"7674a899-de60-4bdc-8759-1ec0670033a5\"><span lang=\"SV\">erythema multiforme, Steven\u2011Johnsons syndrom och toxisk epidermal nekrolys</span></p>", "ID": "7674a899-de60-4bdc-8759-1ec0670033a5", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Mycket s\u00e4llsynt: ", "startWith<upper>Text": null, "Text": "erythema multiforme, Steven\u2011Johnsons syndrom och toxisk epidermal nekrolys", "ParentId": "d9198c15-a170-4b8f-b61e-992889f881b7"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "bde85d64-4e9f-47f1-99bd-1ecdcf545451", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Allm\u00e4nna symtom och/eller symtom vid administreringsst\u00e4llet</span></u></p>", "ID": "a08321f0-ee23-44c5-bf9c-c4af7ff81ddd", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Allm\u00e4nna symtom och/eller symtom vid administreringsst\u00e4llet", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"6bdcdbd2-a581-4fe7-bae7-f7236901b0e6\"></p><i><span lang=\"SV\">Vanlig: </span></i><none></none>", "ID": "a8de8b82-435d-44d5-afbc-0566a9897275", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Vanlig: ", "startWith<upper>Text": null, "Text": "Vanlig: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"6bdcdbd2-a581-4fe7-bae7-f7236901b0e6\"><span lang=\"SV\">feber, letargi, tr\u00f6tthet </span></p>", "ID": "6bdcdbd2-a581-4fe7-bae7-f7236901b0e6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Vanlig: ", "startWith<upper>Text": null, "Text": "feber, letargi, tr\u00f6tthet ", "ParentId": "a8de8b82-435d-44d5-afbc-0566a9897275"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "8030279f-6887-496f-8e83-78abae624864", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Beskrivning av ett urval biverkningar</span></u></p>", "ID": "0a49ad8e-ac5a-41b7-8ce3-2eb5ad0e9fae", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Beskrivning av ett urval biverkningar", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt;text-align:justify\"><i><u><span lang=\"SV\"></span></u></i></p>", "ID": "a71d34f5-823b-4775-b343-8a37e127d887", "Styles": "margin-top:.05pt;text-align:justify", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt;text-align:justify\"><i><u><span lang=\"SV\">\u00d6verk\u00e4nslighetsreaktion mot abakavir</span></u></i></p>", "ID": "617232f6-6129-4b2c-b5c0-cafed532b8c7", "Styles": "margin-top:.05pt;text-align:justify", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00d6verk\u00e4nslighetsreaktion mot abakavir", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"text-align:justify\"><span lang=\"SV\">Tecken och symtom\r p\u00e5 denna \u00f6verk\u00e4nslighetsreaktion redovisas nedan. De har identifierats antingen\r i kliniska studier eller i s\u00e4kerhets\u00f6vervakningen vid normal klinisk\r anv\u00e4ndning. De som markerats med \u2019fetstil \u2019 har rapporterats <b>hos minst 10 % </b>av patienterna med \u00f6verk\u00e4nslighetsreaktion.</span></p>", "ID": "c1ac7b3b-63b7-43ac-af44-b9626ce6fb66", "Styles": "text-align:justify", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Tecken och symtom p\u00e5 denna \u00f6verk\u00e4nslighetsreaktion redovisas nedan. De har identifierats antingen i kliniska studier eller i s\u00e4kerhets\u00f6vervakningen vid normal klinisk anv\u00e4ndning. De som markerats med \u2019fetstil \u2019 har rapporterats hos minst 10 % av patienterna med \u00f6verk\u00e4nslighetsreaktion.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "d2b14bc6-be16-4e64-be04-97d341f1ca18", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">N\u00e4stan alla patienter som utvecklar \u00f6verk\u00e4nslighetsreaktioner f\u00e5r feber och/eller hudutslag (vanligen makulopapul\u00e4ra eller urtikariella) som delsymtom men fall av \u00f6verk\u00e4nslighet utan hudutslag eller feber har intr\u00e4ffat. Andra huvudsymtom \u00e4r symtom fr\u00e5n magtarmkanalen och andningsv\u00e4garna samt allm\u00e4nna symtom som letargi och allm\u00e4n sjukdomsk\u00e4nsla.</span></p>", "ID": "ae24a212-84b5-4314-894a-1bf3a3c4917c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "N\u00e4stan alla patienter som utvecklar \u00f6verk\u00e4nslighetsreaktioner f\u00e5r feber och/eller hudutslag (vanligen makulopapul\u00e4ra eller urtikariella) som delsymtom men fall av \u00f6verk\u00e4nslighet utan hudutslag eller feber har intr\u00e4ffat. Andra huvudsymtom \u00e4r symtom fr\u00e5n magtarmkanalen och andningsv\u00e4garna samt allm\u00e4nna symtom som letargi och allm\u00e4n sjukdomsk\u00e4nsla.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"b0fb6f02-b2b0-4fb8-8541-e5ae3b8fcd02\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "21f5f998-b2e0-4b4c-af96-4453545d9a4d", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": true, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Hud ", "startWith<upper>Text": "Hud                                             ", "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"b0fb6f02-b2b0-4fb8-8541-e5ae3b8fcd02\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Hud\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><b><span lang=\"SV\">Hudutslag </span></b><span lang=\"SV\">(vanligen makulopapul\u00e4ra eller urtikariella)</span></p>", "ID": "b0fb6f02-b2b0-4fb8-8541-e5ae3b8fcd02", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": true, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Hud ", "startWith<upper>Text": "Hud                                             ", "Text": "Hud\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hudutslag (vanligen makulopapul\u00e4ra eller urtikariella)", "ParentId": "21f5f998-b2e0-4b4c-af96-4453545d9a4d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "10901d89-3ceb-457c-9107-0e7444067523", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"b9e1672f-c365-456e-8ad9-cabc39effeba\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "46dcbc1c-a7c4-488a-860e-00ca68a5a982", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Magtarmkanalen ", "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"b9e1672f-c365-456e-8ad9-cabc39effeba\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Magtarmkanalen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><b><span lang=\"SV\">Illam\u00e5ende, kr\u00e4kningar, diarr\u00e9, buksm\u00e4rta</span></b><span lang=\"SV\">, muns\u00e5r</span></p>", "ID": "b9e1672f-c365-456e-8ad9-cabc39effeba", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Magtarmkanalen ", "startWith<upper>Text": null, "Text": "Magtarmkanalen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Illam\u00e5ende, kr\u00e4kningar, diarr\u00e9, buksm\u00e4rta, muns\u00e5r", "ParentId": "46dcbc1c-a7c4-488a-860e-00ca68a5a982"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "ed33451d-70a7-4b54-9760-b13d6c43bdeb", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"34e57af4-5f85-44f4-87d3-842548c49c42\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "3a4509ca-5167-4bf9-85ac-b275c62ff29b", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Andningsv\u00e4gar ", "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"34e57af4-5f85-44f4-87d3-842548c49c42\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Andningsv\u00e4gar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><b><span lang=\"SV\">Dyspn\u00e9, hosta, </span></b><span lang=\"SV\">ont i halsen, \u2019adult respiratory distresssyndrome\u2019, lungsvikt</span></p>", "ID": "34e57af4-5f85-44f4-87d3-842548c49c42", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Andningsv\u00e4gar ", "startWith<upper>Text": null, "Text": "Andningsv\u00e4gar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dyspn\u00e9, hosta, ont i halsen, \u2019adult respiratory distresssyndrome\u2019, lungsvikt", "ParentId": "3a4509ca-5167-4bf9-85ac-b275c62ff29b"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.35pt;margin-right:0in;margin-bottom:\r 0in;margin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt\"></p>", "ID": "bf13b772-44f4-4c7c-9d59-6ad0e891c876", "Styles": "margin-top:.35pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"4ba93dea-75b2-4876-86be-e72aa17cf00a\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "c4db8e3e-206a-4f95-8bfe-8a76684719e1", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": true, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "\u00d6vrigt ", "startWith<upper>Text": "\u00d6vrigt                                          ", "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"4ba93dea-75b2-4876-86be-e72aa17cf00a\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">\u00d6vrigt\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><b><span lang=\"SV\">Feber, letargi, allm\u00e4n sjukdomsk\u00e4nsla</span></b><span lang=\"SV\">, \u00f6dem,\r\nlymfadenopati, hypotension, konjunktivit,anafylaxi</span></p>", "ID": "4ba93dea-75b2-4876-86be-e72aa17cf00a", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": true, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "\u00d6vrigt ", "startWith<upper>Text": "\u00d6vrigt                                          ", "Text": "\u00d6vrigt\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Feber, letargi, allm\u00e4n sjukdomsk\u00e4nsla, \u00f6dem,\r\nlymfadenopati, hypotension, konjunktivit,anafylaxi", "ParentId": "c4db8e3e-206a-4f95-8bfe-8a76684719e1"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "397ddf57-4efb-4e79-9887-e94b2004243b", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"b8f01e33-d6a8-4589-a0c9-ad22078bbc07\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "7a4d3673-6840-424c-b27d-fe718d705880", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Neurologi/psykiatri ", "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"b8f01e33-d6a8-4589-a0c9-ad22078bbc07\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Neurologi/psykiatri\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><b><span lang=\"SV\">Huvudv\u00e4rk</span></b><span lang=\"SV\">,parestesi</span></p>", "ID": "b8f01e33-d6a8-4589-a0c9-ad22078bbc07", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Neurologi/psykiatri ", "startWith<upper>Text": null, "Text": "Neurologi/psykiatri\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Huvudv\u00e4rk,parestesi", "ParentId": "7a4d3673-6840-424c-b27d-fe718d705880"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "b0912328-5464-46f3-b026-d952e121b1fa", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"d162ce4d-4007-461c-89ca-5287785809f4\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "cf32dbb2-9c1a-49bb-8e41-f47079d17d5f", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Blod ", "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"d162ce4d-4007-461c-89ca-5287785809f4\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Blod\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><span lang=\"SV\">Lymfopeni</span></p>", "ID": "d162ce4d-4007-461c-89ca-5287785809f4", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Blod ", "startWith<upper>Text": null, "Text": "Blod\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lymfopeni", "ParentId": "cf32dbb2-9c1a-49bb-8e41-f47079d17d5f"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "aa0fb444-f619-42ca-81ff-816f53f31bb4", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"219b22fb-cab7-4abe-b4ea-ebe43f0e04cd\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;\r\nmargin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt\"></p>", "ID": "bca42ea1-6945-445e-9fbc-61a41d66e7ee", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:0in;\r\nmargin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Lever/pankreas ", "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"219b22fb-cab7-4abe-b4ea-ebe43f0e04cd\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;\r\nmargin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Lever/pankreas\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><b><span lang=\"SV\">F\u00f6rh\u00f6jda leverv\u00e4rden, </span></b><span lang=\"SV\">hepatit<b>,</b>leversvikt</span></p>", "ID": "219b22fb-cab7-4abe-b4ea-ebe43f0e04cd", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:0in;\r\nmargin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Lever/pankreas ", "startWith<upper>Text": null, "Text": "Lever/pankreas\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 F\u00f6rh\u00f6jda leverv\u00e4rden, hepatit,leversvikt", "ParentId": "bca42ea1-6945-445e-9fbc-61a41d66e7ee"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt;margin-right:0in;margin-bottom:\r 0in;margin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt\"></p>", "ID": "dcce8ca4-98eb-4636-985d-4fb41edf7bed", "Styles": "margin-top:.45pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:155.95pt;margin-bottom:.0001pt;text-indent:-155.95pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"cccd2322-5c31-4637-bc08-946921c670a8\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "9b6e4183-23b2-41f5-9425-fdc5a27a51f5", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Muskel/skelett ", "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"cccd2322-5c31-4637-bc08-946921c670a8\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Muskel/skelett\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><b><span lang=\"SV\">Myalgi</span></b><span lang=\"SV\">, myolys (s\u00e4llsynt), artralgi, f\u00f6rh\u00f6jtkreatinfosfokinas</span></p>", "ID": "cccd2322-5c31-4637-bc08-946921c670a8", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Muskel/skelett ", "startWith<upper>Text": null, "Text": "Muskel/skelett\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Myalgi, myolys (s\u00e4llsynt), artralgi, f\u00f6rh\u00f6jtkreatinfosfokinas", "ParentId": "9b6e4183-23b2-41f5-9425-fdc5a27a51f5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "11f5da31-42bc-488f-96ca-0b326b7c2e1d", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"a6c5d8c0-c292-434c-9660-853300842c77\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"></p>", "ID": "b9f6eaf5-da16-47da-8c39-b6d0b88339fe", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": true, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Urologi ", "startWith<upper>Text": "Urologi                                        ", "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" id=\"a6c5d8c0-c292-434c-9660-853300842c77\" style=\"margin-left:155.95pt;text-indent:-155.95pt\"><i><span lang=\"SV\">Urologi\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></i><span lang=\"SV\">F\u00f6rh\u00f6jt kreatinin,njursvikt</span></p>", "ID": "a6c5d8c0-c292-434c-9660-853300842c77", "Styles": "margin-left:155.95pt;text-indent:-155.95pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": true, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Urologi ", "startWith<upper>Text": "Urologi                                        ", "Text": "Urologi\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 F\u00f6rh\u00f6jt kreatinin,njursvikt", "ParentId": "b9f6eaf5-da16-47da-8c39-b6d0b88339fe"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "9dfc875f-126c-4441-ad7e-7fd8616352d0", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Symtomen relaterade till denna \u00f6verk\u00e4nslighetsreaktion f\u00f6rv\u00e4rras vid fortsatt behandling och kan vara livshotande, och har i s\u00e4llsynta fall varit d\u00f6dlig.</span></p>", "ID": "0cae5218-8a24-4eee-9005-23557ab0c413", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Symtomen relaterade till denna \u00f6verk\u00e4nslighetsreaktion f\u00f6rv\u00e4rras vid fortsatt behandling och kan vara livshotande, och har i s\u00e4llsynta fall varit d\u00f6dlig.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "2b5f1917-64f3-4e36-8021-8ac5ff1f71df", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">\u00c5terins\u00e4ttning av abakavir efter en \u00f6verk\u00e4nslighetsreaktion kan leda till att symtomen \u00e5terkommer, inom n\u00e5gra f\u00e5 timmar. Denna \u00e5terkommande reaktion \u00e4r vanligtvis sv\u00e5rare \u00e4n den initiala och kan inkludera livshotande hypotension och leda till att patienten avlider. Liknande reaktioner har ocks\u00e5 intr\u00e4ffat i s\u00e4llsynta fall efter att abakavir \u00e5terinsatts hos patienter som innan behandlingen avbr\u00f6ts endast haft ett av huvudsymtomen p\u00e5 \u00f6verk\u00e4nslighet (se ovan), och har i mycket s\u00e4llsynta fall \u00e4ven setts hos patienter som har \u00e5terupptagit behandlingen utan f\u00f6reg\u00e5ende symtom p\u00e5 en \u00f6verk\u00e4nslighetsreaktion (dvs. patienter som tidigare ansetts tolerera abakavir).</span></p>", "ID": "d5b3bac8-98d7-4e48-85c7-e1f272a6377a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00c5terins\u00e4ttning av abakavir efter en \u00f6verk\u00e4nslighetsreaktion kan leda till att symtomen \u00e5terkommer, inom n\u00e5gra f\u00e5 timmar. Denna \u00e5terkommande reaktion \u00e4r vanligtvis sv\u00e5rare \u00e4n den initiala och kan inkludera livshotande hypotension och leda till att patienten avlider. Liknande reaktioner har ocks\u00e5 intr\u00e4ffat i s\u00e4llsynta fall efter att abakavir \u00e5terinsatts hos patienter som innan behandlingen avbr\u00f6ts endast haft ett av huvudsymtomen p\u00e5 \u00f6verk\u00e4nslighet (se ovan), och har i mycket s\u00e4llsynta fall \u00e4ven setts hos patienter som har \u00e5terupptagit behandlingen utan f\u00f6reg\u00e5ende symtom p\u00e5 en \u00f6verk\u00e4nslighetsreaktion (dvs. patienter som tidigare ansetts tolerera abakavir).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "ec86280c-bad7-46c0-8f10-d5a8443469a6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Metabola parametrar</span></i></p>", "ID": "ff08541d-274f-44f7-821f-434c8484024a", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Metabola parametrar", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Vikt\u00f6kning och \u00f6kade niv\u00e5er av lipider och glukos i blodet kan f\u00f6rekomma under antiretroviral behandling (se avsnitt 4.4).</span></p>", "ID": "0d25bd02-0b3c-4b8c-809b-26dd8767d8c8", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Vikt\u00f6kning och \u00f6kade niv\u00e5er av lipider och glukos i blodet kan f\u00f6rekomma under antiretroviral behandling (se avsnitt 4.4).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "1b460977-7585-472b-998d-ec3cff4d1d08", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">Immunreaktiveringssyndrom</span></i></p>", "ID": "f4be4db0-c4a9-4e3e-8934-20f750bd94e7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Immunreaktiveringssyndrom", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Hos hivinfekterade patienter med sv\u00e5r immunbrist vid tidpunkten f\u00f6r ins\u00e4ttande av antiretroviral kombinationsterapi, kan en inflammatorisk reaktion mot asymtomatiska eller kvarvarande opportunistiska infektioner uppst\u00e5. Autoimmuna sjukdomar (s\u00e5som Graves sjukdom och autoimmun hepatit) har ocks\u00e5 rapporterats i samband med immunreaktivering; emellertid \u00e4r den rapporterade tidpunkten f\u00f6r debut mer varierad och dessa h\u00e4ndelser kan intr\u00e4ffa flera m\u00e5nader efter att behandlingen p\u00e5b\u00f6rjats (se avsnitt 4.4).</span></p>", "ID": "e3c1251a-e89e-421f-a33b-9a93a7a00cf2", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Hos hivinfekterade patienter med sv\u00e5r immunbrist vid tidpunkten f\u00f6r ins\u00e4ttande av antiretroviral kombinationsterapi, kan en inflammatorisk reaktion mot asymtomatiska eller kvarvarande opportunistiska infektioner uppst\u00e5. Autoimmuna sjukdomar (s\u00e5som Graves sjukdom och autoimmun hepatit) har ocks\u00e5 rapporterats i samband med immunreaktivering; emellertid \u00e4r den rapporterade tidpunkten f\u00f6r debut mer varierad och dessa h\u00e4ndelser kan intr\u00e4ffa flera m\u00e5nader efter att behandlingen p\u00e5b\u00f6rjats (se avsnitt 4.4).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "76931414-872a-47dc-b7c7-307c510c4ed1", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Osteonekros</span></i></p>", "ID": "67dc8a7d-9acd-4367-8a2f-5e6cbad7610b", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Osteonekros", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Fall av osteonekros har rapporterats, speciellt hos patienter med k\u00e4nda riskfaktorer, framskriden hivsjukdom eller l\u00e5ngvarig exponering f\u00f6r CART. Frekvensen av detta \u00e4r ok\u00e4nd (se avsnitt 4.4).</span></p>", "ID": "fa7f4667-310c-4c58-bc5e-03c2240c3926", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Fall av osteonekros har rapporterats, speciellt hos patienter med k\u00e4nda riskfaktorer, framskriden hivsjukdom eller l\u00e5ngvarig exponering f\u00f6r CART. Frekvensen av detta \u00e4r ok\u00e4nd (se avsnitt 4.4).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "a45b92cc-98fa-4a8b-846a-f8e6321f2eaa", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">F\u00f6r\u00e4ndringar i labortoriekemiska parametrar</span></u></p>", "ID": "32775b04-a3c9-49ee-843a-a63cb0d4e9f9", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "F\u00f6r\u00e4ndringar i labortoriekemiska parametrar", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">I kontrollerade kliniska studier var laboratorieavvikelser relaterade till abakavirbehandling ovanliga och inga skillnader i incidens noterades mellan patienterna i abakavir- och kontrollgrupperna.</span></p>", "ID": "f8add782-9bda-47a6-ba0c-bb5da8e95ad5", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I kontrollerade kliniska studier var laboratorieavvikelser relaterade till abakavirbehandling ovanliga och inga skillnader i incidens noterades mellan patienterna i abakavir- och kontrollgrupperna.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "cf6c0b2d-b760-4f1b-af0f-fca7d622850a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Pediatrisk population</span></u></p>", "ID": "a9b450c2-8c05-44df-a692-7827a63a47d1", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Pediatrisk population", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">1 206 hivinfekterade pediatriska patienter i \u00e5ldern 3 m\u00e5nader till 17 \u00e5r inkluderades i studien ARROW (COL105677), 669 av dessa fick abakavir och lamivudin antingen en eller tv\u00e5 g\u00e5nger dagligen (se avsnitt 5.1). Inga ytterligare s\u00e4kerhetsproblem j\u00e4mf\u00f6rt med vuxna har identifierats bland de pediatriska patienter som f\u00e5tt l\u00e4kemedlet antingen en eller tv\u00e5 g\u00e5nger dagligen</span></p>", "ID": "24b348df-2663-4315-9e30-93c40dfd3484", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "1 206 hivinfekterade pediatriska patienter i \u00e5ldern 3 m\u00e5nader till 17 \u00e5r inkluderades i studien ARROW (COL105677), 669 av dessa fick abakavir och lamivudin antingen en eller tv\u00e5 g\u00e5nger dagligen (se avsnitt 5.1). Inga ytterligare s\u00e4kerhetsproblem j\u00e4mf\u00f6rt med vuxna har identifierats bland de pediatriska patienter som f\u00e5tt l\u00e4kemedlet antingen en eller tv\u00e5 g\u00e5nger dagligen", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "e0ef6884-08ee-4a1a-8ceb-99105207b915", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"text-align:justify\"><u><span lang=\"SV\">Rapportering av misst\u00e4nkta biverkningar</span></u></p>", "ID": "2d73fb19-3aed-45d9-8881-9fa9c8355702", "Styles": "text-align:justify", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Rapportering av misst\u00e4nkta biverkningar", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Det \u00e4r viktigt att rapportera misst\u00e4nkta biverkningar efter att l\u00e4kemedlet godk\u00e4nts. Det g\u00f6r det m\u00f6jligt att kontinuerligt \u00f6vervaka l\u00e4kemedlets nytta-riskf\u00f6rh\u00e5llande. H\u00e4lso- och sjukv\u00e5rdspersonal uppmanas att rapportera varje misst\u00e4nkt biverkning via:</span></p>", "ID": "c746ac9c-3ab5-4739-92ea-0e93327c4c87", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Det \u00e4r viktigt att rapportera misst\u00e4nkta biverkningar efter att l\u00e4kemedlet godk\u00e4nts. Det g\u00f6r det m\u00f6jligt att kontinuerligt \u00f6vervaka l\u00e4kemedlets nytta-riskf\u00f6rh\u00e5llande. H\u00e4lso- och sjukv\u00e5rdspersonal uppmanas att rapportera varje misst\u00e4nkt biverkning via:", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "b268c53e-c1d8-4c04-b319-5e6bb333d581", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">L\u00e4kemedelsverket</span></p>", "ID": "73f85e2c-a165-48b5-83eb-1b290be54618", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "L\u00e4kemedelsverket", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Box 26</span></p>", "ID": "a5bdd964-018b-4d46-bb5c-1d1d7876f0d3", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Box 26", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">751 03 Uppsala</span></p>", "ID": "ca3085ed-82cb-408a-b821-d79f6c3bc40d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "751 03 Uppsala", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\"><a href=\"http://www.lakemedelsverket.se\">www.lakemedelsverket.se</a> </span></p>", "ID": "c7065546-32aa-4f2d-9897-2198ee39eb85", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "www.lakemedelsverket.se ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "19010244-e069-487f-82d1-e92eef139e69", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin-top:4.55pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>4.9</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>\u00d6verdosering</span></h1>", "ID": "82955c11-cef9-477a-9742-e3320f353d4c", "Styles": "margin-top:4.55pt;margin-right:0in;margin-bottom:0in;margin-left:\r\n0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "4.9 \u00d6verdosering", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "a6ab5781-ed73-4a4b-b914-4cb9afbf3b17", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Enstaka doser p\u00e5 upp till 1 200 mg och dygnsdoser p\u00e5 1 800 mg abakavir har administrerats till patienter i kliniska studier. Inga andra biverkningar rapporterades ut\u00f6ver dem som rapporterades vid normala doser. Effekten av h\u00f6gre doser \u00e4r inte k\u00e4nd. Om \u00f6verdosering intr\u00e4ffar ska patienten \u00f6vervakas noggrant avseende tecken p\u00e5 toxicitet (se avsnitt 4.8) och symtomatisk terapi ska ges vid behov. Det \u00e4r inte k\u00e4nt om abakavir kan elimineras via peritoneal- eller hemodialys.</span></p>", "ID": "0612cc9f-e859-46eb-8a5c-6419574b50c6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Enstaka doser p\u00e5 upp till 1 200 mg och dygnsdoser p\u00e5 1 800 mg abakavir har administrerats till patienter i kliniska studier. Inga andra biverkningar rapporterades ut\u00f6ver dem som rapporterades vid normala doser. Effekten av h\u00f6gre doser \u00e4r inte k\u00e4nd. Om \u00f6verdosering intr\u00e4ffar ska patienten \u00f6vervakas noggrant avseende tecken p\u00e5 toxicitet (se avsnitt 4.8) och symtomatisk terapi ska ges vid behov. Det \u00e4r inte k\u00e4nt om abakavir kan elimineras via peritoneal- eller hemodialys.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "2e9b0f5b-3444-4b8e-8bdc-47cdb0a1cbf1", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "f714f823-91af-47d0-b2e5-582697d985dc", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>5.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>FARMAKOLOGISKAEGENSKAPER</span></h1>", "ID": "0051bc22-13ce-45e8-b146-1350f6f8ce80", "Styles": "margin-top:3.65pt;margin-right:0in;margin-bottom:0in;margin-left:\r\n0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "5. FARMAKOLOGISKA EGENSKAPER", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "a48aefe4-58a1-476e-85b5-3d261aae7768", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in;text-indent:0in\"><b><span lang=\"SV\">5.1</span></b><b><span lang=\"SV\">Farmakodynamiskaegenskaper</span></b></p>", "ID": "fbbbdb86-d572-40ff-ba18-7106996490a3", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListParagraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "5.1 Farmakodynamiska egenskaper", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "debc99b8-371b-461c-9fa0-0a8a9cb94a0d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Farmakoterapeutisk grupp: nukleosidanalog\r omv\u00e4nt transkriptash\u00e4mmare, ATC kod: J05AF06. <u>Verkningsmekanism</u></span></p>", "ID": "21469073-b85c-4b21-a5ff-c3a04205c36f", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Farmakoterapeutisk grupp: nukleosidanalog omv\u00e4nt transkriptash\u00e4mmare, ATC kod: J05AF06. Verkningsmekanism", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Abakavir \u00e4r en NRTI\r och \u00e4r en potent selektiv h\u00e4mmare av hiv\u20111 och hiv\u20112. Abakavir\r metaboliseras intracellul\u00e4rt till den aktiva metaboliten carbovir 5\u2019\u2011trifosfat\r (TP). <i>In vitro\u2011</i>studier har visat att dess verkningsmekanism\r gentemot hiv \u00e4r dess h\u00e4mning av hivs omv\u00e4nt transkriptasenzym, vilket\r resulterar i ett kedjeavbrott och avbrytande av den virala replikationscykeln.\r Ingen antagonism mot abakavirs antivirala effekt i cellodling observerades vid\r kombination med nukleosidanalogerna (NRTI) didanosin, emtricitabin, lamivudin,\r stavudin, tenofovir eller zidovudin, icke-nukleosidanalogen (NNRTI) nevirapin,\r eller proteash\u00e4mmaren (PI) amprenavir.</span></p>", "ID": "bb16d923-5335-41ec-b671-bfd01f28390c", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir \u00e4r en NRTI och \u00e4r en potent selektiv h\u00e4mmare av hiv\u20111 och hiv\u20112. Abakavir metaboliseras intracellul\u00e4rt till den aktiva metaboliten carbovir 5\u2019\u2011trifosfat (TP). In vitro\u2011 studier har visat att dess verkningsmekanism gentemot hiv \u00e4r dess h\u00e4mning av hivs omv\u00e4nt transkriptasenzym, vilket resulterar i ett kedjeavbrott och avbrytande av den virala replikationscykeln. Ingen antagonism mot abakavirs antivirala effekt i cellodling observerades vid kombination med nukleosidanalogerna (NRTI) didanosin, emtricitabin, lamivudin, stavudin, tenofovir eller zidovudin, icke-nukleosidanalogen (NNRTI) nevirapin, eller proteash\u00e4mmaren (PI) amprenavir.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "02d51576-c551-49ca-bd4f-9352494cac2c", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Resistens</span></u></p>", "ID": "d5e8a328-580d-4e94-831f-2785ba287253", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Resistens", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "8d821655-69b5-4547-a128-c4280971b8af", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"44b8dbd4-755d-4d97-babf-c8b2b32b24b1\" style=\"margin-top:4.6pt\"></p><i><span lang=\"SV\">Resistens in vitro: </span></i><none></none>", "ID": "38a6f4a9-c4ad-45f5-9f51-a5b842f41403", "Styles": "margin-top:4.6pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Resistens in vitro: ", "startWith<upper>Text": null, "Text": "Resistens in vitro: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"44b8dbd4-755d-4d97-babf-c8b2b32b24b1\" style=\"margin-top:4.6pt\"><span lang=\"SV\">Abakavirresistenta isolat av hiv-1 har\r\nselekterats fram <i>in vitro </i>och \u00e4r associerade med specifika\r\ngenotypf\u00f6r\u00e4ndringar i regionen kodande f\u00f6r omv\u00e4nt transkriptas (M184V, K65R,\r\nL74V, och Y115F). Viral resistens mot abakavir utvecklas relativt l\u00e5ngsamt <i>in vitro </i>och kr\u00e4ver multipla <span style=\"position:relative;top:-1.0pt\">mutationer\r\nf\u00f6r en kliniskt relevant \u00f6kning i EC<sub>50</sub></span>\u00a0<span style=\"position:relative;top:-1.0pt\">av \u201dwild-type\u201d virus.</span></span></p>", "ID": "44b8dbd4-755d-4d97-babf-c8b2b32b24b1", "Styles": "margin-top:4.6pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Resistens in vitro: ", "startWith<upper>Text": null, "Text": "Abakavirresistenta isolat av hiv-1 har\r\nselekterats fram in vitro och \u00e4r associerade med specifika\r\ngenotypf\u00f6r\u00e4ndringar i regionen kodande f\u00f6r omv\u00e4nt transkriptas (M184V, K65R,\r\nL74V, och Y115F). Viral resistens mot abakavir utvecklas relativt l\u00e5ngsamt in vitro och kr\u00e4ver multipla mutationer\r\nf\u00f6r en kliniskt relevant \u00f6kning i EC50\u00a0av \u201dwild-type\u201d virus.", "ParentId": "38a6f4a9-c4ad-45f5-9f51-a5b842f41403"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.4pt\"></p>", "ID": "be62a94a-2c05-46b7-81ab-3dbae753e047", "Styles": "margin-top:.4pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"304d970b-f7de-4a35-bb00-f992bad66933\"></p><i><span lang=\"SV\">Resistens in vivo (behandlingsnaiva patienter)</span></i><none></none>", "ID": "591a41a7-67ac-4eb1-8100-42a29fe46699", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Resistens in vivo (behandlingsnaiva patienter)", "startWith<upper>Text": null, "Text": "Resistens in vivo (behandlingsnaiva patienter)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"304d970b-f7de-4a35-bb00-f992bad66933\"><span lang=\"SV\">. I pivotala kliniska studier visade isolat fr\u00e5n flertalet patienter med virologisk svikt vid behandling med abakavir antingen inga NRTI\u2011relaterade f\u00f6r\u00e4ndringar j\u00e4mf\u00f6rt med baseline (45\u00a0%) eller endast M184V eller M184I-selektion (45\u00a0%). Den totala selektionsfrekvensen f\u00f6r M184V eller M184I var h\u00f6g (54\u00a0%). Mindre vanlig var selektionen av L74V (5\u00a0%), K65R (1\u00a0%) och Y115F (1\u00a0%). N\u00e4r zidovudin inkluderas i behandlingen har frekvensen av L74V och K65R visat sig minska i n\u00e4rvaro av abakavir (med zidovudin: 0/40, utan zidovudin: 15/192, 8\u00a0%).</span></p>", "ID": "304d970b-f7de-4a35-bb00-f992bad66933", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Resistens in vivo (behandlingsnaiva patienter)", "startWith<upper>Text": null, "Text": ". I pivotala kliniska studier visade isolat fr\u00e5n flertalet patienter med virologisk svikt vid behandling med abakavir antingen inga NRTI\u2011relaterade f\u00f6r\u00e4ndringar j\u00e4mf\u00f6rt med baseline (45\u00a0%) eller endast M184V eller M184I-selektion (45\u00a0%). Den totala selektionsfrekvensen f\u00f6r M184V eller M184I var h\u00f6g (54\u00a0%). Mindre vanlig var selektionen av L74V (5\u00a0%), K65R (1\u00a0%) och Y115F (1\u00a0%). N\u00e4r zidovudin inkluderas i behandlingen har frekvensen av L74V och K65R visat sig minska i n\u00e4rvaro av abakavir (med zidovudin: 0/40, utan zidovudin: 15/192, 8\u00a0%).", "ParentId": "591a41a7-67ac-4eb1-8100-42a29fe46699"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p>", "ID": "df839305-baa6-434d-92dc-f9cbd931a724", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:11.4pt;border-collapse:collapse;border:none\"> <tr style=\"height:50.6pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.45pt;text-align:left\"></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">Behandling</span></b></p> </td> <td style=\"width:79.7pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.05pt;text-align:left\"></p> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><b><span lang=\"SV\">Abakavir\r   + lamivudin/ zidovudin<sup>1</sup></span></b></p> </td> <td style=\"width:79.95pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><b><span lang=\"SV\">Abakavir +   lamivudin + NNRTI</span></b></p> </td> <td style=\"width:79.85pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Abakavir + lamivudin + PI (eller PI/ritonavir)</span></b></p> </td> <td style=\"width:79.85pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.45pt;text-align:left\"></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">Totalt</span></b></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"106\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.1pt;text-align:left\"><b><span lang=\"SV\">Antal patienter</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">282</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">1094</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">909</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">2285</span></p> </td> </tr> <tr style=\"height:37.85pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">Antal med   virologisk svikt</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">43</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">90</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">158</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">291</span></p> </td> </tr> <tr style=\"height:50.6pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Antal genotyper vid p\u00e5g\u00e5ende</span></b></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">behandling</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">40 (100 %)</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:.2pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">51 (100 %)<sup>2</sup></span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">141 (100 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">232 (100 %)</span></p> </td> </tr> <tr style=\"height:25.4pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><b><span lang=\"SV\">K65R</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">0</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">1 (2 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">2 (1 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.4pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">3 (1 %)</span></p> </td> </tr> <tr style=\"height:12.8pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><b><span lang=\"SV\">L74V</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">0</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">9 (18 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">3 (2%)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">12 (5 %)</span></p> </td> </tr> <tr style=\"height:12.7pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Y115F</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">0</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\"><span lang=\"SV\">2 (4 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">0</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">2 (1 %)</span></p> </td> </tr> <tr style=\"height:12.8pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><b><span lang=\"SV\">M184V/I</span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">34 (85 %)</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">22 (43 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">70 (50 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.8pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">126 (54 %)</span></p> </td> </tr> <tr style=\"height:12.65pt\"> <td style=\"width:1.1in;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">TAMs<sup><span style=\"position:relative;\r   top:-4.0pt\">3</span></sup></span></b></p> </td> <td style=\"width:79.7pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">3 (8 %)</span></p> </td> <td style=\"width:79.95pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"107\"> <p class=\"TableParagraph\"><span lang=\"SV\">2 (4 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">4 (3 %)</span></p> </td> <td style=\"width:79.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.65pt\" valign=\"top\" width=\"106\"> <p class=\"TableParagraph\"><span lang=\"SV\">9 (4 %)</span></p> </td> </tr> </table>", "ID": "040f8a34-058f-4cc1-8328-1164a5d41d12", "Styles": "margin-left:11.4pt;border-collapse:collapse;border:none", "Classes": "['TableNormal1']", "Bold": null, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": true, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": "    Behandling    Abakavir   + lamivudin/ zidovudin1   Abakavir +   lamivudin + NNRTI   Abakavir + lamivudin + PI (eller PI/ritonavir)    Totalt     Antal patienter   ", "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "    Behandling     Abakavir  + lamivudin/ zidovudin 1    Abakavir +  lamivudin + NNRTI    Abakavir + lamivudin + PI (eller PI/ritonavir)     Totalt      Antal patienter    282    1094    909    2285      Antal med  virologisk svikt     43     90     158     291      Antal genotyper vid p\u00e5g\u00e5ende  behandling     40 (100 %)     51 (100 %) 2     141 (100 %)     232 (100 %)      K65R    0    1 (2 %)    2 (1 %)    3 (1 %)      L74V    0    9 (18 %)    3 (2%)    12 (5 %)      Y115F    0    2 (4 %)    0    2 (1 %)      M184V/I    34 (85 %)    22 (43 %)    70 (50 %)    126 (54 %)      TAMs 3    3 (8 %)    2 (4 %)    4 (3 %)    9 (4 %)   ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"SV\">1.</span><span lang=\"SV\" style=\"color:white\">Lamivudine/Zidovudine</span><span lang=\"SV\"> \u00e4r en\r fast kombination av lamivudin ochzidovudin</span></p>", "ID": "7901730f-e3b2-4702-882c-cf97ff9dcc07", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "1. Lamivudine/Zidovudine \u00e4r en fast kombination av lamivudin och zidovudin", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:\r 0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt\"><span lang=\"SV\">2.</span><span lang=\"SV\">Inkluderar tre fall av icke-virologisk svikt och fyra obekr\u00e4ftade fall\r av virologisksvikt.</span></p>", "ID": "b68630cf-2bd4-496d-8485-7819a9391f8f", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "2. Inkluderar tre fall av icke-virologisk svikt och fyra obekr\u00e4ftade fall av virologisk svikt.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"SV\">3   Antal individer med \u22651 Tymidinanalog\u2011mutationer (TAMs, i e 41, 67, 70, 210, 215, 219).</span></p>", "ID": "2ca791e2-45f8-430e-802c-16c9353688af", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "3  Antal individer med \u22651 Tymidinanalog\u2011mutationer (TAMs, i e 41, 67, 70, 210, 215, 219).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "ddec6c29-a69d-4ffc-a481-6e1bb9f91100", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">TAMs skulle kunna selekteras d\u00e5 tymidinanaloger \u00e4r associerade med abakavir. I en metaanalys av sex kliniska studier selekterades inga TAMs vid behandlingar d\u00e4r abakavir men inte zidovudin ingick (0/127), men selekterades d\u00e4remot i de behandlingar d\u00e4r abakavir och tymidinanalogen zidovudin ingick (22/86, 26 %).</span></p>", "ID": "f2656f48-1b8b-4b3e-9403-df7c370ab2c8", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "TAMs skulle kunna selekteras d\u00e5 tymidinanaloger \u00e4r associerade med abakavir. I en metaanalys av sex kliniska studier selekterades inga TAMs vid behandlingar d\u00e4r abakavir men inte zidovudin ingick (0/127), men selekterades d\u00e4remot i de behandlingar d\u00e4r abakavir och tymidinanalogen zidovudin ingick (22/86, 26 %).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "755697c1-3e98-484f-a01b-f61888cca7d8", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"72050f22-9bc6-41d4-99c5-97361e024d81\"></p><i><span lang=\"SV\">Resistens in vivo (tidigare behandlade patienter): </span></i><none></none>", "ID": "0d06b1de-a9b8-41b9-b4ea-48c64a2cac3a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Resistens in vivo (tidigare behandlade patienter): ", "startWith<upper>Text": null, "Text": "Resistens in vivo (tidigare behandlade patienter): ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"72050f22-9bc6-41d4-99c5-97361e024d81\"><span lang=\"SV\">Kliniskt signifikant minskad k\u00e4nslighet f\u00f6r abakavir har visats i kliniska isolat fr\u00e5n patienter med virologisk svikt, vilka tidigare behandlats med och \u00e4r resistenta mot andra nukleosidh\u00e4mmare. I en metaanalys av fem kliniska studier d\u00e4r abakavir adderades f\u00f6r att f\u00f6rst\u00e4rka behandlingen hade 123 av 166 individer (74%) M184V/I, 50 (30%) hade T215Y/F, 45 (27\u00a0%) hade M41L, 30 (18\u00a0%) hade K70R och 25 (15\u00a0%) hade D67N. K65R saknades och L74V och Y115F var ovanliga ((\u22643\u00a0%). Logistisk regressionsmodellering av f\u00f6ruts\u00e4gbara v\u00e4rden f\u00f6r genotyp (justerade f\u00f6r basline plasma hiv\u20111 RNA [vRNA], CD4+cellantal, antal och l\u00e4ngd p\u00e5 tidigare antiretrovirala behandlingar) visade att f\u00f6rekomst av tre eller fler mutationer f\u00f6rknippade med NRTI\u2011resistens var associerade med minskad respons vecka 4 (p=0,015) eller fyra eller fler mutationer vecka \u00a04 (median)(p\u22640,012). Dessutom orsakar \u201d69\u2011insertion\u201d\u2011komplexet eller Q151M\u2011mutationen (vanligt f\u00f6rekommande i kombination med A62V, V751, F77L och F116) en h\u00f6gre niv\u00e5 av resistens mot abakavir.</span></p>", "ID": "72050f22-9bc6-41d4-99c5-97361e024d81", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "Resistens in vivo (tidigare behandlade patienter): ", "startWith<upper>Text": null, "Text": "Kliniskt signifikant minskad k\u00e4nslighet f\u00f6r abakavir har visats i kliniska isolat fr\u00e5n patienter med virologisk svikt, vilka tidigare behandlats med och \u00e4r resistenta mot andra nukleosidh\u00e4mmare. I en metaanalys av fem kliniska studier d\u00e4r abakavir adderades f\u00f6r att f\u00f6rst\u00e4rka behandlingen hade 123 av 166 individer (74%) M184V/I, 50 (30%) hade T215Y/F, 45 (27\u00a0%) hade M41L, 30 (18\u00a0%) hade K70R och 25 (15\u00a0%) hade D67N. K65R saknades och L74V och Y115F var ovanliga ((\u22643\u00a0%). Logistisk regressionsmodellering av f\u00f6ruts\u00e4gbara v\u00e4rden f\u00f6r genotyp (justerade f\u00f6r basline plasma hiv\u20111 RNA [vRNA], CD4+cellantal, antal och l\u00e4ngd p\u00e5 tidigare antiretrovirala behandlingar) visade att f\u00f6rekomst av tre eller fler mutationer f\u00f6rknippade med NRTI\u2011resistens var associerade med minskad respons vecka 4 (p=0,015) eller fyra eller fler mutationer vecka \u00a04 (median)(p\u22640,012). Dessutom orsakar \u201d69\u2011insertion\u201d\u2011komplexet eller Q151M\u2011mutationen (vanligt f\u00f6rekommande i kombination med A62V, V751, F77L och F116) en h\u00f6gre niv\u00e5 av resistens mot abakavir.", "ParentId": "0d06b1de-a9b8-41b9-b4ea-48c64a2cac3a"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "4116a979-2fbd-4a23-a461-35485bd3ea0c", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:.85in;border-collapse:collapse;border:none\"> <tr style=\"height:25.3pt\"> <td rowspan=\"2\" style=\"width:129.35pt;border:solid black 1.0pt;\r   border-right:solid black 1.5pt;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"172\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.1pt;text-align:left\"></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">Omv\u00e4nt transkriptash\u00e4mmar-   mutationer vid baseline</span></b></p> </td> <td colspan=\"3\" style=\"width:222.6pt;border-top:solid black 1.0pt;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"297\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Vecka 4</span></b></p> <p class=\"TableParagraph\"><b><span lang=\"SV\">(n = 166)</span></b></p> </td> </tr> <tr style=\"height:50.6pt\"> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">n</span></b></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Median f\u00f6r\u00e4ndring</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:1.9pt\"><b><span lang=\"SV\" style=\"position:relative;top:-1.0pt\">vRNA (log</span></b><b><span lang=\"SV\">10   c/ml)</span></b></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:50.6pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><b><span lang=\"SV\">Procent med</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><b><span lang=\"SV\">&lt;400 kopior/ml   vRNA</span></b></p> </td> </tr> <tr style=\"height:12.55pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Inga</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\"><span lang=\"SV\">15</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\"><span lang=\"SV\">-0,96</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:12.55pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\"><span lang=\"SV\">40 %</span></p> </td> </tr> <tr style=\"height:12.7pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Endast M184V</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\"><span lang=\"SV\">75</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.7pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\"><span lang=\"SV\">-0,74</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:12.7pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\"><span lang=\"SV\">64 %</span></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">En NRTI   mutation, vilken som helst</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">82</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">-0,72</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:25.3pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:6.25pt\"><span lang=\"SV\">65 %</span></p> </td> </tr> <tr style=\"height:37.85pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Tv\u00e5 NRTI-associerade mutationer,   vilka som helst</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">22</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.85pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">-0,82</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:37.85pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt\"></p> <p class=\"TableParagraph\" style=\"margin-top:.05pt\"><span lang=\"SV\">32 %</span></p> </td> </tr> <tr style=\"height:38.0pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:38.0pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Tre NRTI-associerade mutationer,   vilka som helst</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:38.0pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">19</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:38.0pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">-0,30</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:38.0pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">5 %</span></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:129.35pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"172\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">Fyra eller   fler NRTI- associerade mutationer</span></b></p> </td> <td style=\"width:79.05pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"105\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">28</span></p> </td> <td style=\"width:70.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"94\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">-0,07</span></p> </td> <td style=\"width:72.7pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.5pt;padding:0in 0in 0in 0in;\r   height:25.3pt\" valign=\"top\" width=\"97\"> <p class=\"TableParagraph\" style=\"margin-top:6.15pt\"><span lang=\"SV\">11 %</span></p> </td> </tr> </table>", "ID": "76ec96b1-e941-4409-ac1e-c4586eb7c73f", "Styles": "margin-left:.85in;border-collapse:collapse;border:none", "Classes": "['TableNormal1']", "Bold": null, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": true, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": "    Omv\u00e4nt transkriptash\u00e4mmar-   mutationer vid baseline   Vecka 4 (n = 166)     n   Median f\u00f6r\u00e4ndring vRNA (log10   c/ml)   Procent med <400kopior/ml   vRNA     Inga   ", "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "    Omv\u00e4nt transkriptash\u00e4mmar-  mutationer vid baseline    Vecka 4  (n = 166)      n    Median f\u00f6r\u00e4ndring  vRNA (log 10  c/ml)    Procent med  <400 kopior/ml  vRNA      Inga    15    -0,96    40 %      Endast M184V    75    -0,74    64 %      En NRTI  mutation, vilken som helst    82    -0,72    65 %      Tv\u00e5 NRTI-associerade mutationer,  vilka som helst     22     -0,82     32 %      Tre NRTI-associerade mutationer,  vilka som helst     19     -0,30     5 %      Fyra eller  fler NRTI- associerade mutationer    28    -0,07    11 %   ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "eb893dc3-c5d3-4537-8acd-f79d7887e24e", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><i><span lang=\"SV\">Fenotypisk resistens och korsresistens</span></i></p>", "ID": "fb8816d8-3aa7-4993-9193-c9596cce5b32", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Fenotypisk resistens och korsresistens", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "f7c27ac1-b062-45fe-b49d-6b8ae5e4236d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Fenotypisk resistens mot abakavir kr\u00e4ver M184V med minst ytterligare en annan abakavirselekterad mutation, eller M184V med multipla TAMs. Fenotypisk korsresistens mot andra NRTIs med endast M184V- eller M184I\u2011mutationer \u00e4r begr\u00e4nsad. Zidovudin, didanosin, stavudin och tenofovir bibeh\u00e5ller sin antiretrovirala aktivitet mot den typen av hiv\u20111\u2011varianter. F\u00f6rekomst av M184V med K65R f\u00f6rorsakar korsresistens mellan abakavir, tenofovir, didanosin och lamivudin. M184V med L74V f\u00f6rorsakar korsresistens mellan abakavir, didanosin och lamivudin. F\u00f6rekomst av M184V med Y115F f\u00f6rorsakar korsresistens mellan abakavir och lamivudin. V\u00e4gledning f\u00f6r l\u00e4mplig anv\u00e4ndning av abakavir kan f\u00e5s om nuvarande rekommenderad resistensalgoritm anv\u00e4nds.</span></p>", "ID": "23a5d754-30bd-4de4-83d4-49b4db26d982", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Fenotypisk resistens mot abakavir kr\u00e4ver M184V med minst ytterligare en annan abakavirselekterad mutation, eller M184V med multipla TAMs. Fenotypisk korsresistens mot andra NRTIs med endast M184V- eller M184I\u2011mutationer \u00e4r begr\u00e4nsad. Zidovudin, didanosin, stavudin och tenofovir bibeh\u00e5ller sin antiretrovirala aktivitet mot den typen av hiv\u20111\u2011varianter. F\u00f6rekomst av M184V med K65R f\u00f6rorsakar korsresistens mellan abakavir, tenofovir, didanosin och lamivudin. M184V med L74V f\u00f6rorsakar korsresistens mellan abakavir, didanosin och lamivudin. F\u00f6rekomst av M184V med Y115F f\u00f6rorsakar korsresistens mellan abakavir och lamivudin. V\u00e4gledning f\u00f6r l\u00e4mplig anv\u00e4ndning av abakavir kan f\u00e5s om nuvarande rekommenderad resistensalgoritm anv\u00e4nds.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "17864365-973c-4211-a305-f829523dde41", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Korsresistens mellan abakavir och antiretroviraler fr\u00e5n andra klasser (t.ex. PIs eller NNRTIs) \u00e4r inte trolig</span></p>", "ID": "da24c0a3-810b-4c13-83be-c2d5cd72b442", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Korsresistens mellan abakavir och antiretroviraler fr\u00e5n andra klasser (t.ex. PIs eller NNRTIs) \u00e4r inte trolig", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "434ff534-5964-46a1-bb56-f5395ecf7087", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Klinisk effekt och s\u00e4kerhet</span></u></p>", "ID": "23be35de-96a4-4df7-a9b3-8ecbb95bffd1", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Klinisk effekt och s\u00e4kerhet", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "a95421cd-dae1-4543-8260-cb8542ac9f0e", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Det visade kliniska v\u00e4rdet med abakavir \u00e4r fr\u00e4mst baserat p\u00e5 resultat fr\u00e5n studier med behandlingsnaiva vuxna patienter som tog abakavir 300  mg tv\u00e5 g\u00e5nger dagligen i kombination med zidovudin och lamivudin.</span></p>", "ID": "0b939286-aef0-4b1e-972b-eea29bb36d5f", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Det visade kliniska v\u00e4rdet med abakavir \u00e4r fr\u00e4mst baserat p\u00e5 resultat fr\u00e5n studier med behandlingsnaiva vuxna patienter som tog abakavir 300 mg tv\u00e5 g\u00e5nger dagligen i kombination med zidovudin och lamivudin.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "6f8a5fca-f4d9-4d58-b61e-24574191336c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><i><span lang=\"SV\">Dosering (300 mg) tv\u00e5 g\u00e5nger dagligen:</span></i></p>", "ID": "6dbba485-016c-46ef-9ac0-1ba3301da2a3", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Dosering (300 mg) tv\u00e5 g\u00e5nger dagligen:", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "41f5305f-3826-4af4-b643-960a8040a6c7", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"SV\" style=\"font-family:Symbol\">\u00b7</span><i><span lang=\"SV\">Behandlingsnaivavuxna</span></i></p>", "ID": "50b55513-7758-4e8e-a78d-ab72fced8e05", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 Behandlingsnaiva vuxna", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "81ea7be3-4098-4c9b-9311-8604c43e65c4", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Hos vuxna patienter som behandlats med abakavir i kombination med lamivudin och zidovudin hade ca 70 % av patienterna (Intention To Treat-analys vid 48 veckor) inte n\u00e5gra detekterbara virusniv\u00e5er (&lt; 400 kopior/ml) samt en motsvarande h\u00f6jning av antalet CD4\u2011celler.</span></p>", "ID": "45944006-821e-46fa-a721-c9f0c3062c4d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Hos vuxna patienter som behandlats med abakavir i kombination med lamivudin och zidovudin hade ca 70 % av patienterna (Intention To Treat-analys vid 48 veckor) inte n\u00e5gra detekterbara virusniv\u00e5er (< 400 kopior/ml) samt en motsvarande h\u00f6jning av antalet CD4\u2011celler.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "2902e11c-587a-432c-b760-f3dc99186da0", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">I en randomiserad dubbelblind placebokontrollerad studie p\u00e5 vuxna patienter j\u00e4mf\u00f6rdes kombinationen abakavir, lamivudin och zidovudin med kombinationen indinavir, lamivudin och zidovudin. P\u00e5 grund av den h\u00f6ga andelen patienter med f\u00f6rtida behandlingsavbrott (42 % av patienterna hade avbrutit den randomiserade behandlingen under de f\u00f6rsta 48 veckorna) kunde inte n\u00e5gon definitiv slutsats dras betr\u00e4ffande ekvivalens mellan behandlingsalternativen efter 48 veckor. Fast\u00e4n en likartad antiviral effekt observerades mellan de abakavir- och indinavirinneh\u00e5llande regimerna vad g\u00e4ller andel patienter med ej detekterbar virusniv\u00e5 (\u2264400 kopior/ml; intention to treat analys (ITT), 47 % versus 49 %; as treated analys (AT), 86 % versus 94 % f\u00f6r abakavir- respektive indinavirkombinationen), var resultatet b\u00e4ttre f\u00f6r indinavirkombinationen, s\u00e4rskilt i gruppen patienter med h\u00f6ga initiala virustal (&gt;100 000 kopior/ml f\u00f6re behandlingen; ITT, 46 % versus 55 %; AT, 84 % versus 93% f\u00f6r abakavir respektive indinavir).</span></p>", "ID": "f9c8684f-ab35-499a-b935-7a982cf67e38", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I en randomiserad dubbelblind placebokontrollerad studie p\u00e5 vuxna patienter j\u00e4mf\u00f6rdes kombinationen abakavir, lamivudin och zidovudin med kombinationen indinavir, lamivudin och zidovudin. P\u00e5 grund av den h\u00f6ga andelen patienter med f\u00f6rtida behandlingsavbrott (42 % av patienterna hade avbrutit den randomiserade behandlingen under de f\u00f6rsta 48 veckorna) kunde inte n\u00e5gon definitiv slutsats dras betr\u00e4ffande ekvivalens mellan behandlingsalternativen efter 48 veckor. Fast\u00e4n en likartad antiviral effekt observerades mellan de abakavir- och indinavirinneh\u00e5llande regimerna vad g\u00e4ller andel patienter med ej detekterbar virusniv\u00e5 (\u2264400 kopior/ml; intention to treat analys (ITT), 47 % versus 49 %; as treated analys (AT), 86 % versus 94 % f\u00f6r abakavir- respektive indinavirkombinationen), var resultatet b\u00e4ttre f\u00f6r indinavirkombinationen, s\u00e4rskilt i gruppen patienter med h\u00f6ga initiala virustal (>100 000 kopior/ml f\u00f6re behandlingen; ITT, 46 % versus 55 %; AT, 84 % versus 93% f\u00f6r abakavir respektive indinavir).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "decc5afc-e35b-407d-95ab-aba3d926d587", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">I en dubbelblind, kontrollerad, multicenterstudie (CNA30024) randomiserades 654 hivinfekterade behandlingsnaiva patienter till att f\u00e5 antingen 300 mg abakavir tv\u00e5 g\u00e5nger dagligen eller 300 mg zidovudin tv\u00e5 g\u00e5nger dagligen, i b\u00e5da fallen i kombination med 150 mg lamivudin tv\u00e5 g\u00e5nger dagligen och 600 mg efavirenz en g\u00e5ng dagligen. Den dubbelblinda behandlingen p\u00e5gick i minst 48 veckor. I \u201dintent to treat\u201d (ITT)\u2011populationen uppn\u00e5dde 70 % av patienterna i abakavirgruppen, j\u00e4mf\u00f6rt med 69 % av patienterna i zidovudingruppen, ett virologiskt svar p\u00e5 plasma hiv-1-RNA p\u00e5 \u226450 kopior/ml i vecka 48 (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnaden: 0,8, 95 % CI -6,3, 7,9). I analysen av \u201das treated\u201d (AT) var skillnaden mellan de b\u00e5da behandlingsarmarna mer m\u00e4rkbar, 88% av patienterna i abakavirgruppen j\u00e4mf\u00f6rt med 95 % av patienterna i zidovudingruppen (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnaden: -6,8, 95 % CI -11,8, -1,7). Emellertid var b\u00e5da analyserna \u00f6verensst\u00e4mmande n\u00e4r det g\u00e4ller slutsatsen om \u201dnon\u2011inferiority\u201d mellan b\u00e5da behandlingsarmarna.</span></p>", "ID": "4588fb76-c7e4-4cf1-acda-a895b3153cc4", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I en dubbelblind, kontrollerad, multicenterstudie (CNA30024) randomiserades 654 hivinfekterade behandlingsnaiva patienter till att f\u00e5 antingen 300 mg abakavir tv\u00e5 g\u00e5nger dagligen eller 300 mg zidovudin tv\u00e5 g\u00e5nger dagligen, i b\u00e5da fallen i kombination med 150 mg lamivudin tv\u00e5 g\u00e5nger dagligen och 600 mg efavirenz en g\u00e5ng dagligen. Den dubbelblinda behandlingen p\u00e5gick i minst 48 veckor. I \u201dintent to treat\u201d (ITT)\u2011populationen uppn\u00e5dde 70 % av patienterna i abakavirgruppen, j\u00e4mf\u00f6rt med 69 % av patienterna i zidovudingruppen, ett virologiskt svar p\u00e5 plasma hiv-1-RNA p\u00e5 \u226450 kopior/ml i vecka 48 (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnaden: 0,8, 95 % CI -6,3, 7,9). I analysen av \u201das treated\u201d (AT) var skillnaden mellan de b\u00e5da behandlingsarmarna mer m\u00e4rkbar, 88% av patienterna i abakavirgruppen j\u00e4mf\u00f6rt med 95 % av patienterna i zidovudingruppen (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnaden: -6,8, 95 % CI -11,8, -1,7). Emellertid var b\u00e5da analyserna \u00f6verensst\u00e4mmande n\u00e4r det g\u00e4ller slutsatsen om \u201dnon\u2011inferiority\u201d mellan b\u00e5da behandlingsarmarna.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "a62882b4-6c11-4c09-97f8-7874ef971264", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">ACTC5095 var en randomiserad (1:1:1), dubbelblind, placebokontrollerad pr\u00f6vning med 1 147 antiretroviralt naiva hiv\u20111\u2011infekterade vuxna, som j\u00e4mf\u00f6rde tre olika behandlingsregimer: zidovudin (ZDV), lamivudin (3TC), abakavir (ABC) och efavirenz (EFV) eller ZDV/3TC/EFV eller ZDV/3TC/ABC. Vid uppf\u00f6ljning efter 32 veckor (median) visade sig trippelterapin med de tre nukleosiderna ZDV/3TC/ABC vara virologiskt underl\u00e4gsen de andra tv\u00e5 armarna. 26 % av individerna i ZDV/3TC/ABC\u2011armen, 16 % i ZDV/3TC/EFV\u2011armen och 13 % i armen med 4 l\u00e4kemedel, fick virologisk svikt (hiv\u2011RNA &gt;200 kopior/ml). I vecka 48 var andelen individer med hiv\u2011RNA &lt;50 kopior/ml 63 %, 80 % respektive 86 % i ZDV/3TC/ABC-, ZDV/3TC/EFV- respektive ZDV/3TC/ABC/EFV\u2011armen. S\u00e4kerhetskommitt\u00e9n f\u00f6r studien stoppade ZDV/3TC/ABC\u2011armen vid denna tidpunkt baserat p\u00e5 den st\u00f6rre andelen patienter med virologisk svikt. De \u00e5terst\u00e5ende armarna fortsatte i blindad version. Vid uppf\u00f6ljning efter 144 veckor (median) fick 25 % av individerna i ZDV/3TC/ABC/EFV-armen och 26 % i ZDV/3TC/EFV-armen virologisk svikt. Det var ingen signifikant skillnad i tid till f\u00f6rsta virologiska svikt (p-0,73, \u201dlog-rank test\u201d) mellan de 2 armarna. I denna studie f\u00f6rb\u00e4ttrade inte till\u00e4gg av ABC till ZDV/3TC/EFV effekten signifikant.</span></p>", "ID": "e5a66e24-1af4-49be-8d0d-c7c7a2e39749", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "ACTC5095 var en randomiserad (1:1:1), dubbelblind, placebokontrollerad pr\u00f6vning med 1 147 antiretroviralt naiva hiv\u20111\u2011infekterade vuxna, som j\u00e4mf\u00f6rde tre olika behandlingsregimer: zidovudin (ZDV), lamivudin (3TC), abakavir (ABC) och efavirenz (EFV) eller ZDV/3TC/EFV eller ZDV/3TC/ABC. Vid uppf\u00f6ljning efter 32 veckor (median) visade sig trippelterapin med de tre nukleosiderna ZDV/3TC/ABC vara virologiskt underl\u00e4gsen de andra tv\u00e5 armarna. 26 % av individerna i ZDV/3TC/ABC\u2011armen, 16 % i ZDV/3TC/EFV\u2011armen och 13 % i armen med 4 l\u00e4kemedel, fick virologisk svikt (hiv\u2011RNA >200 kopior/ml). I vecka 48 var andelen individer med hiv\u2011RNA <50 kopior/ml 63 %, 80 % respektive 86 % i ZDV/3TC/ABC-, ZDV/3TC/EFV- respektive ZDV/3TC/ABC/EFV\u2011armen. S\u00e4kerhetskommitt\u00e9n f\u00f6r studien stoppade ZDV/3TC/ABC\u2011armen vid denna tidpunkt baserat p\u00e5 den st\u00f6rre andelen patienter med virologisk svikt. De \u00e5terst\u00e5ende armarna fortsatte i blindad version. Vid uppf\u00f6ljning efter 144 veckor (median) fick 25 % av individerna i ZDV/3TC/ABC/EFV-armen och 26 % i ZDV/3TC/EFV-armen virologisk svikt. Det var ingen signifikant skillnad i tid till f\u00f6rsta virologiska svikt (p-0,73, \u201dlog-rank test\u201d) mellan de 2 armarna. I denna studie f\u00f6rb\u00e4ttrade inte till\u00e4gg av ABC till ZDV/3TC/EFV effekten signifikant.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"></p>", "ID": "9870c77b-28d9-4a79-b863-6cf32d5a72c1", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:13.45pt;border-collapse:collapse;border:none\"> <tr style=\"height:25.3pt\"> <td style=\"width:113.4pt;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"151\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"></p> </td> <td style=\"width:66.6pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"89\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"></p> </td> <td style=\"width:75.1pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"100\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">ZDV/3TC/AB   C</span></p> </td> <td style=\"width:86.85pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"116\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">ZDV/3TC/EFV</span></p> </td> <td style=\"width:111.55pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"149\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">ZDV/3TC/ABC/EFV</span></p> </td> </tr> <tr style=\"height:12.55pt\"> <td rowspan=\"2\" style=\"width:113.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"151\"> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">Virologisk   svikt (hiv\u2011RNA &gt;200 kopior/ml)</span></p> </td> <td style=\"width:66.6pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:12.55pt\" valign=\"top\" width=\"89\"> <p class=\"TableParagraph\"><span lang=\"SV\">32 veckor</span></p> </td> <td style=\"width:75.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"100\"> <p class=\"TableParagraph\"><span lang=\"SV\">26 %</span></p> </td> <td style=\"width:86.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"116\"> <p class=\"TableParagraph\"><span lang=\"SV\">16 %</span></p> </td> <td style=\"width:111.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"149\"> <p class=\"TableParagraph\"><span lang=\"SV\">13 %</span></p> </td> </tr> <tr style=\"height:12.55pt\"> <td style=\"width:66.6pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:12.55pt\" valign=\"top\" width=\"89\"> <p class=\"TableParagraph\"><span lang=\"SV\">144 veckor</span></p> </td> <td style=\"width:75.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"100\"> <p class=\"TableParagraph\"><span lang=\"SV\">-</span></p> </td> <td style=\"width:86.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"116\"> <p class=\"TableParagraph\"><span lang=\"SV\">26 %</span></p> </td> <td style=\"width:111.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"149\"> <p class=\"TableParagraph\"><span lang=\"SV\">25 %</span></p> </td> </tr> <tr style=\"height:50.6pt\"> <td style=\"width:113.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"151\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:.55pt;text-align:left\"></p> <p align=\"left\" class=\"TableParagraph\" style=\"text-align:left\"><span lang=\"SV\">Virologisk   framg\u00e5ng (48 veckor hiv\u2011RNA &lt;50 kopior/ml)</span></p> </td> <td style=\"width:66.6pt;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:50.6pt\" valign=\"top\" width=\"89\"> <p class=\"TableParagraph\"></p> </td> <td style=\"width:75.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"100\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">63 %</span></p> </td> <td style=\"width:86.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"116\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">80 %</span></p> </td> <td style=\"width:111.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:50.6pt\" valign=\"top\" width=\"149\"> <p class=\"TableParagraph\" style=\"margin-top:.55pt\"></p> <p class=\"TableParagraph\"><span lang=\"SV\">86 %</span></p> </td> </tr> </table>", "ID": "79d9bb33-e448-4d17-8484-e26b8c0073c4", "Styles": "margin-left:13.45pt;border-collapse:collapse;border:none", "Classes": "['TableNormal1']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": true, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": "         ZDV/3TC/AB   C   ZDV/3TC/EFV   ZDV/3TC/ABC/EFV     ", "Text": "         ZDV/3TC/AB  C    ZDV/3TC/EFV    ZDV/3TC/ABC/EFV      Virologisk  svikt (hiv\u2011RNA >200 kopior/ml)    32 veckor    26 %    16 %    13 %      144 veckor    -    26 %    25 %       Virologisk  framg\u00e5ng (48 veckor hiv\u2011RNA <50 kopior/ml)        63 %     80 %     86 %   ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in\"></p>", "ID": "61344bb2-1851-432d-b21a-42653852f36d", "Styles": "margin-left:0in", "Classes": "['MsoListParagraph']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"SV\" style=\"font-family:Symbol\">\u00b7</span><i><span lang=\"SV\">Behandlingserfarnavuxna</span></i></p>", "ID": "17c3207d-7cbf-48bf-9486-376690f122ed", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 Behandlingserfarna vuxna", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "c9473ad5-c302-4904-89d1-9aa1d32a2723", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"text-align:justify\"><span lang=\"SV\">Till vuxna\r patienter med m\u00e5ttlig tidigare exponering f\u00f6r antiretrovirala l\u00e4kemedel gav\r till\u00e4gget av abakavir till befintlig antiretroviral kombinationsbehandling\r blygsamma effekter n\u00e4r det g\u00e4llde att <span style=\"position:relative;\r top:-1.0pt\">minska virusm\u00e4ngden (medianf\u00f6r\u00e4ndring 0,44 log<sub>10</sub></span> <span style=\"position:relative;top:-1.0pt\">kopior/ml vid 16 veckor).</span></span></p>", "ID": "ad12505e-4c8a-4d9a-8e04-9846ca6f932e", "Styles": "text-align:justify", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Till vuxna patienter med m\u00e5ttlig tidigare exponering f\u00f6r antiretrovirala l\u00e4kemedel gav till\u00e4gget av abakavir till befintlig antiretroviral kombinationsbehandling blygsamma effekter n\u00e4r det g\u00e4llde att minska virusm\u00e4ngden (medianf\u00f6r\u00e4ndring 0,44 log 10  kopior/ml vid 16 veckor).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "f37cec1b-d36e-43b0-ac27-f66be35ffd6f", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Hos patienter med omfattande erfarenhet av behandling med NRTIs var effekten av abakavir marginell. V\u00e4rdet av att addera abakavir till en antiretroviral kombinationsbehandling beror p\u00e5 typ och duration av tidigare behandling, vilken kan ha selekterat fram hiv\u20111\u2011varianter med korsresistens mot abakavir.</span></p>", "ID": "b72f2413-11e6-4812-913e-d146ae627375", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Hos patienter med omfattande erfarenhet av behandling med NRTIs var effekten av abakavir marginell. V\u00e4rdet av att addera abakavir till en antiretroviral kombinationsbehandling beror p\u00e5 typ och duration av tidigare behandling, vilken kan ha selekterat fram hiv\u20111\u2011varianter med korsresistens mot abakavir.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "62803770-be5e-4d57-a812-e5a00c467fa7", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">Dosering (600 mg) en g\u00e5ng dagligen</span></i></p>", "ID": "683d0ebf-4323-468c-b08e-fabba68b5b1f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Dosering (600 mg) en g\u00e5ng dagligen", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "72694e85-67c0-4e1a-bfc0-d35571c46ef3", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><span lang=\"SV\" style=\"font-family:Symbol\">\u00b7</span><i><span lang=\"SV\">Behandlingsnaivavuxna</span></i></p>", "ID": "d6620924-e4bb-4c63-b921-df1f563ce8f2", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 Behandlingsnaiva vuxna", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "88ca62c0-c826-414b-bd11-cbe661fc11fb", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Dosering en g\u00e5ng dagligen st\u00f6ds av en 48\u2011veckors dubbelblind, kontrollerad mulitcenterstudie (CNA30021) p\u00e5 770 hivinfekterade terapinaiva vuxna, som huvudsakligen var symtomfria - Centre for Disease Control and Prevention (CDC) stadie A. De randomiserades till att f\u00e5 antingen 600 mg abakavir en g\u00e5ng dagligen eller 300 mg tv\u00e5 g\u00e5nger dagligen, i kombination med efavirenz och lamivudin som gavs en g\u00e5ng dagligen. Liknande klinisk framg\u00e5ng (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnad -1,7, 95 % CI -8,4, 4,9) s\u00e5gs i b\u00e5da behandlingsregimerna. Fr\u00e5n dessa resultat kan man dra slutsatsen att vid 95 % konfidens \u00e4r den verkliga skillnaden inte st\u00f6rre \u00e4n 8,4 % till f\u00f6rdel f\u00f6r tv\u00e5 g\u00e5nger dagligen doseringen. Denna potentiella skillnad \u00e4r tillr\u00e4ckligt liten f\u00f6r att kunna dra en generell slutsats av \u201dnon\u2011inferiority\u201d f\u00f6r abakavir en g\u00e5ng dagligen \u00f6ver abakavir tv\u00e5 g\u00e5nger dagligen.</span></p>", "ID": "98a54e96-850b-4d18-86fb-25ef37ba86b9", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Dosering en g\u00e5ng dagligen st\u00f6ds av en 48\u2011veckors dubbelblind, kontrollerad mulitcenterstudie (CNA30021) p\u00e5 770 hivinfekterade terapinaiva vuxna, som huvudsakligen var symtomfria - Centre for Disease Control and Prevention (CDC) stadie A. De randomiserades till att f\u00e5 antingen 600 mg abakavir en g\u00e5ng dagligen eller 300 mg tv\u00e5 g\u00e5nger dagligen, i kombination med efavirenz och lamivudin som gavs en g\u00e5ng dagligen. Liknande klinisk framg\u00e5ng (\u201dpoint estimate\u201d f\u00f6r behandlingsskillnad -1,7, 95 % CI -8,4, 4,9) s\u00e5gs i b\u00e5da behandlingsregimerna. Fr\u00e5n dessa resultat kan man dra slutsatsen att vid 95 % konfidens \u00e4r den verkliga skillnaden inte st\u00f6rre \u00e4n 8,4 % till f\u00f6rdel f\u00f6r tv\u00e5 g\u00e5nger dagligen doseringen. Denna potentiella skillnad \u00e4r tillr\u00e4ckligt liten f\u00f6r att kunna dra en generell slutsats av \u201dnon\u2011inferiority\u201d f\u00f6r abakavir en g\u00e5ng dagligen \u00f6ver abakavir tv\u00e5 g\u00e5nger dagligen.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "55c238b5-6462-4232-a6d3-eb48363a482c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Det var en l\u00e5g, likartad total incidens av virologisk svikt (virusm\u00e4ngd \u226450 kopior/ml) i b\u00e5de behandlingsgruppen med dosering en g\u00e5ng dagligen och den med dosering tv\u00e5 g\u00e5nger dagligen (10 % respektive 8 %). I den begr\u00e4nsade m\u00e4ngden prov som fanns tillg\u00e4ngliga f\u00f6r genotypisk analys fanns en trend mot ett h\u00f6gre antal NRTI\u2011mutationer vid dosering med abakavir en g\u00e5ng per dag j\u00e4mf\u00f6rt med dosering tv\u00e5 g\u00e5nger per dag. N\u00e5gon tydlig slutsats kunde inte dras p.g.a. den begr\u00e4nsade datam\u00e4ngden som kunde erh\u00e5llas fr\u00e5n denna studie. L\u00e5ngtidsdata f\u00f6r abakavir med dosering en g\u00e5ng dagligen (l\u00e4ngre \u00e4n 48 veckor) \u00e4r f\u00f6r n\u00e4rvarande begr\u00e4nsade.</span></p>", "ID": "ffdd5f91-a962-4811-ab60-f5535b30bbbe", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Det var en l\u00e5g, likartad total incidens av virologisk svikt (virusm\u00e4ngd \u226450 kopior/ml) i b\u00e5de behandlingsgruppen med dosering en g\u00e5ng dagligen och den med dosering tv\u00e5 g\u00e5nger dagligen (10 % respektive 8 %). I den begr\u00e4nsade m\u00e4ngden prov som fanns tillg\u00e4ngliga f\u00f6r genotypisk analys fanns en trend mot ett h\u00f6gre antal NRTI\u2011mutationer vid dosering med abakavir en g\u00e5ng per dag j\u00e4mf\u00f6rt med dosering tv\u00e5 g\u00e5nger per dag. N\u00e5gon tydlig slutsats kunde inte dras p.g.a. den begr\u00e4nsade datam\u00e4ngden som kunde erh\u00e5llas fr\u00e5n denna studie. L\u00e5ngtidsdata f\u00f6r abakavir med dosering en g\u00e5ng dagligen (l\u00e4ngre \u00e4n 48 veckor) \u00e4r f\u00f6r n\u00e4rvarande begr\u00e4nsade.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "db3b02b7-9308-4c9b-88f6-d3b1b46b447a", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><span lang=\"SV\" style=\"font-family:Symbol\">\u00b7</span><i><span lang=\"SV\">Behandlingserfarnavuxna</span></i></p>", "ID": "d6fa344f-f650-490f-9a5d-975a6926bb7e", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00b7 Behandlingserfarna vuxna", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.4pt\"></p>", "ID": "82a375ae-aa8c-4ced-a94b-e50c5372dee5", "Styles": "margin-top:.4pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">I studie CAL30001 randomiserades 182 behandlingserfarna\r patienter med virologisk svikt till behandling med antingen den fasta\r doskombinationen abakavir/lamivudin en g\u00e5ng dagligen eller abakavir 300 mg\r tv\u00e5 g\u00e5nger dagligen plus lamivudin 300 mg en g\u00e5ng dagligen, b\u00e5da i\r kombination med tenofovir och en PI eller en NNRTI under 48 veckor.\r Resultat visar att gruppen med fast doskombination inte var s\u00e4mre \u00e4n (non\r inferior) gruppen som fick abakavir tv\u00e5 g\u00e5nger per dag, baserat p\u00e5 en liknande\r nedg\u00e5ng av hiv\u20111\u2011RNA uppm\u00e4tt genom medelv\u00e4rdet av AUC minus\r baseline<span style=\"position:relative;top:-1.0pt\"> (AAUCMB, -1,65 log<sub>10</sub></span> <span style=\"position:relative;top:-1.0pt\">kopior/ml respektive -1,83 log<sub>10</sub></span> <span style=\"position:relative;top:-1.0pt\">kopior/ml, 95 % CI -0,13, 0,38). Andelen </span>patienter med hiv\u20111\u2011RNA &lt; 50 kopior/ml (50 %\r mot 47 %) och &lt;400 kopior/ml (54 % mot 57 %) var ocks\u00e5\r likartad i de b\u00e5da grupperna. Dessa resultat b\u00f6r emellertid tolkas med\r f\u00f6rsiktighet, eftersom endast patienter med m\u00e5ttlig behandlingserfarenhet\r ingick i denna studie och n\u00e4r behandling sattes in fanns en obalans i\r virusm\u00e4ngd mellan de b\u00e5da armarna.</span></p>", "ID": "0a839d78-a1ab-4676-8302-3666ad9aaa22", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I studie CAL30001 randomiserades 182 behandlingserfarna patienter med virologisk svikt till behandling med antingen den fasta doskombinationen abakavir/lamivudin en g\u00e5ng dagligen eller abakavir 300 mg tv\u00e5 g\u00e5nger dagligen plus lamivudin 300 mg en g\u00e5ng dagligen, b\u00e5da i kombination med tenofovir och en PI eller en NNRTI under 48 veckor. Resultat visar att gruppen med fast doskombination inte var s\u00e4mre \u00e4n (non inferior) gruppen som fick abakavir tv\u00e5 g\u00e5nger per dag, baserat p\u00e5 en liknande nedg\u00e5ng av hiv\u20111\u2011RNA uppm\u00e4tt genom medelv\u00e4rdet av AUC minus baseline (AAUCMB, -1,65 log 10  kopior/ml respektive -1,83 log 10  kopior/ml, 95 % CI -0,13, 0,38). Andelen patienter med hiv\u20111\u2011RNA < 50 kopior/ml (50 % mot 47 %) och <400 kopior/ml (54 % mot 57 %) var ocks\u00e5 likartad i de b\u00e5da grupperna. Dessa resultat b\u00f6r emellertid tolkas med f\u00f6rsiktighet, eftersom endast patienter med m\u00e5ttlig behandlingserfarenhet ingick i denna studie och n\u00e4r behandling sattes in fanns en obalans i virusm\u00e4ngd mellan de b\u00e5da armarna.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "40422265-f121-4627-80c0-f04fd963f8f2", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">260 patienter med virologisk suppression p\u00e5 en f\u00f6rsta linjens terapi best\u00e5ende av abakavir 300 mg plus lamivudin 150 mg, b\u00e5da givna tv\u00e5 g\u00e5nger dagligen, i kombination med en PI eller NNRTI, randomiserades i en studie, ESS 30008, till att forts\u00e4tta denna regim eller att byta till den fasta kombinationen abakavir/lamivudin plus en PI eller NNRTI under 48 veckor. Resultat visar att gruppen med den fasta kombinationen uppn\u00e5dde samma virologiska utfall (\u201dnon\u2011inferior\u201d) som abakavir plus lamividingruppen, baserat p\u00e5 andelen individer med hiv\u20111\u2011RNA &lt;50 kopior/ml (90 % respektive 85 %, 95 % CI -2,7, 13,5).</span></p>", "ID": "73046aab-8efa-4e7f-8835-420b4dad70e4", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "260 patienter med virologisk suppression p\u00e5 en f\u00f6rsta linjens terapi best\u00e5ende av abakavir 300 mg plus lamivudin 150 mg, b\u00e5da givna tv\u00e5 g\u00e5nger dagligen, i kombination med en PI eller NNRTI, randomiserades i en studie, ESS 30008, till att forts\u00e4tta denna regim eller att byta till den fasta kombinationen abakavir/lamivudin plus en PI eller NNRTI under 48 veckor. Resultat visar att gruppen med den fasta kombinationen uppn\u00e5dde samma virologiska utfall (\u201dnon\u2011inferior\u201d) som abakavir plus lamividingruppen, baserat p\u00e5 andelen individer med hiv\u20111\u2011RNA <50 kopior/ml (90 % respektive 85 %, 95 % CI -2,7, 13,5).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "45602e7a-728b-4cb6-b894-56932c325ead", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><span lang=\"SV\">Ytterligare information</span></i></p>", "ID": "72c04dd9-6d5c-47e5-9cea-35217f6e6c44", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Ytterligare information", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"></p>", "ID": "b77865b7-b182-4e3f-8fa9-243b5e53c4b4", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><span lang=\"SV\">Effekt och s\u00e4kerhet av abakavir givet som en del av olika kombinationsbehandlingar, \u00e4r fortfarande inte fullst\u00e4ndigt utredd (i synnerhet kombinationer med NNRTIs).</span></p>", "ID": "bba56a37-9b08-4077-8692-28e58904cf1d", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Effekt och s\u00e4kerhet av abakavir givet som en del av olika kombinationsbehandlingar, \u00e4r fortfarande inte fullst\u00e4ndigt utredd (i synnerhet kombinationer med NNRTIs).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "2bdb077d-60e9-481f-8827-1049a6744fcb", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir penetrerar till cerebrospinalv\u00e4tskan (se avsnitt 5.2) och har visats minska niv\u00e5erna av hiv\u20111\u2011RNA i likvor. Dock noterades inga effekter p\u00e5 neuropsykologiska variabler n\u00e4r det gavs till patienter med AIDS\u2011relaterad demens.</span></p>", "ID": "bb26e38c-2231-4701-b700-1b80932fc6bb", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir penetrerar till cerebrospinalv\u00e4tskan (se avsnitt 5.2) och har visats minska niv\u00e5erna av hiv\u20111\u2011RNA i likvor. Dock noterades inga effekter p\u00e5 neuropsykologiska variabler n\u00e4r det gavs till patienter med AIDS\u2011relaterad demens.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "9a659143-8937-4113-9f07-698b3c0d3c46", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:.05pt\"><i><u><span lang=\"SV\">Pediatrisk population</span></u></i></p>", "ID": "ff537c0d-64a4-497c-bc02-393d0d3342ec", "Styles": "margin-top:.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Pediatrisk population", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "1a8124bd-8fe6-4bc9-85d5-aaea1c0d8dc4", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">En randomiserad j\u00e4mf\u00f6relse av en doseringsregim med administrering av abakavir och lamivudin en g\u00e5ng dagligen j\u00e4mf\u00f6rt med tv\u00e5 g\u00e5nger dagligen genomf\u00f6rdes inom en randomiserad, multicenter, kontrollerad studie av hivinfekterade pediatriska patienter. 1 206 barn i \u00e5ldern 3 m\u00e5nader till 17 \u00e5r inkluderades i studien ARROW (COL105677) och doserades efter viktintervall enligt doseringsrekommendationerna i V\u00e4rldsh\u00e4lsoorganisationens behandlingsriktlinje (Antiretroviral behandling av hivinfektion hos sp\u00e4dbarn och barn, 2006). Efter 36 veckor p\u00e5 en regim med doseringen av abakavir och lamivudin tv\u00e5 g\u00e5nger dagligen randomiserades l\u00e4mpliga 669 patienter till att antingen forts\u00e4tta med dosering tv\u00e5 g\u00e5nger dagligen eller till att byta dosering till abakavir och lamivudin en g\u00e5ng dagligen under minst 96 veckor. Notera att fr\u00e5n denna studie erh\u00f6lls inga kliniska data f\u00f6r barn under ett \u00e5r. Resultaten sammanfattas i tabellen nedan:</span></p>", "ID": "66dc6414-4b1c-4302-84f0-850b439bf46d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "En randomiserad j\u00e4mf\u00f6relse av en doseringsregim med administrering av abakavir och lamivudin en g\u00e5ng dagligen j\u00e4mf\u00f6rt med tv\u00e5 g\u00e5nger dagligen genomf\u00f6rdes inom en randomiserad, multicenter, kontrollerad studie av hivinfekterade pediatriska patienter. 1 206 barn i \u00e5ldern 3 m\u00e5nader till 17 \u00e5r inkluderades i studien ARROW (COL105677) och doserades efter viktintervall enligt doseringsrekommendationerna i V\u00e4rldsh\u00e4lsoorganisationens behandlingsriktlinje (Antiretroviral behandling av hivinfektion hos sp\u00e4dbarn och barn, 2006). Efter 36 veckor p\u00e5 en regim med doseringen av abakavir och lamivudin tv\u00e5 g\u00e5nger dagligen randomiserades l\u00e4mpliga 669 patienter till att antingen forts\u00e4tta med dosering tv\u00e5 g\u00e5nger dagligen eller till att byta dosering till abakavir och lamivudin en g\u00e5ng dagligen under minst 96 veckor. Notera att fr\u00e5n denna studie erh\u00f6lls inga kliniska data f\u00f6r barn under ett \u00e5r. Resultaten sammanfattas i tabellen nedan:", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "bb243908-a559-498c-8b70-13c09df91827", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin-top:0in\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\r \"Times New Roman\",serif;color:windowtext'>Virologiskt svar baserat p\u00e5 plasma hiv-1 RNA l\u00e4gre \u00e4n 80 kopior/ml vid vecka 48 och vecka 96 hos personer som randomiserats i studien ARROW antingen till doseringen abakavir + lamivudin en g\u00e5ng dagligen eller tv\u00e5 g\u00e5nger dagligen. (observerad analys).</span></h1>", "ID": "3d8cb439-f42d-45da-a30b-50970c201108", "Styles": "margin-top:0in", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Virologiskt svar baserat p\u00e5 plasma hiv-1 RNA l\u00e4gre \u00e4n 80 kopior/ml vid vecka 48 och vecka 96 hos personer som randomiserats i studien ARROW antingen till doseringen abakavir + lamivudin en g\u00e5ng dagligen eller tv\u00e5 g\u00e5nger dagligen. (observerad analys).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.15pt\"></p>", "ID": "0aea4f9c-f6df-4ccc-a9f5-34bab2fa41c4", "Styles": "margin-top:.15pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:7.35pt;border-collapse:collapse;border:none\"> <tr style=\"height:25.3pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"></p> </td> <td style=\"width:120.85pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"161\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">Tv\u00e5 g\u00e5nger   dagligen N (%)</span></b></p> </td> <td style=\"width:155.55pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"207\"> <p class=\"TableParagraph\" style=\"margin-top:.1pt\"><b><span lang=\"SV\">En g\u00e5ng   dagligen N (%)</span></b></p> </td> </tr> <tr style=\"height:12.55pt\"> <td colspan=\"3\" style=\"width:446.5pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"595\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Vecka 0 (Efter \u2265 36 veckor p\u00e5   behandling)</span></b></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Plasma hiv-1 RNA &lt;80 kopior/ml</span></p> </td> <td style=\"width:120.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"161\"> <p class=\"TableParagraph\"><span lang=\"SV\">250/331 (76)</span></p> </td> <td style=\"width:155.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"207\"> <p class=\"TableParagraph\"><span lang=\"SV\">237/335 (71)</span></p> </td> </tr> <tr style=\"height:37.9pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Riskskillnad (en g\u00e5ng dagligen-tv\u00e5   g\u00e5nger dagligen)</span></p> </td> <td colspan=\"2\" style=\"width:276.4pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"369\"> <p class=\"TableParagraph\"><span lang=\"SV\">-4,8 % (95 % KI -11,5 %   till +1,9 %), p=0,16</span></p> </td> </tr> <tr style=\"height:12.55pt\"> <td colspan=\"3\" style=\"width:446.5pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"595\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Vecka 48</span></b></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Plasma hiv-1 RNA &lt;80 kopior/ml</span></p> </td> <td style=\"width:120.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"161\"> <p class=\"TableParagraph\"><span lang=\"SV\">242/331 (73)</span></p> </td> <td style=\"width:155.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"207\"> <p class=\"TableParagraph\"><span lang=\"SV\">236/330 (72)</span></p> </td> </tr> <tr style=\"height:37.9pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Riskskillnad (en g\u00e5ng dagligen-tv\u00e5   g\u00e5nger dagligen)</span></p> </td> <td colspan=\"2\" style=\"width:276.4pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"369\"> <p class=\"TableParagraph\"><span lang=\"SV\">-1,6 % (95 % KI -8,4 %   till +5,2 %), p=0,65</span></p> </td> </tr> <tr style=\"height:12.55pt\"> <td colspan=\"3\" style=\"width:446.5pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:12.55pt\" valign=\"top\" width=\"595\"> <p class=\"TableParagraph\"><b><span lang=\"SV\">Vecka 96</span></b></p> </td> </tr> <tr style=\"height:25.3pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Plasma hiv\u20111 RNA &lt;80 kopior/ml</span></p> </td> <td style=\"width:120.85pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"161\"> <p class=\"TableParagraph\"><span lang=\"SV\">234/326 (72)</span></p> </td> <td style=\"width:155.55pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:25.3pt\" valign=\"top\" width=\"207\"> <p class=\"TableParagraph\"><span lang=\"SV\">230/331 (69)</span></p> </td> </tr> <tr style=\"height:37.9pt\"> <td style=\"width:170.1pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"227\"> <p class=\"TableParagraph\"><span lang=\"SV\">Riskskillnad (en g\u00e5ng dagligen\u2013tv\u00e5   g\u00e5nger dagligen)</span></p> </td> <td colspan=\"2\" style=\"width:276.4pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:37.9pt\" valign=\"top\" width=\"369\"> <p class=\"TableParagraph\"><span lang=\"SV\">-2,3 % (95 % KI -9,3 %   till +4,7 %), p=0,52</span></p> </td> </tr> </table>", "ID": "ed1747d5-aff2-48cb-afbb-b82daef5e28d", "Styles": "margin-left:7.35pt;border-collapse:collapse;border:none", "Classes": "['TableNormal1']", "Bold": null, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": true, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": "      Tv\u00e5 g\u00e5nger   dagligen N (%)   En g\u00e5ng   dagligen N (%)     Vecka 0 (Efter \u2265 36 veckor p\u00e5   behandling)     ", "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "      Tv\u00e5 g\u00e5nger  dagligen N (%)    En g\u00e5ng  dagligen N (%)      Vecka 0 (Efter \u2265 36 veckor p\u00e5  behandling)      Plasma hiv-1 RNA <80 kopior/ml    250/331 (76)    237/335 (71)      Riskskillnad (en g\u00e5ng dagligen-tv\u00e5  g\u00e5nger dagligen)    -4,8 % (95 % KI -11,5 %  till +1,9 %), p=0,16      Vecka 48      Plasma hiv-1 RNA <80 kopior/ml    242/331 (73)    236/330 (72)      Riskskillnad (en g\u00e5ng dagligen-tv\u00e5  g\u00e5nger dagligen)    -1,6 % (95 % KI -8,4 %  till +5,2 %), p=0,65      Vecka 96      Plasma hiv\u20111 RNA <80 kopior/ml    234/326 (72)    230/331 (69)      Riskskillnad (en g\u00e5ng dagligen\u2013tv\u00e5  g\u00e5nger dagligen)    -2,3 % (95 % KI -9,3 %  till +4,7 %), p=0,52   ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "d612dc24-7ecf-4ba7-bcb9-4ce8dd1ebd11", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Non\u2011inferiority uppvisades i gruppen som fick abakavir + lamivudin en g\u00e5ng dagligen j\u00e4mf\u00f6rt med gruppen som fick abakavir + lamivudin tv\u00e5 g\u00e5nger dagligen enligt den f\u00f6rbest\u00e4mda non-inferiority marginalen p\u00e5 -12 %, f\u00f6r prim\u00e4r endpoint &lt;80 kopior/ml vid vecka 48 samt vid vecka 96 (sekund\u00e4r endpoint) och alla andra testade gr\u00e4nsv\u00e4rden (&lt;200 kopior/ml, &lt;400 kopior/ml, &lt;1 000 kopior/ ml). Samtliga av dessa v\u00e4rden var v\u00e4l inom marginalen f\u00f6r non\u2011inferiority. Subgruppsanalyser med syfte att testa f\u00f6r heterogenitet vid en g\u00e5ng mot tv\u00e5 g\u00e5nger dagligen visade ingen signifikant p\u00e5verkan av k\u00f6n, \u00e5lder eller virusm\u00e4ngd vid randomisering. Slutsatserna st\u00f6dde non-inferiority oavsett analysmetod.</span></p>", "ID": "f420bf1c-d826-4d1a-86c1-56fb9c51a103", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Non\u2011inferiority uppvisades i gruppen som fick abakavir + lamivudin en g\u00e5ng dagligen j\u00e4mf\u00f6rt med gruppen som fick abakavir + lamivudin tv\u00e5 g\u00e5nger dagligen enligt den f\u00f6rbest\u00e4mda non-inferiority marginalen p\u00e5 -12 %, f\u00f6r prim\u00e4r endpoint <80 kopior/ml vid vecka 48 samt vid vecka 96 (sekund\u00e4r endpoint) och alla andra testade gr\u00e4nsv\u00e4rden (<200 kopior/ml, <400 kopior/ml, <1 000 kopior/ ml). Samtliga av dessa v\u00e4rden var v\u00e4l inom marginalen f\u00f6r non\u2011inferiority. Subgruppsanalyser med syfte att testa f\u00f6r heterogenitet vid en g\u00e5ng mot tv\u00e5 g\u00e5nger dagligen visade ingen signifikant p\u00e5verkan av k\u00f6n, \u00e5lder eller virusm\u00e4ngd vid randomisering. Slutsatserna st\u00f6dde non-inferiority oavsett analysmetod.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "c6ee88e5-57b0-4ae1-9c9b-75201d6ef2ce", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:3.65pt\"><span lang=\"SV\">I en separat studie p\u00e5 barn d\u00e4r \u00f6ppna NRTI-kombinationer (med eller utan nelfinavir) j\u00e4mf\u00f6rdes hade en h\u00f6gre andel behandlade med abakavir och lamivudin (71 %) eller abakakvir och zidovudin (60 %) hiv-1-RNA \u2264400 kopior/ml efter 48 veckor j\u00e4mf\u00f6rt med dem behandlade med lamivudin och zidovudin (47%) (P = 0,09, Intention To Treat\u2011analys). Analogt med dessa resultat noterades h\u00f6gre procentsiffror f\u00f6r de barn som behandlades med abakavirinneh\u00e5llande regimer vad g\u00e4ller hiv-1-RNA \u226450 kopior/ml efter 48 veckor (53 %, 42 % respektive 28 %; P = 0,07).</span></p>", "ID": "849d9637-f291-4a04-8bdb-c182080bda1c", "Styles": "margin-top:3.65pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I en separat studie p\u00e5 barn d\u00e4r \u00f6ppna NRTI-kombinationer (med eller utan nelfinavir) j\u00e4mf\u00f6rdes hade en h\u00f6gre andel behandlade med abakavir och lamivudin (71 %) eller abakakvir och zidovudin (60 %) hiv-1-RNA \u2264400 kopior/ml efter 48 veckor j\u00e4mf\u00f6rt med dem behandlade med lamivudin och zidovudin (47%) (P = 0,09, Intention To Treat\u2011analys). Analogt med dessa resultat noterades h\u00f6gre procentsiffror f\u00f6r de barn som behandlades med abakavirinneh\u00e5llande regimer vad g\u00e4ller hiv-1-RNA \u226450 kopior/ml efter 48 veckor (53 %, 42 % respektive 28 %; P = 0,07).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "c06d6199-c752-4b6d-a470-cb1b8086fd24", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:4.55pt\"><span lang=\"SV\">I en farmakokinetisk studie (PENTA 15), bytte fyra virologiskt kontrollerade patienter som var yngre \u00e4n 12 m\u00e5nader gamla fr\u00e5n abakavir plus lamivudin oral l\u00f6sning tv\u00e5 g\u00e5nger dagligen till doseringsregimen en g\u00e5ng dagligen. Tre av patienterna hade om\u00e4tbara virusniv\u00e5er och en hade plasma hiv\u2011RNA p\u00e5 900 kopior/ml vid vecka 48. Inga s\u00e4kerhetsproblem observerades hos dessa patienter.</span></p>", "ID": "eda3b31a-8ead-45a0-a3bd-79744bebb089", "Styles": "margin-top:4.55pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I en farmakokinetisk studie (PENTA 15), bytte fyra virologiskt kontrollerade patienter som var yngre \u00e4n 12 m\u00e5nader gamla fr\u00e5n abakavir plus lamivudin oral l\u00f6sning tv\u00e5 g\u00e5nger dagligen till doseringsregimen en g\u00e5ng dagligen. Tre av patienterna hade om\u00e4tbara virusniv\u00e5er och en hade plasma hiv\u2011RNA p\u00e5 900 kopior/ml vid vecka 48. Inga s\u00e4kerhetsproblem observerades hos dessa patienter.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "d3b1f85e-d538-4e95-8e15-27422400da43", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>5.2</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Farmakokinetiskaegenskaper</span></h1>", "ID": "da25d4d1-019e-412e-9646-fd8caaf6187b", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "5.2 Farmakokinetiska egenskaper", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "0bc79e12-3be9-4f55-a259-ddcb81fc748e", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Absorption</span></u></p>", "ID": "ec5ab39c-2233-4410-b67c-d00afe046d77", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Absorption", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "4792b78a-fe34-44b7-bb9b-cec75e3aa988", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir absorberas snabbt och v\u00e4l efter\r oral tillf\u00f6rsel. Den absoluta biotillg\u00e4ngligheten hos vuxna <span style=\"position:relative;top:-1.0pt\">efter oralt intag \u00e4r ca 83 %. Efter\r oral administrering \u00e4r den genomsnittliga tiden (t<sub>max</sub>) till maximala\r serumkoncentrationer (C<sub>max</sub>) av abakavir ca 1,5 timmar f\u00f6r\r tablettberedningen och ca 1,0 timmar f\u00f6r </span>l\u00f6sningen.</span></p>", "ID": "f7bd4d93-ca89-4376-8e01-36496de4e2d2", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir absorberas snabbt och v\u00e4l efter oral tillf\u00f6rsel. Den absoluta biotillg\u00e4ngligheten hos vuxna efter oralt intag \u00e4r ca 83 %. Efter oral administrering \u00e4r den genomsnittliga tiden (t max ) till maximala serumkoncentrationer (C max ) av abakavir ca 1,5 timmar f\u00f6r tablettberedningen och ca 1,0 timmar f\u00f6r l\u00f6sningen.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.2pt\"></p>", "ID": "91589dca-a241-43e2-9372-8ff01ae2f770", "Styles": "margin-top:.2pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\" style=\"position:relative;top:-1.0pt\">Vid\r terapeutisk dosering med dosen 300 mg tv\u00e5 g\u00e5nger dagligen \u00e4r medelv\u00e4rdet\r (CV) av C<sub>max</sub> och C<sub>min</sub></span><span lang=\"SV\"> f\u00f6r abakavir\r vid steady\u2011state ca 3,00 mikrogram/ml (30 %) respektive 0,01\r mikrogram/ml (99 %). Medelv\u00e4rdet (CV) f\u00f6r AUC var \u00f6ver ett dosintervall p\u00e5\r 12 timmar 6,02 mikrogram timme/ml (29 %) <span style=\"position:\r relative;top:-1.0pt\">motsvarande ett dagligt AUC p\u00e5 ca 12,0 mikrogram\r timme/ml. C<sub>max</sub>\u2011v\u00e4rdet f\u00f6r den orala l\u00f6sningen \u00e4r n\u00e5got h\u00f6gre\r \u00e4n f\u00f6r tabletterna. Efter en tablettdos p\u00e5 600 mg abakavir var medelv\u00e4rdet (CV)\r f\u00f6r C<sub>max</sub> </span>ca 4,26 mikrogram/ml (28 %) och\r medelv\u00e4rdet (CV) av AUC<sub>\u221e</sub> var 11,95 mikrogram timme/ml (21 %).</span></p>", "ID": "6fb35b88-c2f6-47c6-a222-2e0edcd1e899", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Vid terapeutisk dosering med dosen 300 mg tv\u00e5 g\u00e5nger dagligen \u00e4r medelv\u00e4rdet (CV) av C max och C min f\u00f6r abakavir vid steady\u2011state ca 3,00 mikrogram/ml (30 %) respektive 0,01 mikrogram/ml (99 %). Medelv\u00e4rdet (CV) f\u00f6r AUC var \u00f6ver ett dosintervall p\u00e5 12 timmar 6,02 mikrogram timme/ml (29 %) motsvarande ett dagligt AUC p\u00e5 ca 12,0 mikrogram timme/ml. C max \u2011v\u00e4rdet f\u00f6r den orala l\u00f6sningen \u00e4r n\u00e5got h\u00f6gre \u00e4n f\u00f6r tabletterna. Efter en tablettdos p\u00e5 600 mg abakavir var medelv\u00e4rdet (CV) f\u00f6r C max  ca 4,26 mikrogram/ml (28 %) och medelv\u00e4rdet (CV) av AUC \u221e var 11,95 mikrogram timme/ml (21 %).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.2pt\"></p>", "ID": "6a7b474e-f150-43f5-8cc2-6e72ec6eea4f", "Styles": "margin-top:.2pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\" style=\"position:relative;top:-1.0pt\">F\u00f6da\r f\u00f6rdr\u00f6jer absorptionen och minskar C<sub>max</sub></span><span lang=\"SV\"> <span style=\"position:relative;top:-1.0pt\">men p\u00e5verkar inte de totala plasmakoncentrationerna </span>(AUC). Abacavir Accord kan d\u00e4rf\u00f6r tas med eller\r utan f\u00f6da.</span></p>", "ID": "8f605a21-038e-4554-a1a6-9e10e7d17ab9", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "F\u00f6da f\u00f6rdr\u00f6jer absorptionen och minskar C max  men p\u00e5verkar inte de totala plasmakoncentrationerna (AUC). Abacavir Accord kan d\u00e4rf\u00f6r tas med eller utan f\u00f6da.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "f49d462c-6fa1-495f-918b-e3ea9caf4fd2", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Administrering av krossade tabletter med en liten m\u00e4ngd halvfast f\u00f6da eller dryck f\u00f6rv\u00e4ntas inte ha n\u00e5gon p\u00e5verkan p\u00e5 den farmaceutiska kvaliteten och borde d\u00e4rf\u00f6r inte f\u00f6r\u00e4ndra den kliniska effekten. Denna slutsats baseras p\u00e5 fysiologisk-kemiska och farmakokinetiska data och f\u00f6ruts\u00e4tter att patienten krossar och intar hela dosen (100 % av tabletten) omedelbart.</span></p>", "ID": "affd6e4b-5c48-46d0-9d98-991ef5ad7ab0", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Administrering av krossade tabletter med en liten m\u00e4ngd halvfast f\u00f6da eller dryck f\u00f6rv\u00e4ntas inte ha n\u00e5gon p\u00e5verkan p\u00e5 den farmaceutiska kvaliteten och borde d\u00e4rf\u00f6r inte f\u00f6r\u00e4ndra den kliniska effekten. Denna slutsats baseras p\u00e5 fysiologisk-kemiska och farmakokinetiska data och f\u00f6ruts\u00e4tter att patienten krossar och intar hela dosen (100 % av tabletten) omedelbart.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "cedd18c7-d995-4ed7-9217-158dcb88a081", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Distribution</span></u></p>", "ID": "48201246-711c-4d6f-a3be-7080cdc5dbf4", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Distribution", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "8ce9f7b0-bd57-4dd0-923c-1528808d8215", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Efter intraven\u00f6s administrering var distributionsvolymen ca 0,8 liter/kg, vilket talar f\u00f6r att abakavir fritt penetrerar till kroppens v\u00e4vnader.</span></p>", "ID": "bb72d513-b0de-4d3d-81b9-e85a3aea0882", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Efter intraven\u00f6s administrering var distributionsvolymen ca 0,8 liter/kg, vilket talar f\u00f6r att abakavir fritt penetrerar till kroppens v\u00e4vnader.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "7ac2eb8e-9c4b-4e25-8f56-33ff624c0ba6", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Studier p\u00e5 hivinfekterade patienter har\r visat god penetration av abakavir till CSF, AUC-ratio i likvor/plasma p\u00e5 30\r till 44 %. N\u00e4r abakavir ges i dosen 600 mg tv\u00e5 g\u00e5nger dagligen \u00e4r\r observerade <span style=\"position:relative;top:-1.0pt\">maximala koncentrationer\r i likvor 9 g\u00e5nger h\u00f6gre \u00e4n abakavirs IC<sub>50</sub></span> <span style=\"position:relative;top:-1.0pt\">som \u00e4r 0,08 mikrog/ml eller 0,26 </span>mikroM.</span></p>", "ID": "178e3dfb-8521-473c-a1f7-38b2dd9f50cd", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Studier p\u00e5 hivinfekterade patienter har visat god penetration av abakavir till CSF, AUC-ratio i likvor/plasma p\u00e5 30 till 44 %. N\u00e4r abakavir ges i dosen 600 mg tv\u00e5 g\u00e5nger dagligen \u00e4r observerade maximala koncentrationer i likvor 9 g\u00e5nger h\u00f6gre \u00e4n abakavirs IC 50  som \u00e4r 0,08 mikrog/ml eller 0,26 mikroM.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "25e594e8-2a63-4628-9a13-89a2cc54f1d1", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"f3788fde-c3c4-49a7-bd6e-7edaba55690e\"></p><i><span lang=\"SV\">In vitro</span></i><none></none>", "ID": "d97859bf-d24d-4d61-ab14-a4fa29abe11b", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "In vitro", "startWith<upper>Text": null, "Text": "In vitro", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" id=\"f3788fde-c3c4-49a7-bd6e-7edaba55690e\"><span lang=\"SV\">-studier avseende bindning till plasmaproteiner pekar p\u00e5 att abakavir endast har en l\u00e5g till m\u00e5ttlig bindningsgrad (ca 49\u00a0%) till humana plasmaproteiner vid terapeutiska koncentrationer. Detta talar f\u00f6r en l\u00e5g risk f\u00f6r l\u00e4kemedelsinteraktioner genom p\u00e5verkan p\u00e5 plasmaproteinbindning.</span></p>", "ID": "f3788fde-c3c4-49a7-bd6e-7edaba55690e", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": null, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": true, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": "In vitro", "startWith<upper>Text": null, "Text": "-studier avseende bindning till plasmaproteiner pekar p\u00e5 att abakavir endast har en l\u00e5g till m\u00e5ttlig bindningsgrad (ca 49\u00a0%) till humana plasmaproteiner vid terapeutiska koncentrationer. Detta talar f\u00f6r en l\u00e5g risk f\u00f6r l\u00e4kemedelsinteraktioner genom p\u00e5verkan p\u00e5 plasmaproteinbindning.", "ParentId": "d97859bf-d24d-4d61-ab14-a4fa29abe11b"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "11285404-e8cc-4e86-9438-0bb1353c174e", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Metabolism</span></u></p>", "ID": "42ab97cd-8691-49bb-9ac8-b88db719f4ff", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Metabolism", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "7ce6f72a-a93e-47fb-b5f9-24b4644fe9cf", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir metaboliseras huvudsakligen i levern med cirka 2 % av den administrerade dosen uts\u00f6ndrad renalt i of\u00f6r\u00e4ndrad form. Huvudsaklig metabolismv\u00e4g hos m\u00e4nniska \u00e4r via alkoholdehydrogenas och via glukuronidering varvid 5\u00b4\u2011karboxylsyra och 5\u00b4\u2011glukuronid bildas. Dessa utg\u00f6r omkring 66 % av administrerad dos. Metaboliterna uts\u00f6ndras i urinen.</span></p>", "ID": "826b6226-80df-4921-afdd-0081b8477b85", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir metaboliseras huvudsakligen i levern med cirka 2 % av den administrerade dosen uts\u00f6ndrad renalt i of\u00f6r\u00e4ndrad form. Huvudsaklig metabolismv\u00e4g hos m\u00e4nniska \u00e4r via alkoholdehydrogenas och via glukuronidering varvid 5\u00b4\u2011karboxylsyra och 5\u00b4\u2011glukuronid bildas. Dessa utg\u00f6r omkring 66 % av administrerad dos. Metaboliterna uts\u00f6ndras i urinen.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "475f41ab-adb4-4dac-98cb-3e5459b48fac", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Eliminering</span></u></p>", "ID": "f04a135a-cda3-4f79-a692-1ca5320d14aa", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Eliminering", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Den genomsnittliga halveringstiden f\u00f6r abakavir \u00e4r ca 1,5 timmar. Det sker ingen signifikant ackumulering av abakavir efter upprepade orala doser av 300 mg tv\u00e5 g\u00e5nger dagligen. Eliminationen av abakavir sker via levermetabolism med efterf\u00f6ljande uts\u00f6ndring av metaboliter i f\u00f6rsta hand i urinen. I urinen \u00e5terfinns omkring 83 % av administrerad abakavirdos som metaboliter och of\u00f6r\u00e4ndrat abakavir. Resten av dosen elimineras via feces.</span></p>", "ID": "413eeb4b-5a14-4e99-9ac5-6ccff6432d89", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Den genomsnittliga halveringstiden f\u00f6r abakavir \u00e4r ca 1,5 timmar. Det sker ingen signifikant ackumulering av abakavir efter upprepade orala doser av 300 mg tv\u00e5 g\u00e5nger dagligen. Eliminationen av abakavir sker via levermetabolism med efterf\u00f6ljande uts\u00f6ndring av metaboliter i f\u00f6rsta hand i urinen. I urinen \u00e5terfinns omkring 83 % av administrerad abakavirdos som metaboliter och of\u00f6r\u00e4ndrat abakavir. Resten av dosen elimineras via feces.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "551a609a-7161-4ea0-a97d-5ce50699a7b2", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><u><span lang=\"SV\">Intracellul\u00e4r farmakokinetik</span></u></p>", "ID": "5bac969c-3e76-4dad-960b-84b318661c10", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Intracellul\u00e4r farmakokinetik", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><u><span lang=\"SV\"></span></u></p>", "ID": "11d7c31c-e8f2-452c-9ebb-ea4257d29467", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">I en studie p\u00e5 20 hivinfekterade\r patienter som fick 300 mg abakavir tv\u00e5 g\u00e5nger dagligen, med bara en 300 mg\r dos tagen f\u00f6re provtagningsperioden p\u00e5 24\u2011timmar, var det geometriska\r terminala medelv\u00e4rdet f\u00f6r halveringstiden av intracellul\u00e4rt carbovir\u2011TP\r vid steady\u2011state 20,6 timmar, j\u00e4mf\u00f6rt med 2,6 timmar som var\r det uppm\u00e4tta geometriska medelv\u00e4rdet f\u00f6r halveringstiden av abakavir i plasma i\r denna studie. I en cross\u2011over\u2011studie med 27 hivinfekterade\r patienter var exponeringen f\u00f6r intracellul\u00e4rt<span style=\"position:relative;\r top:-1.0pt\"> carbovir\u2011TP h\u00f6gre f\u00f6r abakavir 600 mg en g\u00e5ng dagligen (AUC</span><sub>24,ss</sub> <span style=\"position:relative;top:-1.0pt\">+32%, C</span><sub>max24,ss\r </sub><span style=\"position:relative;top:-1.0pt\">+99% ochC</span><sub>trough</sub> +18 %)\r j\u00e4mf\u00f6rt med 300 mg tv\u00e5 g\u00e5nger dagligen. Sammantaget st\u00f6der dessa data anv\u00e4ndning\r av abakavir 600 mg en g\u00e5ng dagligen f\u00f6r behandling av hivinfekterade\r patienter. Dessutom har effekten och s\u00e4kerheten av abakavir doserat en g\u00e5ng\r dagligen visats i en pivotal klinisk studie (CNA30021 \u2013 Se avsnitt 5.1\r Klinisk erfarenhet).</span></p>", "ID": "cb5d945e-e621-4d3a-945a-32bae5ee8590", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I en studie p\u00e5 20 hivinfekterade patienter som fick 300 mg abakavir tv\u00e5 g\u00e5nger dagligen, med bara en 300 mg dos tagen f\u00f6re provtagningsperioden p\u00e5 24\u2011timmar, var det geometriska terminala medelv\u00e4rdet f\u00f6r halveringstiden av intracellul\u00e4rt carbovir\u2011TP vid steady\u2011state 20,6 timmar, j\u00e4mf\u00f6rt med 2,6 timmar som var det uppm\u00e4tta geometriska medelv\u00e4rdet f\u00f6r halveringstiden av abakavir i plasma i denna studie. I en cross\u2011over\u2011studie med 27 hivinfekterade patienter var exponeringen f\u00f6r intracellul\u00e4rt carbovir\u2011TP h\u00f6gre f\u00f6r abakavir 600 mg en g\u00e5ng dagligen (AUC 24,ss  +32%, C max24,ss +99% och C trough +18 %) j\u00e4mf\u00f6rt med 300 mg tv\u00e5 g\u00e5nger dagligen. Sammantaget st\u00f6der dessa data anv\u00e4ndning av abakavir 600 mg en g\u00e5ng dagligen f\u00f6r behandling av hivinfekterade patienter. Dessutom har effekten och s\u00e4kerheten av abakavir doserat en g\u00e5ng dagligen visats i en pivotal klinisk studie (CNA30021 \u2013 Se avsnitt 5.1 Klinisk erfarenhet).", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.4pt\"></p>", "ID": "d4072296-2583-48fb-ab5b-a7a39793aceb", "Styles": "margin-top:.4pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\">Speciella patientgrupper</span></u></p>", "ID": "0850331b-106c-495a-8ded-e8eb204354f3", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Speciella patientgrupper", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><u><span lang=\"SV\"></span></u></p>", "ID": "876d5304-3f4d-4adf-83bd-f8853116e2df", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><i><span lang=\"SV\">Nedsatt leverfunktion</span></i></p>", "ID": "b60e4d9e-1d1e-4129-bed2-752f4811e34d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Nedsatt leverfunktion", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"><span lang=\"SV\">Abakavir metaboliseras huvudsakligen i levern. Abakavirs farmakokinetik har studerats hos patienter med mild leverfunktionsneds\u00e4ttning (Child\u2011Pugh score 5\u20116) vilka erh\u00f6ll 600 mg abakavir som en singeldos, median (intervall) AUC\u2011v\u00e4rdet var 24,1 (10,4 till 54,8) \u00b5g\u00b7h/ml. Resultaten visade att abakavirs genomsnittliga AUC (90 % CI) \u00f6kar 1,89 g\u00e5nger (1,32; 2,70) och att halveringstiden f\u00f6r abakavir \u00f6kar i genomsnitt 1,58 g\u00e5nger (1,22; 2,04). P\u00e5 grund av v\u00e4sentligt varierande abakavirexponeringar var det inte m\u00f6jligt att fastst\u00e4lla n\u00e5gon definitiv rekommendation f\u00f6r hur stor dosreduktion som beh\u00f6vs hos patienter med mild neds\u00e4ttning av leverfunktionen.</span></p>", "ID": "da46ab3a-869c-4ad8-97d5-fb690a9d5fcb", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir metaboliseras huvudsakligen i levern. Abakavirs farmakokinetik har studerats hos patienter med mild leverfunktionsneds\u00e4ttning (Child\u2011Pugh score 5\u20116) vilka erh\u00f6ll 600 mg abakavir som en singeldos, median (intervall) AUC\u2011v\u00e4rdet var 24,1 (10,4 till 54,8) \u00b5g\u00b7h/ml. Resultaten visade att abakavirs genomsnittliga AUC (90 % CI) \u00f6kar 1,89 g\u00e5nger (1,32; 2,70) och att halveringstiden f\u00f6r abakavir \u00f6kar i genomsnitt 1,58 g\u00e5nger (1,22; 2,04). P\u00e5 grund av v\u00e4sentligt varierande abakavirexponeringar var det inte m\u00f6jligt att fastst\u00e4lla n\u00e5gon definitiv rekommendation f\u00f6r hur stor dosreduktion som beh\u00f6vs hos patienter med mild neds\u00e4ttning av leverfunktionen.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "b84f2371-dba7-4355-b625-84f946b7982b", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir rekommenderas inte till patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning.</span></p>", "ID": "5f4aeef9-b1ca-46cf-999c-84dc5798db4d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir rekommenderas inte till patienter med m\u00e5ttlig eller kraftig leverfunktionsneds\u00e4ttning.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "3c528391-a9b7-46c4-af5e-d65078aeabb9", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">Nedsattnjurfunktion</span></i></p>", "ID": "99b9ad9b-3a61-475b-92c6-32ed2c30b396", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Nedsatt njurfunktion", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"><span lang=\"SV\">Abakavir\r metaboliseras huvudsakligen i levern. Cirka 2 % av given dos abakavir\r uts\u00f6ndras of\u00f6r\u00e4ndrad i urinen. Abakavirs farmakokinetik hos patienter med\r njursjukdom i slutstadiet \u00e4r likartad den hos patienter med normal\r njurfunktion. D\u00e4rf\u00f6r beh\u00f6vs inte n\u00e5gon dosreduktion hos patienter med nedsatt\r njurfunktion. P\u00e5 grund av den begr\u00e4nsade erfarenheten b\u00f6r Abacavir Accord\r undvikas hos patienter med gravt nedsattnjurfunktion.</span></p>", "ID": "2c9f5512-d495-4069-b20e-c0b78ae07755", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir metaboliseras huvudsakligen i levern. Cirka 2 % av given dos abakavir uts\u00f6ndras of\u00f6r\u00e4ndrad i urinen. Abakavirs farmakokinetik hos patienter med njursjukdom i slutstadiet \u00e4r likartad den hos patienter med normal njurfunktion. D\u00e4rf\u00f6r beh\u00f6vs inte n\u00e5gon dosreduktion hos patienter med nedsatt njurfunktion. P\u00e5 grund av den begr\u00e4nsade erfarenheten b\u00f6r Abacavir Accord undvikas hos patienter med gravt nedsatt njurfunktion.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "287b619d-93cd-4c2e-a926-7c948104b772", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><u><span lang=\"SV\">Pediatrisk population</span></u></p>", "ID": "44e150b8-c223-4482-96ef-03853d125d8a", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Pediatrisk population", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.1pt\"><span lang=\"SV\">Enligt studier utf\u00f6rda p\u00e5 barn absorberas abakavir snabbt och v\u00e4l efter intag av oral l\u00f6sning och tablettformuleringar. Exponeringen av abakavir i plasma har visat sig vara densamma f\u00f6r b\u00e5da formuleringarna n\u00e4r de administreras med samma dosering. Barn som f\u00e5r abakavir oral l\u00f6sning enligt rekommenderad doseringsregim uppn\u00e5r liknande exponering av abakavir i plasma som hos vuxna.</span></p>", "ID": "3fb2f1c8-0821-44c8-8389-57de84012ffe", "Styles": "margin-top:.1pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Enligt studier utf\u00f6rda p\u00e5 barn absorberas abakavir snabbt och v\u00e4l efter intag av oral l\u00f6sning och tablettformuleringar. Exponeringen av abakavir i plasma har visat sig vara densamma f\u00f6r b\u00e5da formuleringarna n\u00e4r de administreras med samma dosering. Barn som f\u00e5r abakavir oral l\u00f6sning enligt rekommenderad doseringsregim uppn\u00e5r liknande exponering av abakavir i plasma som hos vuxna.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Barn som f\u00e5r abakavir orala tabletter enligt rekommenderad doseringsregim uppn\u00e5r h\u00f6gre exponering av abakavir i plasma \u00e4n barn som f\u00e5r oral l\u00f6sning eftersom h\u00f6gre doser i mg/kg administreras med tabletten.</span></p>", "ID": "5b4e194d-e187-447a-bf37-d70bd942d4d4", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Barn som f\u00e5r abakavir orala tabletter enligt rekommenderad doseringsregim uppn\u00e5r h\u00f6gre exponering av abakavir i plasma \u00e4n barn som f\u00e5r oral l\u00f6sning eftersom h\u00f6gre doser i mg/kg administreras med tabletten.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "33f30d24-d549-4ec0-a1f9-e5d47c275942", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r n\u00e4rvarande saknas tillr\u00e4ckligt med s\u00e4kerhetsdata f\u00f6r att kunna rekommendera Abacavir Accord till barn yngre \u00e4n tre m\u00e5nader. De begr\u00e4nsade data som f\u00f6religger pekar p\u00e5 att dosen 2 mg/kg oral l\u00f6sning till barn yngre \u00e4n 30 dagar ger upphov till liknande eller h\u00f6gre AUC j\u00e4mf\u00f6rt med dosen 8 mg/kg oral l\u00f6sning till \u00e4ldre barn.</span></p>", "ID": "cc4fb19e-d727-4436-a1f0-784747bfc837", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "F\u00f6r n\u00e4rvarande saknas tillr\u00e4ckligt med s\u00e4kerhetsdata f\u00f6r att kunna rekommendera Abacavir Accord till barn yngre \u00e4n tre m\u00e5nader. De begr\u00e4nsade data som f\u00f6religger pekar p\u00e5 att dosen 2 mg/kg oral l\u00f6sning till barn yngre \u00e4n 30 dagar ger upphov till liknande eller h\u00f6gre AUC j\u00e4mf\u00f6rt med dosen 8 mg/kg oral l\u00f6sning till \u00e4ldre barn.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "e3ef4158-26b1-4c46-9d9c-ebf74979d6d5", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Farmakokinetisk data har erh\u00e5llits fr\u00e5n 3 farmakokinetiska studier (PENTA 13, PENTA 15 och substudien ARROW PK) p\u00e5 barn yngre \u00e4n 12 \u00e5r gamla. Data visas i tabellen nedan: </span></p>", "ID": "9542a8ff-eba6-4e7b-839b-c3b7acf27ddf", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Farmakokinetisk data har erh\u00e5llits fr\u00e5n 3 farmakokinetiska studier (PENTA 13, PENTA 15 och substudien ARROW PK) p\u00e5 barn yngre \u00e4n 12 \u00e5r gamla. Data visas i tabellen nedan: ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "d1a1187c-2394-4920-9d81-fbd08fab9f7a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">Sammanfattning av abakavir AUC (0\u201124) (mikrog.h/ml) i plasma vid steady state och statistiska j\u00e4mf\u00f6relser f\u00f6r oral administrering en och tv\u00e5 g\u00e5nger dagligen mellan olika studier</span></b></p>", "ID": "95ae3dc5-1f53-4d46-ad85-c2245d0b2d4d", "Styles": "page-break-after:avoid", "Classes": "['MsoBodyText']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Sammanfattning av abakavir AUC (0\u201124) (mikrog.h/ml) i plasma vid steady state och statistiska j\u00e4mf\u00f6relser f\u00f6r oral administrering en och tv\u00e5 g\u00e5nger dagligen mellan olika studier", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt;page-break-after:avoid\"></p>", "ID": "6b7a0d6f-59c5-4935-9c6f-b34399fe7e37", "Styles": "margin-top:.05pt;page-break-after:avoid", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableNormal1\" style=\"margin-left:11.5pt;border-collapse:collapse;border:none\"> <tr style=\"height:98.0pt\"> <td style=\"width:89.4pt;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">Studie</span></b></p> </td> <td style=\"width:91.1pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">\u00c5ldersgrupp</span></b></p> </td> <td style=\"width:91.1pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">Abakavir</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">16 mg/kg Dosering <span style=\"letter-spacing:-.35pt\">en </span>g\u00e5ng\r   <span style=\"letter-spacing:-.15pt\">dagligen </span>Geometriskt medelv\u00e4rde</span></b></p> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">(95%   KI)</span></b></p> </td> <td style=\"width:91.1pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">Abakavir</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">8 mg/kg Dosering tv\u00e5 g\u00e5nger dagligen Geometriskt medelv\u00e4rde</span></b></p> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"><b><span lang=\"SV\">(95%   KI)</span></b></p> </td> <td style=\"width:90.25pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:98.0pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><b><span lang=\"SV\">J\u00e4mf\u00f6relse mellan dosering en och tv\u00e5 g\u00e5nger dagligen GLS mean ratio   (90 % Kl)</span></b></p> </td> </tr> <tr style=\"height:14.85pt\"> <td style=\"width:89.4pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">ARROW PK</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">3 till 12 \u00e5r</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">15,3</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">15,6</span></p> </td> <td style=\"width:90.25pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">0,98</span></p> </td> </tr> <tr style=\"height:13.95pt\"> <td style=\"width:89.4pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">Substudie</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(N=36)</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(13,3\u201117,5)</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(13,7\u201117,8)</span></p> </td> <td style=\"width:90.25pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.95pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(0,89, 1,08)</span></p> </td> </tr> <tr style=\"height:13.1pt\"> <td style=\"width:89.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">Del 1</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:90.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> </tr> <tr style=\"height:14.85pt\"> <td style=\"width:89.4pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">PENTA 13</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">2 till 12 \u00e5r</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">13,4</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">9,91</span></p> </td> <td style=\"width:90.25pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.85pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">1,35</span></p> </td> </tr> <tr style=\"height:13.05pt\"> <td style=\"width:89.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(N=14)</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(11,8-15,2)</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(8,3-11,9)</span></p> </td> <td style=\"width:90.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.05pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:.4pt;page-break-after:avoid\"><span lang=\"SV\">(1,19-1,54)</span></p> </td> </tr> <tr style=\"height:14.9pt\"> <td style=\"width:89.4pt;border-top:none;border-left:\r   solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">PENTA 15</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">3 till 36 m\u00e5nader</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">11,6</span></p> </td> <td style=\"width:91.1pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">10,9</span></p> </td> <td style=\"width:90.25pt;border:none;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:14.9pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:1.35pt;page-break-after:avoid\"><span lang=\"SV\">1,07</span></p> </td> </tr> <tr style=\"height:13.1pt\"> <td style=\"width:89.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"119\"> <p class=\"TableParagraph\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">(N=18)</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">(9,89-13,5)</span></p> </td> <td style=\"width:91.1pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"121\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">(8,9-13,2)</span></p> </td> <td style=\"width:90.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:13.1pt\" valign=\"top\" width=\"120\"> <p class=\"TableParagraph\" style=\"margin-top:.45pt;page-break-after:avoid\"><span lang=\"SV\">(0,92-1,23)</span></p> </td> </tr> </table>", "ID": "cc33f21c-8777-4edb-a2cc-a2b5ef31a6bd", "Styles": "margin-left:11.5pt;border-collapse:collapse;border:none", "Classes": "['TableNormal1']", "Bold": null, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": true, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": "   Studie   \u00c5ldersgrupp   Abakavir 16mg/kg Dosering en g\u00e5ng   dagligen Geometriskt medelv\u00e4rde (95%   KI)   Abakavir 8mg/kg Dosering tv\u00e5 g\u00e5nger dagligen Geometriskt medelv\u00e4rde (95%   KI)   J\u00e4mf\u00f6relse mellan dosering en och tv\u00e5 g\u00e5nger dagligen GLS mean ratio   (90% Kl)     ", "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "   Studie    \u00c5ldersgrupp    Abakavir  16 mg/kg Dosering en g\u00e5ng  dagligen Geometriskt medelv\u00e4rde  (95%  KI)    Abakavir  8 mg/kg Dosering tv\u00e5 g\u00e5nger dagligen Geometriskt medelv\u00e4rde  (95%  KI)    J\u00e4mf\u00f6relse mellan dosering en och tv\u00e5 g\u00e5nger dagligen GLS mean ratio  (90 % Kl)      ARROW PK    3 till 12 \u00e5r    15,3    15,6    0,98      Substudie    (N=36)    (13,3\u201117,5)    (13,7\u201117,8)    (0,89, 1,08)      Del 1                  PENTA 13    2 till 12 \u00e5r    13,4    9,91    1,35         (N=14)    (11,8-15,2)    (8,3-11,9)    (1,19-1,54)      PENTA 15    3 till 36 m\u00e5nader    11,6    10,9    1,07         (N=18)    (9,89-13,5)    (8,9-13,2)    (0,92-1,23)   ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "bc03ec76-6239-4ef2-8b7d-019f55224441", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">F\u00f6r de fyra patienterna i studien PENTA 15 som var under 12 m\u00e5nader och som bytte fr\u00e5n doseringsregimen tv\u00e5 g\u00e5nger dagligen till en g\u00e5ng dagligen (se avsnitt 5.1) var det geometriska medelv\u00e4rdet f\u00f6r AUC (0\u201124) (95 % KI) f\u00f6r lamivudin i plasma 15,9 (8,86, 28,5) \u00b5g.h/ml vid dosering en g\u00e5ng dagligen och 12,7 (6,52, 24,6) \u00b5g.h/ml vid dosering tv\u00e5 g\u00e5nger dagligen.</span></p>", "ID": "5c8b5710-d17a-4bbd-8a10-2800aeae2bc5", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "F\u00f6r de fyra patienterna i studien PENTA 15 som var under 12 m\u00e5nader och som bytte fr\u00e5n doseringsregimen tv\u00e5 g\u00e5nger dagligen till en g\u00e5ng dagligen (se avsnitt 5.1) var det geometriska medelv\u00e4rdet f\u00f6r AUC (0\u201124) (95 % KI) f\u00f6r lamivudin i plasma 15,9 (8,86, 28,5) \u00b5g.h/ml vid dosering en g\u00e5ng dagligen och 12,7 (6,52, 24,6) \u00b5g.h/ml vid dosering tv\u00e5 g\u00e5nger dagligen.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "8554531b-dcf4-4b5c-9a07-721fc0bbc44c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">\u00c4ldre</span></i></p>", "ID": "9aaa2a9b-a70f-4d36-817a-adc88e2d7514", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "\u00c4ldre", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavirs farmakokinetik har inte studerats hos patienter \u00e4ldre \u00e4n 65 \u00e5r.</span></p>", "ID": "8e99ffa2-b5ef-42cf-b0ec-7a2e4efedb4e", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavirs farmakokinetik har inte studerats hos patienter \u00e4ldre \u00e4n 65 \u00e5r.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "a160501d-5f96-4862-ab7c-d654b3a92e30", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>5.3</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Prekliniskas\u00e4kerhetsuppgifter</span></h1>", "ID": "ee2cb086-0389-4047-8cc2-e90b8257fc2f", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "5.3 Prekliniska s\u00e4kerhetsuppgifter", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "33f58469-49a7-435f-8083-c2075a12f342", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Abakavir var inte mutagent i bakterietester\r men visade aktivitet <i>in vitro </i>i kromosomaberrationstest utf\u00f6rt p\u00e5\r humana lymfocyter, muslymfomtest och <i>in vivo </i>i mikrok\u00e4rntest. Detta\r \u00f6verensst\u00e4mmer med k\u00e4nda effekter av andra nukleosidanaloger<i>. </i>Dessa\r resultat indikerar att abakavir vid h\u00f6ga koncentrationer, s\u00e5v\u00e4l <i>in vitro </i>som <i>in vivo</i>, medf\u00f6r liten risk f\u00f6r kromosomskador<i>.</i></span></p>", "ID": "a0edae96-64de-41af-8705-7c6d03c7122b", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Abakavir var inte mutagent i bakterietester men visade aktivitet in vitro i kromosomaberrationstest utf\u00f6rt p\u00e5 humana lymfocyter, muslymfomtest och in vivo i mikrok\u00e4rntest. Detta \u00f6verensst\u00e4mmer med k\u00e4nda effekter av andra nukleosidanaloger . Dessa resultat indikerar att abakavir vid h\u00f6ga koncentrationer, s\u00e5v\u00e4l in vitro som in vivo , medf\u00f6r liten risk f\u00f6r kromosomskador .", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "5ae2ec32-c12c-4657-a623-a1bcf963d5d6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Karcinogenicitetsstudier med oralt administrerat abakavir till mus och r\u00e5tta visade en \u00f6kning av incidensen maligna och icke-maligna tum\u00f6rer. Maligna tum\u00f6rer intr\u00e4ffade i preputialk\u00f6rteln hos handjur och i klitoralk\u00f6rteln hos hondjur av b\u00e5da djurslagen och hos hanr\u00e5ttor i tyreoidea samt hos honr\u00e5ttor i levern, urinbl\u00e5san, lymfk\u00f6rtlarna och i underhuden.</span></p>", "ID": "bede2534-1a70-4fea-83c1-e376c7013e74", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Karcinogenicitetsstudier med oralt administrerat abakavir till mus och r\u00e5tta visade en \u00f6kning av incidensen maligna och icke-maligna tum\u00f6rer. Maligna tum\u00f6rer intr\u00e4ffade i preputialk\u00f6rteln hos handjur och i klitoralk\u00f6rteln hos hondjur av b\u00e5da djurslagen och hos hanr\u00e5ttor i tyreoidea samt hos honr\u00e5ttor i levern, urinbl\u00e5san, lymfk\u00f6rtlarna och i underhuden.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "676e07ec-f86c-46cd-b29b-fd9241fcc09e", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Majoriteten av dessa tum\u00f6rer intr\u00e4ffade vid den h\u00f6gsta abakavirdosen p\u00e5 330 mg/kg/dag hos mus och 600 mg/kg/dag hos r\u00e5tta med undantag av tum\u00f6rerna i preputialk\u00f6rteln som uppkom hos m\u00f6ss vid dosen 110 mg/kg. Den systemiska exponeringen vid de h\u00f6gsta dosniv\u00e5er d\u00e5 ingen effekt konstaterats hos m\u00f6ss och r\u00e5ttor motsvarade 3 respektive 7 g\u00e5nger den humana exponeringen vid rekommenderad dosering. S\u00e5 l\u00e4nge som abakavirs karcinogena potential hos m\u00e4nniska \u00e4r ok\u00e4nd, talar dessa data f\u00f6r att l\u00e4kemedlets potentiella kliniska f\u00f6rdelar \u00f6verv\u00e4ger risken f\u00f6r karcinogena effekter hos m\u00e4nniska.</span></p>", "ID": "2f43eb65-5371-4510-8527-341220e7a4cf", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Majoriteten av dessa tum\u00f6rer intr\u00e4ffade vid den h\u00f6gsta abakavirdosen p\u00e5 330 mg/kg/dag hos mus och 600 mg/kg/dag hos r\u00e5tta med undantag av tum\u00f6rerna i preputialk\u00f6rteln som uppkom hos m\u00f6ss vid dosen 110 mg/kg. Den systemiska exponeringen vid de h\u00f6gsta dosniv\u00e5er d\u00e5 ingen effekt konstaterats hos m\u00f6ss och r\u00e5ttor motsvarade 3 respektive 7 g\u00e5nger den humana exponeringen vid rekommenderad dosering. S\u00e5 l\u00e4nge som abakavirs karcinogena potential hos m\u00e4nniska \u00e4r ok\u00e4nd, talar dessa data f\u00f6r att l\u00e4kemedlets potentiella kliniska f\u00f6rdelar \u00f6verv\u00e4ger risken f\u00f6r karcinogena effekter hos m\u00e4nniska.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "4115cbdb-3d50-4202-87fb-3834ca24fcbe", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">I prekliniska toxikologiska studier visades behandling med abakavir \u00f6ka levervikterna hos r\u00e5tta och apa. Den kliniska betydelsen av detta \u00e4r inte k\u00e4nd. Fr\u00e5n kliniska studier finns inga fynd som visar att abakavir \u00e4r levertoxiskt. Dessutom har hos m\u00e4nniska inte observerats autoinduktion av abakavirs metabolism eller induktion av andra l\u00e4kemedels metabolism i levern.</span></p>", "ID": "92adccc5-e91d-4aa3-b612-494352a13a6e", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I prekliniska toxikologiska studier visades behandling med abakavir \u00f6ka levervikterna hos r\u00e5tta och apa. Den kliniska betydelsen av detta \u00e4r inte k\u00e4nd. Fr\u00e5n kliniska studier finns inga fynd som visar att abakavir \u00e4r levertoxiskt. Dessutom har hos m\u00e4nniska inte observerats autoinduktion av abakavirs metabolism eller induktion av andra l\u00e4kemedels metabolism i levern.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.55pt\"></p>", "ID": "2a1e51de-6521-49e2-b9f6-ffcdda106bee", "Styles": "margin-top:.55pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Mild myokardiell degeneration i hj\u00e4rtat hos mus och r\u00e5tta observerades efter administrering av abakavir under tv\u00e5 \u00e5r. De systemiska exponeringarna motsvarade 7 till 24 g\u00e5nger den f\u00f6rv\u00e4ntade systemiska exponeringen hos m\u00e4nniska. Den kliniska relevansen av dessa fynd har inte kunnat avg\u00f6ras.</span></p>", "ID": "a92964d7-b155-48af-bce9-2f92df43f16c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Mild myokardiell degeneration i hj\u00e4rtat hos mus och r\u00e5tta observerades efter administrering av abakavir under tv\u00e5 \u00e5r. De systemiska exponeringarna motsvarade 7 till 24 g\u00e5nger den f\u00f6rv\u00e4ntade systemiska exponeringen hos m\u00e4nniska. Den kliniska relevansen av dessa fynd har inte kunnat avg\u00f6ras.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "615784e0-cee0-4b3b-acee-d84e712ca9a6", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">I reproduktionstoxikologiska studier har hos r\u00e5tta noterats embryonal och fetal toxicitet men inte hos kanin. Dessa fynd omfattade minskad kroppsvikt och \u00f6dem hos fostren, en \u00f6kning av antalet skelettf\u00f6r\u00e4ndringar/missbildningar samt ett \u00f6kat antal tidiga intrauterina d\u00f6dsfall och antalet d\u00f6df\u00f6dda djur. P\u00e5 grund av denna embryonala/fetala toxicitet kan inga slutsatser dras avseende abakavirs teratogena potential.</span></p>", "ID": "3d897219-9cf4-4089-9e43-f7554bcd1a83", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "I reproduktionstoxikologiska studier har hos r\u00e5tta noterats embryonal och fetal toxicitet men inte hos kanin. Dessa fynd omfattade minskad kroppsvikt och \u00f6dem hos fostren, en \u00f6kning av antalet skelettf\u00f6r\u00e4ndringar/missbildningar samt ett \u00f6kat antal tidiga intrauterina d\u00f6dsfall och antalet d\u00f6df\u00f6dda djur. P\u00e5 grund av denna embryonala/fetala toxicitet kan inga slutsatser dras avseende abakavirs teratogena potential.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "551dbbec-43f7-4614-8ab7-114f84f75bf2", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">En fertilitetsstudie p\u00e5 r\u00e5tta har visat att abakavir inte har n\u00e5gon effekt p\u00e5 fertiliteten hos han- eller hondjur.</span></p>", "ID": "642c7b8d-be19-4e08-9ce0-2d0cb484d18d", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "En fertilitetsstudie p\u00e5 r\u00e5tta har visat att abakavir inte har n\u00e5gon effekt p\u00e5 fertiliteten hos han- eller hondjur.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "a72af798-551d-47b4-a7e7-6b8de49e3af6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "bf1436c9-c2e2-412e-97ef-813d1e625b22", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>FARMACEUTISKAUPPGIFTER</span></h1>", "ID": "33aeb409-5422-4044-8c2a-6353d88b8c40", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "6. FARMACEUTISKA UPPGIFTER", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "ebac9330-94a3-4012-afe2-0d0e17d12392", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-top:.05pt;margin-right:0in;margin-bottom:\r 0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in\"><b><span lang=\"SV\">6.1</span></b><b><span lang=\"SV\">F\u00f6rteckning \u00f6verhj\u00e4lp\u00e4mnen</span></b></p>", "ID": "df4a45dd-aa67-4e93-a61f-d4773ad649cd", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:\r\n0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in", "Classes": "['MsoListParagraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "6.1 F\u00f6rteckning \u00f6ver hj\u00e4lp\u00e4mnen", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "e7efd7fb-d857-4112-8c12-9a1c72d96d20", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">K\u00e4rna:</span></i></p>", "ID": "3752a97a-f986-4e49-b17e-57d47591f76f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "K\u00e4rna:", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Mikrokristallin cellulosa PH102 (E460)</span></p>", "ID": "5b96db82-cb3a-4859-ad5b-ffab35987aaa", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Mikrokristallin cellulosa PH102 (E460)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Natriumst\u00e4rkelseglykolat (typ A)</span></p>", "ID": "b85e30ca-ecd5-49b9-833e-08bf26b986f2", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Natriumst\u00e4rkelseglykolat (typ A)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Kiseldioxid, kolloidal vattenfri</span></p>", "ID": "d04156bf-b7f2-4f69-8de8-97b667533acb", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Kiseldioxid, kolloidal vattenfri", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Magnesiumstearat (E470b)</span></p>", "ID": "a8d8e1ed-a2b1-49cf-9e2c-2581b38cb308", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Magnesiumstearat (E470b)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5811ab5b-40c9-48c9-8d07-8c241c4c47d5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"SV\">Filmdragering:</span></i></p>", "ID": "af42827b-e35d-4e66-b1b6-ac7311a404f1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Filmdragering:", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Polyvinylalkohol, delvis hydrolyserad (E1203)</span></p>", "ID": "f5507262-2aa5-4524-9002-15e1fd437c69", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Polyvinylalkohol, delvis hydrolyserad (E1203)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Titandioxid (E171)</span></p>", "ID": "925b45c9-a197-4a6b-9616-2cfdf7389c24", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Titandioxid (E171)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Talk (E553b)</span></p>", "ID": "f647aea8-f207-415d-99f5-398317b4b964", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Talk (E553b)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">J\u00e4rnoxid (gul) (E172)</span></p>", "ID": "e3610fec-d081-4e0f-a2d2-eb2e7b6d21e2", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "J\u00e4rnoxid (gul) (E172)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Makrogol (E1521)</span></p>", "ID": "bf0a5810-1f9a-4efe-be87-26089ac2f361", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Makrogol (E1521)", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "66e76319-902d-4a48-9b83-5f90b96eca0d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.2</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>Inkompatibiliteter</span></h1>", "ID": "335cc161-321b-4a60-b56e-6ab46ccb3b89", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "6.2 Inkompatibiliteter", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "a4a96fe3-fa62-4e97-91f3-a7e27bfbf050", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"><span lang=\"SV\">Ej relevant</span></p>", "ID": "b2b8b930-e916-4e0f-a95b-010245c53d55", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Ej relevant", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "e36bea0b-925c-40db-83b9-bab899589fb4", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.3</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>H\u00e5llbarhet</span></h1>", "ID": "754768d7-3afe-478e-9e6d-b69750da1a40", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "6.3 H\u00e5llbarhet", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "cafae5c5-ab80-4f88-8ef7-3c28e6a86673", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">2 \u00e5r</span></p>", "ID": "0646df44-3031-421d-b921-6f3919e1ad4c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "2 \u00e5r", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "912c7408-2fa4-44f0-bcaf-3096836c7eb1", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>6.4</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>S\u00e4rskildaf\u00f6rvaringsanvisningar</span></h1>", "ID": "bee77fe1-1822-45ec-909e-a7645209c1ee", "Styles": "margin-top:.05pt;margin-right:0in;margin-bottom:0in;margin-left:\r\n0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "6.4 S\u00e4rskilda f\u00f6rvaringsanvisningar", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "bd2b2817-b7ad-43d1-98ce-ba190d0d08ad", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Inga s\u00e4rskild f\u00f6rvaringanvisningar.</span></p>", "ID": "68e411b0-9086-47f4-b72d-04ba90dcd9b6", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Inga s\u00e4rskild f\u00f6rvaringanvisningar.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "0ea5f7ec-0e02-4203-aa95-9844a1c87a22", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.5</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>F\u00f6rpackningstyp ochinneh\u00e5ll</span></h1>", "ID": "c1db987e-9a9a-4e63-90fd-7ead789981b6", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "6.5 F\u00f6rpackningstyp och inneh\u00e5ll", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.5pt\"></p>", "ID": "b1143e60-d97d-4e96-a10f-af113cb39bc4", "Styles": "margin-top:.5pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Vitt ogenomskinligt blister av PVC\u2011aluminium inneh\u00e5llande 30, 60, 90 och 120 tabletter.</span></p>", "ID": "69eba549-3fe9-45bd-a704-40502dccf13c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Vitt ogenomskinligt blister av PVC\u2011aluminium inneh\u00e5llande 30, 60, 90 och 120 tabletter.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Blister av aluminium\u2011aluminium inneh\u00e5llande 30, 60, 90 och 120 tabletter.</span></p>", "ID": "651a3055-df68-4363-8f02-778287c35349", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Blister av aluminium\u2011aluminium inneh\u00e5llande 30, 60, 90 och 120 tabletter.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "d8f93737-5cbb-466d-9d75-3104ee78ad2c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Eventuellt kommer inte alla f\u00f6rpackningsstorlekar att marknadsf\u00f6ras.</span></p>", "ID": "c2f0c8c6-5d45-4d2e-afa5-2afeb9ebe5a0", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Eventuellt kommer inte alla f\u00f6rpackningsstorlekar att marknadsf\u00f6ras.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "61d76372-675e-4922-a1e2-abb39439c386", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "082bc63e-2e45-4904-ac53-a983f5ed6d70", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>6.6</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>S\u00e4rskilda anvisningar f\u00f6rdestruktion</span></h1>", "ID": "1ee5cc11-034c-4ef4-ae16-1ef36d53f8d7", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "6.6 S\u00e4rskilda anvisningar f\u00f6r destruktion", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "53f194e1-2f92-4017-83f8-6a6c0c7024e4", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">Inga s\u00e4rskilda anvisningar f\u00f6r destruktion.</span></p>", "ID": "16f4aa96-f72c-4a3c-abf6-cf1e2ba5dc82", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Inga s\u00e4rskilda anvisningar f\u00f6r destruktion.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "0fbde59c-afac-400b-8b0d-ff6bd69b2e93", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "6cd07d32-b096-4daa-b18f-ac47051f0c6a", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin-top:3.65pt;margin-right:0in;margin-bottom:0in;margin-left:\r 0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext'>7.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>INNEHAVARE AV GODK\u00c4NNANDE F\u00d6RF\u00d6RS\u00c4LJNING</span></h1>", "ID": "f2e055fb-5ce5-469d-a03d-e65b4aeaa885", "Styles": "margin-top:3.65pt;margin-right:0in;margin-bottom:0in;margin-left:\r\n0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:auto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "7. INNEHAVARE AV GODK\u00c4NNANDE F\u00d6R F\u00d6RS\u00c4LJNING", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "6cd6cc3c-d6af-4744-98db-562a8c6e6555", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">Accord Healthcare B.V.</span></p>", "ID": "926e2262-70e5-4536-b025-e4c4dbd40756", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Accord Healthcare B.V.", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">Winthontlaan 200</span></p>", "ID": "4ea7ad64-dc8f-4c13-9555-8428fa034491", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Winthontlaan 200", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">3526 KV Utrecht</span></p>", "ID": "b3b7c534-bacc-441a-bf81-7e0bb762c99f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "3526 KV Utrecht", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">Nederl\u00e4nderna</span></p>", "ID": "44cd250e-38cb-41c1-a165-b022b646528d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Nederl\u00e4nderna", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "1d2d037b-ad8c-4112-a30a-645e61098dd4", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>8.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>NUMMER P\u00c5 GODK\u00c4NNANDE F\u00d6RF\u00d6RS\u00c4LJNING</span></h1>", "ID": "428ca643-4baa-4bff-86ea-e5d281761183", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "8. NUMMER P\u00c5 GODK\u00c4NNANDE F\u00d6R F\u00d6RS\u00c4LJNING", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "378706b2-d274-4106-98cc-b13969bb816c", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">59643</span></p>", "ID": "58498ff9-79ba-4a56-85f5-5a978e2dd3f5", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "59643", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "5adbc6ab-98be-48b8-ab01-40e0aaa20236", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "f2afa0da-9890-40e6-9f59-4b3054c5047d", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>9.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>DATUM F\u00d6R F\u00d6RSTA GODK\u00c4NNANDE/F\u00d6RNYATGODK\u00c4NNANDE</span></h1>", "ID": "06c6d3f8-9712-4096-badd-a36313b1e09c", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "9. DATUM F\u00d6R F\u00d6RSTA GODK\u00c4NNANDE/F\u00d6RNYAT GODK\u00c4NNANDE", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"></p>", "ID": "5634502b-bfd6-4155-9882-10979ca680cf", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"SV\">2020-06-22/2021-07-25</span></p>", "ID": "3ad86479-de39-4185-b7e2-d3a2595b71b9", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "2020-06-22/2021-07-25", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "e90c6173-cc63-4b03-bbe1-f0c88c89065d", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.05pt\"></p>", "ID": "a48ff6dc-cbd9-44f7-a57c-414f48b9fda3", "Styles": "margin-top:.05pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<h1 style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r auto\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>10.</span><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext'>DATUM F\u00d6R \u00d6VERSYN AVPRODUKTRESUM\u00c9N</span></h1>", "ID": "e1e5ef55-4686-46fb-9b8e-b1b673f7a698", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:\r\nauto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "10. DATUM F\u00d6R \u00d6VERSYN AV PRODUKTRESUM\u00c9N", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "162acead-f1cd-48f2-8714-2a2c762e69f4", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"><span lang=\"SV\">2020-12-22</span></p>", "ID": "c8b38ec6-3c74-4ecc-a5db-89fc50880017", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "2020-12-22", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "cd2156b9-e462-4b48-be3c-0d104531e901", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoBodyText\" style=\"margin-top:.45pt\"></p>", "ID": "d59edf92-1e1a-4fbf-8021-4554d92d1c05", "Styles": "margin-top:.45pt", "Classes": "['MsoBodyText']", "Bold": null, "Italics": null, "Uppercased": null, "Underlined": null, "Indexed": null, "IsListItem": null, "HasBorder": null, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">Ytterligare information om detta l\u00e4kemedel\r finns p\u00e5 L\u00e4kemedelsverkets webbplats <a href=\"http://www.lakemedelsverket.se\">www.lakemedelsverket.se</a> </span></p>", "ID": "1cf70f77-10a9-4034-b341-9e50f997dada", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "IsULTag": null, "startWith<b>": false, "startWith<u>": false, "startWith<i>": false, "startWith<upper>": false, "startWith<b>Text": null, "startWith<u>Text": null, "startWith<i>Text": null, "startWith<upper>Text": null, "Text": "Ytterligare information om detta l\u00e4kemedel finns p\u00e5 L\u00e4kemedelsverkets webbplats www.lakemedelsverket.se ", "ParentId": "b07fd546-cac0-4b5f-a545-df9fb5ca4e25"}]}